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ABSTRACT OF DISSERTATION

DEVELOPING SYNTHETIC STRATEGIES FOR MULTIFACETED APPLICATIONS
OF STABLE GOLD-BASED COMPLEXES
Development of stable gold-based complexes has been a rapidly advancing field
due to the popularity of gold complexes, particularly for use in biomedical research and
catalytic transformations. Given that auranofin, a gold(I) complex with FDA approval for
the treatment of rheumatoid arthritis is used in the clinic, the development of stable goldbased molecules of clinical relevance is urgently needed. Herein are reported, synthetic
strategies used for the development of new classes of gold(I) and gold(III) complexes for
advancement in mitochondrial modulation for use as chemotherapeutics as well as
application to gold catalysis due to the unique geometry of complexes presented within.
Mitochondrial structure and function are integral to maintaining mitochondrial
homeostasis and are emerging biological targets in aging, inflammation,
neurodegeneration, and cancer. Meanwhile, targeting cellular metabolism has emerged as
a key cancer hallmark that has led to the therapeutic targeting of glycolysis. The study of
mitochondrial structure and its functional implications remain challenging partially
because of the lack of available tools for direct engagement, particularly in a disease
setting. Furthermore, agents that target dysfunctional mitochondrial respiration for targeted
therapy remain underexplored. Both the synthesis and characterization of highly potent
organometallic gold(III) complexes supported by dithiocarbamate ligands as selective
inhibitors of mitochondrial respiration and a gold-based approach using tricoordinate
gold(I) complexes to perturb mitochondrial structure and function for selective inhibition
of cancer cells have been elucidated. Mitochondrial targeting and inhibitory effects are
characterized using a plethora of both in vitro and in vivo experiments. While developing
the tricoordinate framework, the unique geometry led to the pursuit of identifying other
applications for these distinct gold(I) complexes. The development of oxidant-free, goldcatalyzed, cross-coupling reactions involving aryl halides have been hampered by the lack
of gold catalysts capable of performing oxidative addition at Au(I) centers under mild
conditions or without some external oxidant. Expanding gold-catalyzed C-H
functionalization with readily available aryl halides complements widely used Pd-catalysis
in the construction of complex organic structures containing biaryl scaffolds. Herein, is
reported the development of novel tricoordinate gold(I) catalysts, which are supported by

N,N-bidentate ligands and ligated by phosphine or arsine ligands for C-H functionalization
without external oxidants to form biaryls without homocoupling. The catalytic method is
insensitive to air or moisture. Computational investigation into the mechanism suggests an
oxidative addition step followed by a C(sp2) – H auration and reductive elimination to
afford C – H functionalized products in high yields. The asymmetrical character of the airstable gold(I) catalyst is critical to facilitating this necessary orthogonal transformation.
This study unveils another potential of Au(I) catalysis in biaryl synthesis.
KEYWORDS: Synthetic Gold Chemistry, Mitochondrial Metabolism, Anticancer, Gold
Catalysis, Structure Activity Relationship
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CHAPTER 1. GOLD COMPLEXES: AN INTRODUCTION TO MULTIPLE APPLICATIONS
Some text and figures within this chapter were reproduced by permission of The
American Chemical Society. Reference: Mertens, R. T. and S. G. Awuah (2019). Gold
Catalysis: Fundamentals and Recent Developments. Catalysis by Metal Complexes and
Nanomaterials: Fundamentals and Applications, American Chemical Society. 1317: 1955. DOI: 10.1021/bk-2019-1317.ch002.
1.1

Brief History of Gold in Medicine
Gold (Au) has captured the imagination of humanity for years and still does, due to

its inertness and unparalleled use in jewelry, currency, decorations, electronics, and even
medicine.1-8 Over the past two decades, tremendous progress has been made to advance
applications of this precious metal. These include gold in medicine, Au-catalyzed
transformations, gold in cosmetics, and many more.2, 8-24 Moreover, the demand for gold
has skyrocketed due to its wide array of uses from cosmetics, jewelry, currency,
electronics, and even medicine. With a recent peak at $2,000 per oz., the demand for this
precious metal is becoming unparalleled to any other (Figure 1-1). The body of this work
will focus on the development of new gold-based agents, investigation of their
chemotherapeutic properties, followed by a unique application to gold catalysis. Given the
high demand of gold, it is imperative that there is thorough investigation of these scaffolds
across a range of applications, so that there is no untapped potential.

1

Figure 1-1. Price trend of gold over the past 20 years. Image was taken and reproduced
from www.goldprice.org. Copyright © 2002 - 2020.
Over the course of history, dating back to ancient Egypt, gold was highly valued
(Figure 1-2). Ancient Egyptians would send caravans out searching for gold in hopes to
find them in tombs. Furthermore, gold amulets were used in Egypt and India as they
believed these gave magico-religious powers to the non-divine. Continuing this trend,
evidence of gold in medicine is referenced to ancient China around 2500 BC.13, 25 Gold was
used by both physicians and surgeons, being listed as a natural medicine in books on
Chinese medical practices such as the Compendium of Materia Medica developed from the
Han Dynasty up until the Qing Dynasty. Examples of prescriptions used include Zixuedan
and Zhibaodan; both are multi-component mixtures containing gold for the treatment of
high body temperature and measles.26, 27

2

Figure 1-2. Brief historical timeline of gold in medicine highlighting key steps towards
the development of gold in the clinical setting.
As the lore of gold for medicinal purposes was passed down from generation to
generation, the Europeans became interested in the application for gold as well. In the
1300’s, Arnald of Villanova had suggested the idea that gold could treat ‘melancholy’ and
such developed a recipe that could be consumed internally known as aurum potabile.28 'It
owes its perfection to the unique and admirable balance of elementary constituents and
virtues therein. In addition, it harbors specific virtues which are due to celestial influence.
In its stability and permanence, gold is itself like a star of heaven. Though an object
composed of elements, it is unalterable, insoluble, incorruptible — a miracle of nature. It
helps vision, and above all, cleanses and clears the substance of the heart and the fountain
of life'. –Arnald of Villanova.28 Further use of this ‘school of thought’ continued through
the 17th century, as many proclaimed alchemists fancied the use of aurum potabile.29-31
One such medical skeptic, Paracelsus, prescribed this gold-based mixture again for the use
of melancholy, as it “made one’s heart happy.”32 As the 17th century approached, many
medical iconoclasts became skeptical of chemically prepared medicines and touted the use
of gold for medicinal applications as dangerous. Nevertheless, gold continued to find its
way back in common medical practice.
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In the 17th century, gold agents officially entered the drug compendia, specifically
in “Pharmacopeia Iondinensis” as introduced by German alchemists. However, by the end
of the 19th century, gold had been dropped from many pharmacopeias due to drastic
decline of its use.33, 34 It was not until the late 19th century that gold started to become
popular again with Chreistien and Figuier using the sodium salt of gold chloride for the
treatment of syphilis.35 With this success, other scientists began to develop gold-based
treatments for various disease indications. To mention a few, Keeley attempted the cure of
alcoholism in the mid 1800’s, Koch’s discovery of gold cyanide exhibited antibacterial
effects in 1895, and Forestier discovered antiarthritic activity of gold complexes in 1920.3639

All of these scientific innovations led to the development of auranofin, a gold(I)

complex, which received FDA approved in 1985 for the treatment of rheumatoid
arthritis.39-46 Other thiolate based compounds that were developed along with auranofin
included myochrysine, allochrysine, solganal, and sanochrysine (Figure 1-3).8, 47-52 Since
then, numerous developments in synthetic strategies have been employed to establish novel
gold complexes for a plethora of disease treatments.
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Figure 1-3. Examples of clinically relevant gold complexes, with auranofin being used
for the treatment of rheumatoid arthritis.
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1.2

Developments of Gold Chemistry for Medicinal Applications
Newer and safer alternatives to gold-based treatments have been developed since

the discovery of auranofin, and as such, there has become less reliance on gold for
rheumatoid arthritis patients. However, the ability of auranofin to modulate multiple
biological mechanisms has prompted a vast repurposing effort for the treatment of other
diseases including cancer, tuberculosis, viral and parasitic infections. It is worth
mentioning that auranofin has completed phase I/II clinical trials (NCT01419691) for CLL
(chronic lymphocytic leukemia) as well as for ovarian cancer (NCT03456700).53, 54 In fact,
promising data revealed auranofin inhibited viral replication of the SARS-COV-2 virus
and reduced inflammation in human cells.55
Recent developments in synthetic gold chemistry have been focused on designing
novel gold scaffolds for medicinal applications that include but are not limited to
anticancer, antifungal, antibacterial, antimalarial, antiviral, and antileishmanial purposes.10,
13, 56-64

Development of these gold-based therapeutics has led to the evolvement of a variety

of scaffolds that vary in ligand and oxidation state (predominantly +1 and +3) (Figure 14). Although other oxidation states have been found to exist for gold-based complexes,
Au(I) and Au(III) are predominantly used in medicinal applications.51
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Figure 1-4. Overview of design and ligand tuning capabilities for gold(I) and gold(III)
complexes.
Given the presence of gold in medicine and the early success of auranofin, recent
developments of new gold-based scaffolds are rooted in a few fundamental principles: 1)
analogous electronic similarities between square planar complexes of Au(III) and Pt(II),
both being isoelectronic d8 metal ions, 2) development of stable gold complexes bearing
softer donor atoms such as nitrogen, sulfur, and phosphorous grounded on the hard-soft
acid base theory, and 3) stabilization of the easily reduced Au(III) metal center with
organometallic bonds.8, 52
1.3

Relationship Between Gold and Platinum
A key challenge that inspired researchers to pursue gold-based drugs included

overcoming the resistance of cancer cells to platinum therapies and severe side effects
associated with treatment.65-73 Concomitantly with the development of gold-drugs,
platinum-based therapies arose from the accidental discovery of cisplatin in 1956 (Figure
1-5), with clinical approval for the treatment of a variety of cancer types (ovarian, bladder,
and testicular).74-80 Since, it has shown extremely high efficacy for the treatment of
testicular germ cell cancer.81, 82
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Figure 1-5. Examples of clinically relevant platinum based therapeutics.
However, given the deleterious side effects such as neurotoxicity, nephrotoxicity,
and ototoxicity to name a few, cisplatin is commonly administered in low doses that are
less efficacious in treating certain tumors.83, 84 Second generation platinum drugs including
carboplatin and oxaliplatin, (Figure 1-5) showed higher efficacy while limiting the
deleterious side effects; however, key challenges with regards to resistance remains.76, 84-86
Particularly, the aggressive and metastatic cancer types such as triple negative breast
cancers (TNBC) are refractory to the next generation platinum drugs. In a continued effort
to discover and design metal-based therapeutics, gold was brought back into the
foreground. The isoelectronic character of Au(III) and Pt(II) gave rise to the hypothesis
that gold complexes may exhibit anti-cancer activities, but through different mechanisms
of action given the distinct relativistic character and reactivity of gold.57, 87-89
1.4

Development of Gold-Based Complexes: Relevance to Gold Stability
Gold phosphine compounds and thiolates have been integral to gold drug discovery

over the past twenty years especially, following their integration in the auranofin
framework.12, 16, 45, 61, 90-99 With the use of coordinating phosphine ligands and pro-drug
nature of the thiolate sugar backbone of auranofin, significant work has been done to
advance the development of these scaffolds as depicted in Figure 1-6.100 Original work
included a four-coordinate cationic gold(I) complex with diphenylphosphinoethane (dppe)
as well as the linear dinuclear gold(I) complex of the same ligand (Figure 1-6, 1 and 2 ).60,
101-104

These compounds proved to be rather stable with modest in vitro and in vivo efficacy;

however, severe side effects including toxicity to the heart prevented further applications
in the clinical setting. Further developments of this framework continued by changing the
alkyl backbone to benzene (Figure 1-6, 3) and cyclohexyl backbones (Figure 1-6, 4), yet
the same deleterious side effects were observed. Additional developments led to the
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exploration on the effect of lipophilicity on in vitro cytotoxicity. Studies showed that
increase the lipophilic character of the phosphine ligand increased the cytotoxic effects of
the compounds. Replacement of the phosphorous ligand with arsenic or antimony led to an
overall decrease in cytotoxic effects due to reduced stability of the overall gold complex
(Figure 1-6, 5). Further modification using PTA (1,3,5-triaza-7-phosphaadamantane,
Figure 1-6, 6), another highly hydrophilic moiety, exhibited great cytotoxicity. Work by
Berners-Price et al. demonstrated the anticancer effect of gold-phosphine complexes and
have also tried to improve the in vitro and in vivo efficacy of this class of compounds.60, 62,
64, 88, 98, 99, 101, 105-109

Development upon that included the synthesis of gold(I) phospholes

(Figure 1-6, 7), which displayed optimal stability and was found to bind thioredoxin and
efficacious against glioma.110 Recent developments from our lab have included achiral
quinoxaline phosphine derivatives to help stabilize the gold(I) center (Figure 1-6, 8).111,
112

These compounds have proven to be effective in a panel of cancer cell lines including:

ovarian, leukemia, and lung. Furthermore, mechanistic investigation provides insights that
these compounds selectively alter mitochondrial dynamics and have shown promising in
vivo efficacy.

Improving the biological activity of gold-phosphine complexes requires

ligand tuning that expand diversity, lipophilicity, physiological stability, and high selective
cytotoxicity in cancer cells compared to normal cells.
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Figure 1-6. Selected depiction of relevant gold-phosphine molecules used for medicinal
purposes.
Continuing on the aspect of physiological stability and improvement of stable gold
complexes, sulfur containing ligands have also been employed to improve solution stability
through coordination of another soft base with the soft metal center of gold (Figure 1-7).113
This phenomenon is observed in auranofin, which possesses a thiolate sugar as a ligand.
Furthermore, sulfur based ligands exist in bidentate form, which improve binding through
the chelate effect to the metal center. The most common of this ligand type is the
dithiocarbamate moiety, with the canonical form (2-S2N=C+R1R2), having an electronic
9

nature that can help stabilize Au(III) center.114-122 It is worth mentioning that given
previous mechanisms of action of gold-based compounds including coordination with
sulfur containing amino acids in proteins or enzymes such as thioredoxin reductase
(TRxR), there must exist intrinsic stability of the Au-S bond.123-128 Work presented herein
is a development on previous reports of gold dithiocarbamate complexes. By employing
an organometallic gold bond through cyclometalation to further stabilize the gold center,
we chose dithiocarbamates as the ancillary moiety given their precedence in the literature.
Gold compounds bearing a dithiocarbamate ligand and two halides have exhibited high
antitumor properties both in vitro and in vivo, with the compound inducing an 85%
reduction of prostate tumors in mice (Figure 1-7, 9).114, 119, 129, 130 Fregona and coworkers
took this framework a step further by changing the dithiocarbamate ligand to contain
peptide substituents, with the most promising candidate being a derivative of sarcosine
(Figure 1-7, 10).131-133 This complex was efficacious in treating prostate and ovarian
cancers that were resistant to cisplatin treatment. It was further confirmed that this complex
induced apoptosis in Hodgins’s lymphoma and revealed to mediate apoptotic cell death in
the TNBC model MBA-MB-231.117, 134 Gold dithiocarbamates within the past ten years
were recommended for phase I clinical trials.130 Expansion of this framework included
exchange of the halide ligands to another bidentate framework using bipyridine to try and
generate a more stable, active complex (Figure 1-7, 11). The synthetic approach described
herein employs a cyclometalated bidentate ligand to stabilize the Au(III) center, a feature
which will be discussed in the next section.
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Figure 1-7. Selected depiction of sulfur-based gold molecules that have been pursued for
medicinal applications.
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It is of need to mention that other chemotypes of the dithiocarbamate exist. One of
the most relevant and extensively researched framework of this type is the
thiosemicarbazone. Thiosemicarbazones and similar compounds are of considerable
interest with respect to their biological and pharmaceutical properties. Many of them
possess remarkable activities against a number of diseases such as cancer, HIV,
tuberculosis, and also against parasitic diseases. Pioneered by Abram and coworkers, these
gold(III) molecules possessing a tridentate (S^N^S) system (Figure 1-8, 12-17) were
proven to enhance overall complex stability over known dithiocarbamate as well as offer
higher in vitro efficacy in comparison to the precursor [Cl2Au(damp)] (18).135-138 in 1999,
one of the primary reports by Abram et al. described the preparation of a few gold(III)
thiosemicarbazone derivatives, detailing their bonding motif and further characterization
by X-ray crystallography.135 In 2004, Abram et al. further demonstrated that new
derivatives of the gold(III) thiosemicarbazones were stable in water and organic solvents,
which prompted this class of complexes to be further evaluated in a biological setting.136
Fast forward to 2016, after synthetic modification and detailed characterization, Abram et
al. followed up on the previous reports by demonstrating that organometallic gold(III)
complexes with hybrid SNS-donating thiosemicarbazone ligands exhibited high
cytotoxicity and antitrypanosoma cruzi activity.137 In brief, when incubated with
glutathione, HPLC studies revealed no evidence for the formation of decomposition
products.
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Figure 1-8. Recent reports of stale gold(III) thiosemicarbazones that possess high
antiproliferative properties.
In vitro biological activity show that these complexes exhibit reasonable cytotoxic
and potent trypanocidal effects (< 2 µM). Furthermore, the structure activity relationship
(SAR) of this series compounds indicates that substituents drastically influence the
biological activities. Compound (15) was furthermore identified as a highly selective
complex for the amastigote form of T. cruzi with a selectivity index of approximately 30,
which makes this compound a promising lead candidate for the development of an effective
trypanocidal agent for the treatment of Chagas’ disease. With this promising data,
researchers have tried to further develop the field of gold(III) thiosemicarbazones and their
derivatives. Such example was published in 2018 by Pizarro et al., demonstrating the
synthesis of gold(III) bisthiosemicarbazone complexes (Figure 1-8, 17).138 These
molecules displayed IC50 values below 10 µM in MCF-7 breast cancer cells. Further
mechanistic insight revealed high metal accumulation in the mitochondria and a high
affinity for thioredoxin reductase. With these recent reports in the literature, it is of great
12

importance to further elucidate the mechanism of action develop of gold(III) sulfur-based
complexes, as there is strong precedence for great biological activity.
1.5

Gold Complexes Stabilized via Cyclometalation
Organometallic gold complexes have been widely explored and developed alongside

other scaffolds to improve compound stability. These classes of complexes have been used
in a plethora of applications including catalysis, materials science, and medicinal inorganic
chemistry (Figure 1-9, 18-26).139-151 The applications of gold in medicine has seen a
renaissance and thus overcoming the lack of stability of high-valent gold(III) complexes is
of great importance. The innate ability of a direct organometallic Au-C bond would
guarantee increased stability under physiological conditions.152, 153 A key example is that
of Au(III) phosphine complexes. Cyclometalated versions were shown to be inert towards
reduction by glutathione or N-acetyl-L-cysteine.111, 112 Cyclometalation is a well-known
sigma-donating strategy to stabilize transition metal centers.154, 155 Combining the direct
organometallic character of an Au(III) bond with the chelate effect of a bidentate
cyclometalated framework (C^N), the proposed stability of these complexes would help
propel gold-based medicinal chemistry that had been hamstrung. One of the first examples
of this class of compounds was the combination of the C^N ligand with 2-(N,Ndimethylamino)methylphenyl (Figure 1-9, 18).156 These complexes displayed higher in
vitro efficacy than that of cisplatin, of which all had improved solution stability.148, 157
Following the success of these frameworks, work done by Che et al. pioneered the use of
tridentate pincer cyclometalation ligands (C^N^C, C^N^N, and N^C^N) (Figure 1-9,
24).142, 158-161 These compounds were shown to have very promising anticancer activity,
again both in vitro and in vivo. Not only do these cyclometalated scaffolds provide a solid
foundation for new bidentate/tridentate gold complexes, they possess halide ligands which
can be easily substituted for compound diversification. Other classical examples include a
form of pyridyl donor ligand within the framework to facilitate the coordination to the
gold(III) center (Figure 1-9, 19, 20, 22, and 23). Exchanges of a halide(s), typically
chloride, from the parent compounds allows for robust structure activity relationship with
the use of ancillary oxalates, thiolates, phosphines, and N-heterocyclic carbenes to name a
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few. Overall, this diversification of different families of gold(III) complexes provides a
wide variety of agents to further investigate their mechanism of action.
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Figure 1-9. Selected illustration of common gold(III) cyclometalated motifs that have
been used for SAR for development of medicinally relevant gold complexes.
Our lab has taken advantage of this design and developed novel gold(III)
organometallic complexes employing the cyclometalated backbone to improve upon the
biological stability. A preliminary report from our lab that utilized these frameworks
involved the 2-benzoylpyridine cyclometalated framework. This foundation was then
synthetically transformed into a cyclometalated framework coupled to a c-MYC affinity
ligand, 100058-F4 (Figure 1-10, 27).162 Ofori et al. demonstrated via mass spectrometry,
cellular target engagement, comparative cellular assays, functional transcriptional assays,
and whole cell transcriptomics, that gold warheads offer a promising route to irreversible
inhibition of expressed MYC proteins, and that they suppress MYC transcriptional
program in living cancer cells.162 It is worth mentioning that these complexes exhibited
minimal changes in stability after incubation with RPMI, DMEM (Dulbecco's Modified
Eagle Medium), or BSA (bovine serum albumin).
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Figure 1-10. A stable cyclometalated gold(III)-based pharmacophore which inhibits the
intracellular MYC protein.
Our lab continued the use of cyclometalation by exchanging the ancillary chlorides
with bidentate substituents. Reports included the combination of the achiral-(R,R)QuinoxP phosphorous ligand (as seen in structure 8) with the cyclometalated framework
(2-benzoylpyridine) gave rise to a novel organometallic gold(III) complex with IC50 values
as low as 500 nM across a panel of cancer cell lines.112 To validate the improved stability,
the complex was incubated with bovine serum albumin (BSA) for 24 hours. HPLC and
UV-vis analysis revealed no changes after 24 hours, indicative of no covalent modification
of BSA or changes to the gold compounds.112 With this success, our lab further expanded
on both the cyclometalated portion as well as the phosphine moiety used. Kim et al. were
able to synthesize several new cyclometalated gold(III) complexes (Figure 1-11, 28-34),
which inhibit the tumor growth of metastatic TNBC and represent a new strategy to study
the modulation of mitochondrial respiration for the treatment of aggressive cancer and
other disease states where mitochondria play a pivotal role in the pathobiology.111 These
complexes were highly stable, remaining intact even when incubated with physiologically
relevant levels of glutathione. Furthermore, the lead compound (29) demonstrated high
tolerability in vivo and induced significant tumor inhibition in 4T1 mouse model.
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Figure 1-11. Examples of anticancer gold(III)-bisphosphine complexes developed in the
Awuah lab which exhibit high antiproliferative properties.
Similarly, the Awuah lab explored the N^N bidentate system combined with the
cyclometalated framework (Figure 1-12, 35-39). First, work by Gukathasan et al. were
successfully able to coordinate the (1R,2R)-(+)-1,2-diaminocyclohexane (DACH) ligand
to the cyclometalated 2-benzylpyridine cyclometalated framework (Figure 1-12, 35-36).163
DACH is commonly known for its use in the FDA approved platinum(II) drug,
oxaliplatin.164 Whereas the DACH ligand has gained traction, motivated by the outlined
successes in the fields of catalysis and medicine, very few gold DACH compounds exist.165167

These complexes also exhibited high stability in complete Dulbecco’s modified Eagle

medium (DMEM) over 72 h and do not interact with plasmid DNA. Furthermore, it was
shown that these complexes have high antiproliferative effects in ovarian cancer models.163
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Figure 1-12. Recent developments of gold(III) cyclometalated complexes containing a
N^N bidentate bonding moiety.
Furthermore, Kim et al. and Ang and coworkers simultaneously published articles
on cyclometalated gold(III)-Metformin complexes (Figure 1-12, 37-39).168,

169

Both

groups successfully identified that these complexes decrease mitochondrial respiration by
100-fold. Kim et al. reported that these complexes remain stable in physiologically relevant
buffers as well as high thermal stability measured by variable temperature NMR.169
Compound (37) displayed superior antiproliferative activity in comparison to Metformin
alone. The use of the delocalized lipophilic gold(III) cation enhances selective uptake in
cancer cells, thus targeting bioenergetic pathways. Analogous to these findings, Ang et al.
reported that compound (38) was up to 6000-fold cytotoxic than uncoordinated
Metformin.168 Furthermore, they ascribe these effects to (38) interfering with energy
production in TNBCs and inhibiting associated pro-survival responses to induce deadly
metabolic catastrophe.168 Furthermore, compound (38) halted the growth of aggressive
breast tumors in a mammary fat pad breast cancer model. Overall, these N^N bidentate
ligands coordinate to cyclometalated gold(III) frameworks prove that this subset of
molecules is highly stable and potent across multiple cancer cell lines.
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Although just a brief overview is presented here, it is important to communicate the
high need for stable gold-based complexes. In all reports, the cyclometalated derivatives
offer enhanced stability and potency. Development of this framework is of high
importance, thus the work presented herein was to apply this same concept to the bidentate
dithiocarbamates. Improving stability of gold(III) complexes will ultimately lead to more
successful clinical candidates as more and more scaffolds are developed.
1.6

Applications of Gold in Catalysis: A Brief Description
Concomitantly with gold-drug development, gold catalysis has been heavily

developed over the past few decades (Figure 1-13). With the rise in popularity of
palladium, rhenium, rhodium, and iridium for catalytic transformations, gold, another late
transitional metal has seen a large increase in catalytic applications. However, metallic Au
possesses inherent chemical and physical properties that limit utility including: i) large
relativistic effects, ii) increased ionization energies, and iii) high redox potential. These
factors contribute to the sluggish participation of Au in Mn/n+2 redox processes unlike its
Pd counterpart. In an attempt to circumvent the problems outlined to set the stage for
practically relevant Au catalysis, several oxidative and redox neutral catalytic reactions
have been developed. In addition, intelligently designed catalysts with unique reactivities
and activation paradigms have been employed. A plethora of outstanding reviews,
chapters, perspectives and monographs provide deep insights into various aspects of
homogenous Au catalysis including activation of unsaturated carbon-carbon bonds; ligand
effects; synthetic transformations of hydroamination of C–C multiple bonds, propargylic
esters, hydroarylation of alkynes, and cross-coupling to mention a few. Within the context
Chapter 6, our goal is to detail the fundamental steps involved in homogenous Au
catalysis, namely: ligand activation/oxidative addition and reductive elimination. We hope
that this knowledge will catapult Au catalyst design in this ever-expanding field.
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Figure 1-13. Illustration of key catalytic processes involved in gold catalysis that have
been extensively researched to develop redox neutral gold catalyzed transformation
The reactivity of Au can be derived partially from the uniqueness of the atoms’
properties. The relativistic effects of Au provide the element with characteristics such as
higher ionization energies and electron affinities (discussed later in the chapter), and a very
high redox potential (i.e. Au+3 + 2e- → Au+1 Eo=1.41 V and Au+1 + e- → Au(s) Eo=1.69 V).
(Figure 1-14)170 When compared to palladium, it is easy to discern why the oxidative
addition process to gold proceeds much slower and therefore has seen less success in
classical oxidation addition/reductive elimination transformations.
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1.41
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Figure 1-14. Comparison of reduction potentials of gold and palladium. This depicts why
class cross-coupling transformations are challenging for gold in comparison to other late
transition metals.
All of these properties make the reactivity of Au unique. The relativistic effect also
contributes to the Lewis acidity of the metal. The relativistic effects lead to contraction of
the s and p orbitals, which affects the expansion of the outer d and f orbitals. This allows
Au for coordination by donating ligands such as phosphines or carbenes.171 In the case of
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Au(I) complexes, the contracted empty 6s orbital allows for significant overlap with sigmadonor ligands. Initial design of Au catalysts relied heavily on the classical two coordinate
gold(I) system which have distinctly shown Lewis acid character.91
In addition to these common coordination or organometallic compounds existing
in Au(I) and Au(III) oxidation states, Au has the capability of adopting rare oxidation states
such as Au(II) and Au(V) (Figure 1-15).172, 173 In fact, Au(II) intermediates have been
implicated in homogenous catalysis and biology, however their geometric and electronic
structures remain unexplored until recent discoveries.118, 174, 175 They are still considered to
be less common than the conventional Au(I) or Au(III) derivative.176 Au(II) species are d9
in character and possess an unpaired electron in an orbital, this contributes to its lability. A
few mononuclear Au(II) complexes have been isolated.177, 178 Other Au(II) species exist as
dinuclear complexes with Au-Au bond.178-182 The lack of compounds still did not deter
researchers from exploring oxidative addition to Au(II) complexes, though minimal
success has been achieved.183 In one specific case, oxidative addition to Au(I) produced
Au(II) compounds.184 Whereas this report is unique, its application to Au catalysis is
limited by the instability of Au(II) complexes. Despite reports of Au(V) compounds,173, 185
there exist no practical use in catalysis since their initial discovery. The extremely high
oxidation potential of these complexes makes it impractical for catalysis.

Figure 1-15. Illustration of varying oxidation states of gold.
In the 1970’s early insights into Au(I)/Au(III) alkyl aurates revealed remarkable
thermal stability, a feature that remains to be desired by modern catalysts.186,

187

A

pentanuclear Au(I) mesityl complex has been reported.188 Although this compound has not
seen practical utility, insight into stabilizing factors for the Au(I) by the mesityl ligand has
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been obtained. This is important as ligands with similar frameworks have been used in
stabilizing Au(I)/Au(III) complexes. In the era of a gold renaissance, this chapter will fill
the gap and drive further research on structure and reactivity of Au complexes in Aucatalyzed organic synthesis.
1.7

Oxidative Addition
The research on catalysis involves considerable optimization of catalysts and their

influence on the various steps of the catalytic cycle. Oxidative addition is a very crucial
step, especially in cross-coupling reactions. Given the high ionization energy and redox
potential of AuIII/I cycle, a large energy barrier needs to be overcome in order to transform
low-valent Au(I) to high valent Au(III).189 Recent literature shows progress in overcoming
this barrier to unleash insightful reactivity useful for Au catalysis. One of the first reports
of successful oxidative addition was reported in 1972 by Shiotani and Schmidbaur.190 They
highlighted that it was feasible for Au to undergo such a transformation. Their work
showed oxidative addition of methyl iodide to an Au(I) alkyl complex: (CH3)Au(PPh3).190
In this same year, another group used the same Au(I) alkyl complex and did an initial
mechanistic study in which they saw ethane produced from a reaction of the Au(I) alkyl
complex and methyl iodide (Figure 1-16).191
X
(X=OTF, Cl, Br, I)
PMe3

Au
(I)

Cl

Oxidative Addition

Me3P

Au
Cl (III)

X

Figure 1-16. Seminal work demonstrating the capability of gold to undergo oxidative
addition rom Au(I) to Au(III).
By using bidentate ligands with short bite angles, a “pre-organized” Au(I) complex
was made readily accessible to oxidative addition. These Au(I) complexes would adopt a
tricoordinate geometry, which is rare. In doing so, the oxidatively added species would be
added to Au to form the square planar Au(III) framework. This strategy, although simple,
had not been employed in prior work as a vast majority of bidentate ligands formed
dinuclear species.93, 192-197 There is strong preference for Au(I) species to adopt a linear
21

geometry, rather than other geometries, which can be explained due to stable aurophilic
interactions.193, 196, 198 These complexes, especially with coordinating phosphine ligands,
do exhibit remarkable stability at room temperature

93, 195, 196

and have provided a

foundational framework for researchers to develop oxidative addition protocols.197
Importantly, geometry turns on reactivity towards oxidative addition as well
illustrated by Bourissou’s tricoordinate phosphine carborane Au(I) and P,N- Au(I) chelate
even at low/room temperatures (Figure 1-17).17,

192, 197, 199

This is significant in the

development of gold catalysis since the synthetic design opens up a new field for study.

Figure 1-17. Ligand design and tuning promotes reactivity for oxidative addition.
With these bidentate chelated Au(I) complexes successfully synthesized, other
platforms could also be employed besides P-P ligands, such as: N-N, N-P, N-S, S-P, etc.
as evident by a more recent publication showing successful oxidative addition to a gold
complex bearing an N-N bidentate ligand.200 Not only does using a bidentate ligand help
stabilize the metal complex itself due to the chelate effect, it also aids in overcoming the
energy barrier by helping facilitate the conformational change required to oxidize from the
+1 to +3 state. A case for how structure affects reactivity was thus supported.
1.8

Reductive Elimination
Reductive elimination is a common product releasing step or decomposition

mechanism associated with high-valent transition metal compounds including Au(III)201203

. Analogous d8 transition metals, like Pt(IV), have been investigated and mechanistic

insight was reported long before the development of Au catalysis.204 In seminal
investigations, Kochi205-207 and Tobias208 revealed C–C coupling using alkyl-Au(III) and
Vicente demonstrated that unsymmetrical biaryls can be generated via C–C coupling from
cis-diaryl-Au(III) with concomitant Au(I) species as proof of reductive elimination.209-211
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Other work by Tobias illustrated facile reductive elimination of alkyls, (ethane, butane, and
octane) from readily synthesized Au(III) compounds with the generic formula [L2AuR2]X
(L are commonly used π-acceptors: phosphines, arsines, and stibines).212 Other studies of
reductive elimination from Au(III) revealed that electronics also play a factor in the
products formed. From the complex with formula Me2AuR(PPh3), when R was an alkenyl,
furyl, or aryl group R-Me was observed; however, when R was alkynyl or an electron
withdrawing group, ethane was observed.213 Further work done by Schmidbaur illustrated
that trialkynyl Au(III) complexes (LAu(CCR)3) undergo facile reductive elimination
unless stabilized by strong electron donor ligands.214 This seminal work provides evidence
that electronics of the ligands and R groups attached to Au play significant role in the
mechanism of reductive elimination.
Toste et al. has since probed the kinetic rates of C–C reductive elimination.215
Halide-dependent mechanisms of reductive elimination of Au(III) have also been recently
studied.216,

217

The mechanism by which reductive elimination occur is not definitely

defined. Prior studies did show that when species were oxidatively added there are two
possibilities. First, it immediately undergoes reductive elimination and second,
isomerization followed by reductive elimination. It has been found that while undergoing
these transformations, Au(III) complexes will adopt one of two conformations, (“T” –
shaped or “Y” – shaped conformation) before undergoing reductive elimination (Figure 118).218 These two conformations represent the lowest relative energies. The complex can
undergo isomerization between the “T” and “Y” conformation which facilitates the
reductive elimination mechanism.218 A more recent work published in 2016 illustrates the
synthesis and characterization of such a complex; being a “T” – shaped pincer complex.219
Although this complex was not used in a reductive elimination platform, the isolation of
the complex further elucidates stable structural conformations of Au.
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Figure 1-18. Rendition of the different states observed in the reductive elimination
pathway of Au(III). Included in the pathway is seen the isomerization states between each
reductive pathway.
The insight gained confirms the ability of Au(III) species to successfully undergo
this catalytic step and proves the catalytic viability of Au. This reductive elimination
pathway has been key in the C–C bond formation. As shown in Figure 1-19, we highlight
recent examples of C–C bond formation via reductive elimination.
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Figure 1-19. Four recent examples of C-C bond formation via reductive elimination from
a gold(III) complex. A) C(sp2) - C(sp2) reductive elimination from a neutral Au(III) to
neutral Au(I) complex. B) C(sp2) - C(sp2) reductive elimination via transmetalation of
boronic acids. C) Halide dependent reductive elimination to aryl halides. D) C(sp2) C(sp2) coupling via reductive elimination from a cationic Au(III) complex. E) Reductive
elimination from Au(III) cyanide complexes.
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Other studies detail the halide dependence on the reductive elimination pathway from
substrates bearing halides (X = I, Cl, Br, F), to which was oxidatively added to form the
Au(III) complex. The study was to show competition between C(aryl)-X vs. C(aryl)-CF3
(a commonly used derivative in oxidative addition reactions to Au).220 The study revealed
that when the halogen, X, is iodine, there is complete selectivity to form the C(aryl)-X
bond. However, when the halogen, X, is fluorine, the opposite is observed.216 This insight
provides a potential mechanistic insight into the reductive elimination process and shows
the potential to tune gold complexes in a specific way to achieve a desired transformation.
Continuing on the importance of CF3 reductive elimination, a report in 2017 further
established mechanistic insight into this pathway. Toste et al. were able to identify a
“rebound mechanism” in which CF3 moiety has a fluoride abstracted, followed by
migratory insertion of the alkyl substituent, and then formal reductive elimination.221 This
insight provides further evidence of the mechanism behind Au-catalyzed reactions and
allowed Toste et al. to harness this process to synthesize 18F compounds, which are useful
tracers in positron emission tomography.221 A final example that should be discussed is
recent work published in 2018. In this work, Au(I) complex undergoes oxidative addition,
proceeds through transmetalation, and closes the catalytic cycle with reductive elimination
to perform a Negishi type reaction (Figure 1-20).200
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Figure 1-20. Catalytic scheme of the oxidative addition, transmetalation, and reductive
elimination from a Au(I) tricoordinate species to form a C(sp2)-C(sp2) bond reported by
Russell et al. in 2018.
During the development of novel scaffolds for biological applications that are
presented within this dissertation, we hypothesized that the novel three coordinate
geometry which exhibited high in vitro activity compared to its linear predecessors would
also exhibit unique catalytic activity. With the knowledge from the literature in hand, we
hypothesized the three coordinate geometry would facilitate oxidative addition and
overcome the high energy potential of oxidation from Au(I) to Au(III). Following halide
abstraction, the aurophilic nature of gold would promote C-H activation from arenes.
Combining these steps and given the fast rate of reductive elimination, we proposed that
this benchtop catalysts could perform the rudimentary steps of catalysis without external
oxidants. Overall, the robustness of these compounds prove that these synthetic strategies
allowed us to make a unique class of gold(I) complexes that are multi-dimensional. These
parent compounds will pave the way for further structure activity relationship development
so that 2nd and 3rd generation compounds have improved activity.

26

CHAPTER 2. REVISITING THE REACTIVITY OF TETRACHLOROAURIC ACID WITH N,NBIDENTATE LIGANDS: STRUCTURAL AND SPECTROSCOPIC INSIGHTS
The text and figures within this chapter were reproduced by permission of The Royal
Society of Chemistry. Reference: R. T. Mertens, J. H. Kim, W. C. Jennings, S. Parkin
and S. G. Awuah, Dalton Trans., 2019, 48, 2093. DOI: 10.1039/C8DT04960B.
2.1

Preface
The reactivity of tetrachloroauric acid (HAuCl4) with readily accessible bidentate N-

donor ligands affords N,N-ligated Au(III) center complexes. These compounds are useful
precursors of stable catalysts, ant-cancer agents, and building block for materials. This
report provides detailed insight into intermediates, equilibria, the counter anion effect, and
structural variability using spectroscopy and crystallography. Novel mixed-valance Au(I)
and Au(III) complexes [Au(phen)Cl2]20.5[AuCl2]0.5[AuCl4] and [Au(phen)Cl2]2[AuCl2]
were discovered. Other competing side products of the reaction studied revealed protonated
N,N-bidentate ligands With [AuCl4]- anions. Quantitative variable temperature NMR
studies reveal that for a mixture of target Au(III) salt and the protonated bidentate ligand,
the reactions favors the irreversible formation of the side product. Using a rapid (30
minutes) temperature controlled protocol, the desired coordinated species is accessible in
respectable yields while avoiding side products.
2.2

Introduction
Gold complexes possess enormous utility due to their unique relativistic and

electrochemical behavior.16, 222-224 These complexes act as carbophilic Lewis acids that
readily interact with nucleophilic and π-activated systems, such as alkenes and alkynes.225227

This has led to an ignition of gold chemistry in catalysis and biology, with the dominant

use of Au(I) and Au(III) complexes. Gold(III) reagents are isoelectronic to platinum(II) in
the 5d8 configuration and can be subjected to ligand variability with mono- and polydentate ligands in ways superior to gold(I). Owing to this distinguishing feature, bidentate
coordinating ligands to stabilize and tune the reactivity of the Au(III) center (Figure 2-1)
have become very attractive.

Figure 2-1. Bipyridiyl ligated frameworks of Au(III) bidentate complexes.
The oxalates, phosphines, dithiolates, and heterocyclic N,N-bidentates, including
1,10-phenanthroline, 2,2′-bipyridine, and bathophenanthroline, are such ligand systems.59,
154, 228-235

Recent intensified efforts in redox gold catalysis and gold-containing antiarthritic

and anticancer drugs make investigating the chemistry of gold in solution imperative.117,
231, 232, 236, 237

In gold catalysis, bidentate N-donor ligands have been used as additives. These
commonplace ligands play crucial roles in the rudimentary stages of the organogold
chemistry including oxidative addition, trans-metalation, and reductive elimination.200, 238
Additionally, square-planar bipyridyl ligated gold(III) complexes exhibit potent anticancer
activity in cells and weak DNA binding properties.229, 231, 239, 240 The use of dinuclear
gold(III)-oxo complexes bearing phenanthroline and other bipyridyl ligands shows
interesting antiproliferative effects with protein binding to serum albumin, cytochrome c,
ubiquitin, and histone deacetylase inhibition.159, 241
The reactions of gold(III) with bidentate coordinating ligands first reported by
Block et al. investigated the use of aliphatic diamines such as 1,2-ethanediamine and 1,2propanediamine as well as heterocyclic N-donor ligands, including 2,2’-bipyridine and
phenanthroline.242 Ever since, a significant body of work has employed this reaction
method with slight variations using different N,N-bidentate ligands.60, 105, 106, 243 Initial
mechanistic work to elucidate ligand substitution in gold-based square planar complexes
has employed Au(III) amine complexes. In addition, whereas the aqueous solution
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chemistry and structural investigations of Au(III) complexes bearing tridentate amine and
terpyridine ligands have been well studied, mechanistic investigation of Au(III) complexes
supported by bidentate ligands will expand our understanding of their overall reactivity.244247

We report the preparation of Au(III) complexes bearing heterocyclic N-donor ligands

by a streamlined rapid synthetic protocol and offer detailed insights into structural
characterization via X-ray crystallography. In this report, we discovered novel mixed
valence Au(I)–Au(III) complexes. Furthermore, isolation of protonated ligands
demonstrates that the hydrolysis of HAuCl4 lowers the pH of the reaction medium leading
to protonated ligands as byproducts. Our temperature-controlled method described in this
report circumvents the formation of byproducts.
2.3

Solution Chemistry of HAuCl4
Reaction optimization towards the formation of bipyridyl ligated Au(III) complexes

is needed to minimize protonolysis and increase yield. Furthermore, understanding the
reactivity of tetrachloroauric acids with N-donor ligands in solution is crucial for effective
utilization of these building blocks in gold chemistry.231, 248-250 Our quest to elucidate the
reactivity of HAuCl4 or NaAuCl4 with N,N-bipyridyl ligands led to the discovery of new
coordinated Au(III) species with gold counter anions ([AuCl2]-) or [AuCl2/AuCl4]-). Mixed
valence Au(I) and Au(III) complexes following the reaction of HAuCl4 with representative
bipyridyl ligands such as phenanthroline demonstrate the broad spectrum of possible
complexes, which require further investigation. Previous reports showed the formation of
[Au(phen)Cl2][AuCl4] or [Au(phen)Cl2]Cl complexes. For example, the reaction by Block
et al. was carried out in ethyl alcohol and heated on a steam cone for 4 h.242 Other methods
have also optimized the methodology by using different solvents, such as acetonitrile or a
mixture of water and ethyl alcohol. Here, we describe a short temperature-controlled
method that leads to the formation of [Au(phen)Cl2]Cl as well as mixed valence
Au(I)/Au(III)

complexes

of

the

type,

[Au(phen)Cl2][AuCl2],

2a

and

[Au(phen)Cl2]2[AuCl2][AuCl4], 2b if no additives are used (Figure 2-2). The solvent used
may likely be a reductant for the described reaction.
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Figure 2-2. Optimization of reaction conditions of NaAuCl4-2H2O with phenanthroline.
For each reaction, an equimolar amount of sodium tetrachloroaurate and phenanthroline
were added together in 10 mL of EtOH and subjected to the above reaction conditions.
The solid was vacuum filtered, washed with excess ether, and vacuum dried in air. 1H
NMR spectra were recorded in DMSO-d6. A) Original methodology reported in the
literature, B) Optimized methodology that allows synthetic control of desired product.
When we reacted HAuCl4·3H2O and 1,10-phenanthroline monohydrate in ethanol
under reflux conditions for 4 h, the yellow-orange precipitates were recrystallized to obtain
a coordinated Au(III) complex with Au(I) counter anions, 2a. Upon analysis of the filtrate
of this reaction using GC-MS (Figure 2-3), an m/z value corresponding to free
phenanthroline was found.
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Figure 2-3. GC-MS of filtrate. GC-MS analysis of the filtrate upon reacting
HAuCl4.3H2O with phenanthroline reveals no Au(I) byproduct.
This reveals that all reduction of Au(III) to Au(I) occurs by means of the ligand and
no other products are formed. Evidence of any other Au(I) species was not found.
Moreover, the isolated yellow precipitate comprised 2a, and a protonated phenanthroline
ligand with an [AuCl4]− counter ion. With the use of 1H NMR, we confirmed the
instantaneous formation of bright yellow precipitates following the addition of an ethanolic
solution of HAuCl4 and phenanthroline at room temperature was the protonated ligand.
This was subsequently confirmed by single-crystal X-ray diffraction. The irreversibility of
the reaction was therefore established by the characterization of products and analysis of
the filtrate. To address the issue of unwanted side products, we resorted to controlling the
temperature and duration of the reaction. Thus, we reasoned that the strong coordinating
effect of N-donor ligands from bidentate species may not warrant high temperatures and
longer reaction times as commonly reported.242 Thus, to an ethanolic solution of HAuCl4
were added respective bipyridyl ligands and the yellow solution was warmed to 75 °C and
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stirred for 30 min. The reaction generated single crystals of both 2a and 2b (Table S-1 and
Figures S-7-1 and S-7-2). All other ellipsoid plots can be found in the APPENDIX 1
(Figures S-7-3 through S-7-10). An equimolar stoichiometric ratio of HAuCl4 and
phenanthroline at 70 °C for 10 minutes makes the formation of [Au(phen)Cl2]Cl, 2d,
possible as confirmed by X-ray crystallography (Table S-2 and Figure S-7-4).
To investigate the effect of alkali salts on the reaction methodology described
(supra), we utilized NaAuCl4·2H2O and phenanthroline as reactants. The reaction of
equimolar amounts of NaAuCl4·2H2O and phenanthroline proceeded in ethanol under
reflux conditions for 4 h. A mixture of coordinated Au(III)-phenanthroline complex and
protonolysis of the phenanthroline ligand were observed (Figure 2-4A). In contrast, the
reaction with phenanthroline and NaAuCl4·2H2O following our methodology yielded
complex 2a exclusively (Figure 2-4B). Regardless of the Au(III) starting material,
protonation of phenanthroline occurred, which can be attributed to the abundance of
protons in the solvent or starting materials. To eliminate protonation from the solvent and
the atmosphere, the same reaction was carried out under inert conditions using dry
acetonitrile. The precipitate obtained again revealed protonation of the phenanthroline
ligand, despite the use of dry conditions. The Au(III) starting material exists as hydrate
salts and is the potential source of protonation.
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Figure 2-4. 1H NMR of compound 2a in DMSO-d6 (green letters) and the protonated
phenanthroline ligand (orange letters) upon reactivity with NaAuCl4-2H2O in DMSO-d6.
A) 1H NMR spectrum recorded after subsequent reaction using the original methodology
reported in the literature. B) 1H NMR spectrum recorded after using an optimized
methodology aforementioned resulting in no unwanted by product formation and thus
less loss of gold material.
Control of counter ions in these gold compounds is essential to avoid the presence
of precious Au-containing counter anions. Potentiation of counter ions can be achieved by
the use of additives to improve ionic strength. We therefore considered the use of
perchlorate or hexafluorophosphate salts as additives and their impact on the formation of
ligated bipyridyl Au(III) complexes. In this approach, we reacted HAuCl4 with
phenanthroline in the presence of ethanol and excess [ClO4]− or [PF6]− salts. The identity
of anions in these compounds was confirmed by X-ray crystallography and NMR in the
case of [PF6]− salt. When the reaction was subjected to high temperature, 100 °C for 4 h,
the protonated N-donor ligand in addition to the expected [Au(phen)Cl2][X], where X is
[ClO4]− or [PF6]−, was formed.
Recrystallization from acetonitrile gave pure [Au(phen)Cl2][X]. This purification
approach is not applicable to complexes with gold counter ions; hence there is a need for
optimization of reaction conditions to access distinct complexes. To avoid the purification
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steps, and improve yields, we subjected the reaction to our temperature-controlled protocol
(72 °C for 30 minutes), giving rise to the desired complexes in approximately 80% yield.
For example, we used [PF6]− as the additive in the synthesis of complexes 2e and 2f, which
bear 4,7-dimethylphenanthroline and 2,2′-bipyridine ligands, respectively. The yields of
these reactions were >80%. Overall, using additives such as [ClO4]−, [PF6]−, or [BF4]−
eliminates the presence of gold-containing sacrificial counter ions.
The pH of a solution of HAuCl4 is acidic, which leads to the instantaneous
formation of the protonated salts. Adjusting the pH to a more basic solution with a 1M
NaOH(ethanol) solution to a pH above 7 resulted in reduction to elemental gold. There is
no optimal pH that controls the amount of protonated salt formed during the reaction;
however, maintaining the pH between 2–5 reduced the formation of the protonated salts
but not completely. Mixed valence Au(III) compounds arise predominantly from reactions
that utilize a slight excess (2.5 equivalents) of HAuCl4. Keeping this stoichiometric ratio
under acidic conditions (pH = 2) results in the formation of [Au(phen)Cl2][AuCl4].
Generally, an equimolar reaction of HAuCl4 and phenanthroline leads to 4 as a bright
yellow solid instead of the yellowish-orange color for mixed valence complexes or Au(III)
compounds with [AuCl2]− or [AuCl4]− counter ions. Solution chemistry studies using
Au(III)dien compounds as well as Au(III)terpyridine showed that pH affects product
formation. Our present studies provide a comprehensive insight into the factors that affect
the reactivity of HAuCl4 with bipyridyl ligands in solution, different products formed, and
ways to access predominantly N,N-bipyridyl Au-ligated complexes.244, 251 The methods
most widely used to obtain [Au(phen)Cl2]Cl and its derivatives in the literature produce
protonated bipyridyl ligands with respective sacrificial gold counter-anions. Furthermore,
we investigated the dependence of pH on product formation and importantly, the
elimination of protonated ligands.
There have been few reports of such protonated ligands in the literature, but our
studies reveal that temperature shifts the equilibrium more to the protonated ligands.252 We
confirmed this by variable temperature NMR studies using a mixture of [Au(phen)Cl2]ClO4
and [Phen-H][ClO4] (Figure S-7-25) in DMSO-d6 from 22 °C to 75 °C and X-ray
crystallography to unambiguously differentiates target compounds from side products.
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2.4

Temperature Dependence and Variable Temperature Studies
Following the reaction of an equimolar ratio of HAuCl4 and phenanthroline in

ethanol for 4 h at 100 °C in the presence of excess additive [ClO4] − or [PF6] −, 10%
protonated ligand was observed by 1H NMR (Figure 2-5). Using variable temperature
NMR, we sought to understand the stability of generated species within the reaction.
Variable temperature 1H NMR studies were performed on a Varian Unity 400 NMR
spectrometer with a Spectro Spin superconducting magnet. Complex 2c was chosen for
VT- 1H NMR studies. The mixture was subjected to variable temperature 1H NMR in
DMSO-d6 from 20 °C – 75 °C. It was observed that at 75 °C there was nearly complete
conversion to the protonated species (Figure 2-5).

Figure 2-5. VT – 1H NMR of complex 2c in DMSO-d6. Different temperature points
were taken to observe conversion of the Au(III) coordination complex (green asterisks) to
the protonated salt of phenanthroline (orange asterisks).
This can be attributed to the cleavage of the Au–N bonds at high temperature and
subsequent protonation of the ligand by water in the NMR solvent or reaction medium. The
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study reveals conversion of the Au(III) complex to its corresponding protonated
phenanthroline salt. The conversion of the gold complex to its corresponding salt was not
affected by the particular counterion present. Taken together, this explains the presence of
high amounts the protonolysis product when reactions are subjected to high temperatures
(100 °C) for 4 h.
2.5

Quantitative Variable Temperature (VT) 1H NMR.
Quantitative VT 1H NMR was performed using 2c to study the change in the amount

of the Au(III) complex and corresponding protonated phenanthroline salt using
trimethoxybenzene (TMB) as the internal standard. For quantification, the most deshielded
proton of 2c (9.71 ppm) or [H-phen][ClO4] (9.32 ppm) was used in reference to the
aromatic peak (6.09 ppm) of trimethoxybenzene (Figures S-7-26 through S-7-30). The
area under each denoted proton was integrated at the same values for the duration of the
experiment. Initially, 0.038 mmol of 2c and 0.051 mmol of the standard were placed in an
NMR tube and subjected to variable temperature studies. After the sample had been heated
to 75 °C and cooled back to room temperature, approximately 0.00 mmol of 2c was found
and 0.038 mmol of the corresponding phenanthroline salt was left in the NMR sample
(Figure 2-6).
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Figure 2-6. Q – VT- 1H NMR of 2c in DMSO-d6 reveals irreversible conversion of the
coordinated Au(III) complex (green bars) to the protonated phenanthroline ligand (orange
bars) in a quantitative amount. Trimethoxybenzene was used as an internal standard for
comparison. Integrations of each peak for reference were maintained the same throughout
the measurements of each spectra using MNOVA NMR processing software.
This reveals that the Au(III) complex is converted to the corresponding
phenanthroline salt in a stoichiometric manner. A plot of mmol versus temperature reveals
rapid conversion of complex 2c to the corresponding protonated salt. Once the NMR
solution had been re-cooled to 25 °C, the solution was subjected to direct temperature ramp
back to 75 °C to study the reversibility of the process. The study showed that 0.038 mmol
of [H-phen][ClO4] was still observed, indicating that even with good mass balance, the
process is irreversible. This explains why a substantial amount of protonated salts can be
found in the crude product for reactions performed under high temperature conditions for
4 h and upon formation, persist in the reaction mixture due to the irreversible nature of the
protonolysis event.
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2.6

Crystal Structures of [Au(phen)Cl2][AuCl2] and
[Au(phen)Cl2]2[AuCl4][AuCl2]
The coordinated phenanthroline Au(III) complex bearing the [AuCl2]− counterion

was solved from a yellow slab, dimensions of 0.060 × 0.050 × 0.030 mm, which was grown
by slow diffusion of diethyl ether into DMF (Figure 2-7).

Figure 2-7. Ellipsoid plot of 2a illustrating stacking of alternating cations and anions
through the c-axis with an inversion center lying on the Au(III) atom of the [AuCl2]counterion. Ellipsoids are drawn at the 50% probability level. Hydrogen atoms are
omitted for clarity.
The structure was refined by full-matrix least-squares to give R1 = 0.0193. This novel
compound also crystallizes in the space group P1� , with an asymmetric unit containing one
coordinated phenanthroline Au(III) complex cation and two half [AuCl2]− anions. The

Au1–N1 (2.037(4) Å) and Au1–N2 (2.041(4) Å) bond lengths are also comparable to the
Au–N bond lengths found in other four-coordinate Au(III) amine complexes, such as
[Au(dien)Cl2] and [Au(en)(SO3)2], which exhibit typical bond lengths between 1.97 and
2.14 Å. The typical Au–Cl bond distance (2.26–2.42 Å) can also be observed for the
structure with each respective Au–Cl bond distance being 2.2571(1) Å and 2.2595(12)
Å.247, 253
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The novel mixed valence Au(III) crystal (0.070 × 0.060 × 0.030 mm) structure (2b)
was solved using MoKα radiation at 90.0(2)K. Structure refinement by full-matrix leastsquares analysis converged to an R1 value of 0.0150. This molecule is shown to crystallize
in the triclinic crystal system, space group P1� . The asymmetric unit of the mixed valence

compound contains one [Au(phen)Cl2]+ cation, half of one [AuCl4]− counterion and half of
a linear [AuCl2]− counterion. Each anion lies on an inversion center, which leads to the
formula [Au(phen)Cl2]2[AuCl4][AuCl2] (Figure 2-8).

Figure 2-8. Ellipsoid plot of 2b illustrating one half of each counterion ([AuCl4]- and
[AuCl2]- in the unit cell through the b-axis with an inversion center lying between the two
cationic units. Each counterion lies between two inversion centers giving an extended
linear geometry and even spacing of each respective cation in the crystal lattice.
Ellipsoids are drawn at the 50% probability level. Hydrogen atoms are omitted for clarity.
2.7

Conclusion
In summary, we used a rapid temperature-controlled method to synthesize new N,N-

bipyridyl ligated Au(III) centers with mixed valence character. The approach circumvents
protonated bipyridyl salts that compete with the desired product following literature
protocols that use high temperature for 4 h. X-ray crystallography sheds light on the
structural character of these complexes, particularly on those with gold counteranions.
Complexes 2a and 2b crystallize in a unit cell with low symmetry in comparison with 2e
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and 2f, which crystallize in a monoclinic crystal system. Complex 2c exhibits a much
higher order of symmetry, space group Pbca, and is consistent with 2f, which has been
reported by Ferraz de Paiva et al.254 All crystallographic parameters and refinement details
can be found in APPENDIX 1 (Table S-1 through Table S-4). Additionally, variable
temperature 1H NMR studies support the rationale for the studies as high temperatures shift
the equilibrium to the formation of protonated bipyridyl salts over the desired coordinated
products and that the process is irreversible. This report offers a facile and relatively fast
method to access mononuclear Au(III) complexes bearing N,N-bidentate ligands and
reactivity of HAuCl4 in solution without protonolysis.
2.8
2.8.1

Experimental Details
General Experimental Details
All reagents were purchased from Oakwood chemicals, VWR, Acros Organics, Alfa

Aesar, and TCI and used as received. All reactions were carried out under normal
atmospheric conditions in a fume hood. Compounds 2a-f were synthesized by a rapid
temperature-controlled protocol utilizing a Variac temperature controller in combination
with a thermostat inside a reflux condenser. Protonated compounds were formed by
following literature procedures.255-257
2.8.2

Physical Measurements
Deuterated solvents were purchased from Cambridge Isotope Laboratories

(Andover, MA). 1H NMR spectra were recorded on a Varian Unity 400 NMR spectrometer
with a Spectro Spin superconducting magnet in the University of Kentucky NMR facility.
Chemical shifts in 1H NMR spectra were internally referenced to solvent signals (1H NMR:
DMSO-d6 at δ = 2.50 ppm and CD3CN at δ 1.94 ppm; 13C NMR: DMSO-d6 at δ = 39.52
ppm and CD3CN at δ = 118.7 ppm, 1.39 ppm) and those in
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P NMR spectra were

externally referenced to 85% H3PO4 in D2O (δ = 0 ppm). Electrospray ionization mass
spectrometry (ESI-MS) was performed on an Agilent Technologies 1100 series liquid
chromatography/MS instrument. High-resolution mass spectra (HRMS) were obtained by
direct flow injection (injection volume = 5 or 2 μL) ElectroSpray Ionization (ESI) on a
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Waters Qtof API US instrument in the positive mode (CIC, Boston University). Typical
conditions are as follows: capillary = 3000 kV, cone = 35 volts or 15 volts, source
temperature = 120 °C, and desolvation temperature = 350 °C. Elemental analyses for
compounds 2b, 2e and 2g were performed by Atlantic microlabs (commercial laboratory
in Norcross, GA).
2.8.3

Synthesis of [Au(phen)Cl2][AuCl2] (2a)
Phenanthroline monohydrate (267 mg, 1.35 mmol) was added to a solution of

tetrachloroauric(III) acid trihydrate (197 mg, 0.5 mmol) in 10 mL of ethanol. The solution
was placed on a rotary evaporator and heated at 72 °C for 10 minutes. The precipitate that
formed changed color from yellow to orange within the course of the reaction. The
precipitate was filtered and washed with ether (10 mL × 3). Crystals were grown using
DMF/ether. Yield: 307 mg, 80%. 1H NMR (400 MHz, MeCN-d3) δ 9.66 (d, J = 4.4 Hz,
2H), 9.16 (d, J = 7.2 Hz, 2H), 8.38 (s, 2H), 8.30 (t, J = 7.2 Hz, 2H). 13C NMR (400 MHz,
DMSO-d6) δ 148.60, 148.13, 145.01, 132.96, 129.41, 128.03. MS (m/z, HRMS): [M + H].
Calcd. for C12H8N2Cl4Au2 716.8821, found 716.8822.
2.8.4

Synthesis of [Au(phen)Cl2]2[AuCl4][AuCl2] (2b)
Phenanthroline monohydrate (557 mg, 2.81 mmol) and tetrachloroauric(III) acid

trihydrate (539.5 mg, 1.37 mmol) were added together in 35 mL of ethanol. A yellow
precipitate formed immediately and the solution was placed on a rotary evaporator and
heated at 72 °C for 10 minutes. The color of the precipitate turned from yellow to orange
and the reaction was stopped after 30 min. Yield: 58 mg, 11%. 1H NMR (400 MHz, MeCNd3) δ 9.66 (d, J = 6.0 Hz, 2H), 9.16 (d, J = 8.4 Hz, 2H), 8.38 (s, 2H), 8.30 (t, J = 7.2 Hz,
2H). 13C NMR (400 MHz, DMSO-d6) δ 156.12, 147.47, 146.07, 130.05, 127.04, 123.40.
Anal calcd. for C12H8Au2Cl5N2: C, 19.18; H, 1.07; N, 3.73. Found: C, 19.57; H, 1.33; N,
3.93.
2.8.5

Synthesis of [Au(phen)Cl2][ClO4] (2c)
Phenanthroline monohydrate (60.4 mg, 0.305 mmol) and tetrachloroauric(III) acid

trihydrate (100 mg, 0.254 mmol) were added to 10 mL of ethanol and sonicated for 10
41

minutes. Sodium perchlorate (93 mg, 0.762 mmol) was added to the mixture and further
sonicated for 5 min. The solution was refluxed at 80 °C for 12 h. The precipitate was
filtered and washed with ether. Crystals were grown by slow diffusion of DMF/ether. Bulk
purification was achieved by dissolving the crude solid in acetonitrile followed by
centrifugation of the undissolved salt. The solution was then decanted out and dried under
vacuum to give complex 2c. Yield: 92 mg, 62%. 1H NMR (400 MHz, MeCN-d3) δ 9.67 (d,
J = 4.0 Hz, 2H), 9.15 (d, J = 4.0 Hz, 2H), 8.38 (s, 2H), 8.33 (t, J = 1.6 Hz, 2H). 13C NMR
(400 MHz, DMSO-d6) δ 148.60, 148.1, 145.0, 132.96, 129.41, 128.07.
2.8.6

Synthesis of [Au(phen)Cl2][Cl] (2d)
To an ethanolic solution (14 mL) of tetrachloroauric(III) acid trihydrate (199 mg,

0.51 mmol) was added phenanthroline monohydrate (202 mg, 1.02 mmol) and placed on
the rotovap. While stirring, the solution was heated to 72 °C for 30 min. The solution was
cooled and then filtered to leave behind a light-orange colored solid. The collected solid
was washed with ether and ethanol and dried under vacuum. Yield: 76 mg, 31%. 1H NMR
(400 MHz, DMSO-d6) δ 9.70 (d, J = 4.0 Hz, 2H), 9.36 (d, J = 4.0 Hz, 2H), 8.53 (s, 2H),
8.43 (t, J = 16.0 Hz, 2H).

13

C NMR (400 MHz, DMSO-d6) δ 148.08, 142.47, 137.87,

130.07, 128.02, 126.21. Anal calcd. for C12H8AuCl3N2: C, 29.81; H, 1.67; N, 5.79.
Found: C, 30.05; H, 1.66; N, 5.75.
2.8.7

Synthesis [Au(4,7-dmp)Cl2][PF6] (2e)
4,7-Dimethylphenanthroline,

tetrachloroauric(III)

acid

trihydrate

(4,7-dmp),
(503

mg,

(319.7
1.28

mg,
mmol),

0.141
and

mmol),

ammonium

hexafluorophosphate (417 mg, 2.56 mmol) were dissolved in 25 mL of an ethanol/water
mixture 2 : 1 and sonicated for 1 min. The mixture was placed on a rotovap and heated at
72 °C while rotating for 30 minutes. The solution was cooled and filtered to leave behind
a dull yellow solid, which was washed with ethanol (10 mL × 3) and then with ether (10
mL × 3). Yield: 725 mg, 81%. 1H NMR (400 MHz, DMSO-d6) δ 9.55 (d, J = 8.0 Hz, 2H),
8.57 (s, 2H), 8.27 (d, J = 8.0 Hz, 2H), 3.09 (s, 6H).

13

C NMR (400 MHz, DMSO-d6) δ

156.72, 147.67, 145.47, 132.38, 127.94, 126.34, 19.78. 31P NMR (400 MHz, DMSO-d6) δ
−130.66, −135.05, −139.44, −143.84, −148.23, −152.62.
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2.8.8

Synthesis of [Au(bpy)Cl2][PF6] (2f)
Bipyridine (207.1 mg, 1.33 mmol), tetrachloroauric(III) acid trihydrate (469.8 mg,

1.19 mmol), and ammonium hexafluorophosphate (392.5 mg, 2.41 mmol) were dissolved
in 16 mL of a 2 : 1 ethanol/water mixture and sonicated for 1 min. The mixture was placed
on a rotovap and heated at 72 °C while rotating for 30 minutes. The solution was cooled
and filtered to leave behind a bright, fluffy yellow powder, which was washed with ethanol
(10 mL × 3) and then with ether (10 mL × 3). Yield: 529 mg, 84%. 1H NMR (400 MHz,
DMSO-d6) δ 9.41 (d, J = 4.0 Hz, 2H), 8.93 (d, J = 8.0 Hz, 2H), 8.40 (t, J = 8.0 Hz, 2H),
8.14 (t, J = 8.0 Hz, 2H). 13C NMR (400 MHz, DMSO-d6) δ 156.12, 149.84, 147.70, 147.47,
146.07, 141.99, 130.05, 127.04, 126.91, 123.40.
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P NMR (400 MHz, DMSO-d6) δ

−130.66, −135.05, −139.44, −143.84, −148.23, −152.62.
2.8.9

Synthesis of [Au(phen)Cl2][PF6] (2g)
Phenanthroline monohydrate (172.3 mg, 0.870 mmol), tetrachloroauric(III) acid

trihydrate (302 mg, 0.767 mmol), and ammonium hexafluorophosphate (258.8 mg, 1.59
mmol) were dissolved in 20 mL of a 2 : 1 ethanol/water mixture and sonicated for 1 min.
The mixture was placed on a rotovap and heated at 72 °C while rotating for 1.5 hours. The
solution was cooled and filtered to leave behind a bright yellow solid, which was washed
with ethanol (10 mL × 3) and then with ether (10 mL × 3). Yield: 287 mg, 63%. 1H NMR
(400 MHz, MeCN-d3) δ 9.69 (d, J = 8.0 Hz, 2H), 9.17 (d, J = 8.0 Hz, 2H), 8.40 (s, 2H),
8.34 (t, J = 6.0 Hz, 2H). 13C NMR (400 MHz, DMSO-d6) δ 148.22, 142.61, 138.01, 130.21,
128.16, 126.36. 31P NMR (400 MHz, MeCN-d3) δ −135.41, −139.80, −144.19, −152.98,
−157.36. Anal calcd. for C12H8AuCl2N2PF6: C, 24.30; H, 1.36; N, 4.72. Found: C, 24.57;
H, 1.33; N, 4.73.
2.8.10 Synthesis of [H-phen][AuCl4]
Phenanthroline monohydrate (0.620 mmol) and tetrachloroauric(III) acid trihydrate
(0.507 mmol) were added to 10 mL of ethanol and sonicated for 10 min. Sodium
perchlorate or ammonium hexafluorophosphate (1.524 mmol) was added and the mixture
was further sonicated for 5 minutes. The solution was refluxed at 85 °C for 4 hours. The
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solid collected was dissolved in DMF and ether was slowly diffused into the solution. Two
types of crystals were isolated and examined by X-ray diffraction. The two structures found
were 2c or 2g and the protonated phenanthroline gold salt.
2.8.11 Tuning Reactivity with NaAuCl4-2H2O
Both experimental conditions were performed in a standard reflux setup under
ambient conditions. In each case, phenanthroline monohydrate (50 mg, 0.25 mmol) was
added to a solution of NaAuCl4-2H2O (100 mg, 0.25 mmol) in 10 mL of EtOH. Depending
on the reaction type, the reactions were refluxed for either 30 minutes or 4 hours. After the
reaction was complete, the solid was vacuum filtered, washed with ether, and dried in air
to afford pale yellow solids. 1H NMR was taken of each solid to determine extent of side
product formation.
2.8.12 pH Dependence on Product Formation
In each case, phenanthroline monohydrate (267 mg, 1.35 mmol) was added to a
solution of HAuCl4-3H2O (197 mg, 0.5 mmol) in 10 mL of EtOH. The pH of each reaction
was adjusted to either pH = 2 (intial pH of the solution), or pH = 5, 7 using a 1M solution
of NaOH in EtOH. At a pH of 7, the reaction turned dark brown/purple and the round
bottom flask exhibited signs of deposition of colloidal gold.
2.8.13 Q – VT – 1H NMR
In an Eppendorf tube, trimethoxybenzene (8.7 mg, 0.051 mmol) and compound 2c
(20.7 mg, 0.038 mmol) were dissolved in 0.5 mL of DMSO-d6. The solution was placed
into an NMR tube and recorded on were recorded on a Varian Unity 400 NMR
spectrometer with a Spectro Spin superconducting magnet. Temperature ramping was
performed over 10 minutes. When the sample was re-cooled to room temperature,
acquisition was held until 10 minutes after the temperature reading on the instrument read
25 °C to ensure the sample had completely cooled. Prior to acquiring each spectrum, the
sample was re-locked and shimmed at each temperature. 128 scans were used for each
spectra. Integration ranges were held consistent for each spectra when calculating the mmol
compared to the internal standard. Initial total mass and final total mass were consistent
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indicating no mass loss/gain during the course of the experiment to further validate the
quantitative nature of the experiment.
2.9

X-ray crystallography
Crystals of 2a-g (see APPENDIX 1 for table and figures: Tables S-1 through S-4;

Figures S-7-1 through S-7-10) were grown at room temperature by vapor diffusion of
diethyl ether into a DMF or MeCN solution of each complex. All crystals were mounted
using polyisobutene oil on the tip of a fine glass fibre, which was fastened in a copper
mounting pin with an electrical solder. It was placed directly into the cold gas stream of a
liquid-nitrogen based cryostat.258,

259

A Bruker D8 Venture diffractometer with

gradedmultilayer focused MoKα X-rays (λ = 0.71073 Å) was used to collect diffraction.
Raw data were integrated, scaled, merged, and corrected for Lorentz-polarization effects
using the APEX3 package.260-262 Space group determination and structure solution and
refinement were carried out with SHELXT and SHELXL, respectively.263-265 All nonhydrogen atoms were refined with anisotropic displacement parameters. Hydrogen atoms
were placed at calculated positions and refined using a riding model with their isotropic
displacement parameters (Uiso) set to either 1.2Uiso or 1.5Uiso of the atom to which they
were attached. Ellipsoid plots were drawn using SHELXTL-XP.265 The structures,
deposited in the Cambridge Structural Database, were checked for missed symmetry,
twinning, and overall quality with PLATON, an R-tensor, and finally validated using
CheckCIF.266, 267
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CHAPTER 3. CANCER CELL-SELECTIVE MODULATION OF MITOCHONDRIAL RESPIRATION
AND METABOLISM BY POTENT ORGANOGOLD(III) DITHIOCARBAMATES
The text and figures within this chapter were reproduced by permission of The Royal
Society of Chemistry. Reference: R. T. Mertens, S. Parkin and S. G. Awuah, Chem. Sci.,
2020, 11, 10465. DOI: 10.1039/D0SC03628E.
3.1

Preface
Metabolic reprogramming is a key cancer hallmark that has led to the therapeutic

targeting of glycolysis. However, agents that target dysfunctional mitochondrial respiration
for targeted therapy remains underexplored. We report the synthesis and characterization
of ten (10) novel, highly potent organometallic gold(III) complexes supported by
dithiocarbamate ligands as selective inhibitors of mitochondrial respiration. The structure
of dithiocarbamates employed dictates the biological stability and cellular cytotoxicity.
Most of the compounds exhibit 50% inhibitory concentration (IC50) in the low-micromolar
(0.50–2.9 μM) range when tested in a panel of aggressive cancer types with significant
selectivity for cancer cells over normal cells. Consequently, there is great interest in the
mechanism of action of gold chemotherapeutics, particularly, considering that DNA is not
the major target of most gold complexes. We investigate the mechanism of action of
representative complexes in the recalcitrant triple negative breast cancer (TNBC) cell line,
MDA-MB-231. Whole-cell transcriptomics sequencing revealed genes related to three
major pathways, namely: cell cycle, organelle fission, and oxidative phosphorylation.
Compound 3f irreversibly and rapidly inhibits maximal respiration in TNBC with no effect
on normal epithelial cells, implicating mitochondrial OXPHOS as a potential target.
Furthermore, the modulation of cyclin dependent kinases and G1 cell cycle arrest induced
by these compounds is promising for the treatment of cancer. This work contributes to the
need for mitochondrial respiration modulators in biomedical research and outlines a
systematic approach to study the mechanism of action of metal-based agents.
3.2

Introduction
Developing next generation metal-based drugs that exploit the cancer cell

vulnerabilities will offer more effective therapies and tools to study the disease. Tumors
harbor inherent complexities that present therapeutic challenges and evasion of the
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physiological machinery to fix the neoplastic disease state.268 The biological hallmarks of
cancer, which define alterations in cell physiology to promote tumor growth include, (i)
insensitivity to growth-inhibitory (antigrowth) signals, (ii) evasion of programmed cell
death (apoptosis), (iii) limitless replicative potential, (iv) sustained angiogenesis, (v) tissue
invasion & metastasis, (vi) avoiding immune destruction, (vii) reprogramming of energy
metabolism with genetic instability and tumor-promoting inflammation as primary
drivers.268-270 The complexities however present opportunities for targeted therapy. The
redox properties of transition metal constructs, can influence metabolic reprogramming of
cancer cells given the inherent redox activity associated with bioenergetics and
mitochondrial processes such as the electron transport chain (ETC).271-273 Metabolically
active tumors are addicted to glycolysis (known as the Warburg effect) and this has been
exploited therapeutically through inhibition of glucose metabolism and the use of 2-deoxy2-fluoro-D-glucose (FDG-PET) to detect tumors.274-277 Additionally, many tumor types
depend on OXPHOS (oxidative phosphorylation), an electron transfer chain driven by
substrate oxidation that is coupled to the synthesis of ATP through an electrochemical
transmembrane gradient to coordinate their bioenergetic states and promote
proliferation.278, 279
Over 50% of cancer patients receive platinum agents worldwide.280 Platinum are
particularly effective in bladder and testicular cancers.76, 281 Although widely used in other
cancer types such as colon and ovarian, their response rate is stymied by recurrence due to
acquired and innate mechanisms.282-284 The discovery of new transition metal complexes
with new biological targets and mechanism of action have become alternate strategies to
improve treatment outcomes.285, 286 Gold (Au) is a third-row transition metal just like
platinum which can be tolerated in humans as displayed in the FDA approved drug,
auranofin.44, 287, 288 Both Au(I) and (III) complexes have gained considerable interest over
the years as anticancer agents with preferential targeting of mitochondria, thioredoxin
proteasome, and inducing endoplasmic reticulum stress.60,

92, 96, 105, 106, 121, 289-291

Gold

complexes with multifaceted target mechanisms to evade resistance pathways are
attractive.
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Renewed interest in Au(III) as antitumor agents in recent reports since the mid1970’s attest to their high cytotoxicity, reduced cross-resistance with cisplatin, and
tolerance in tumor-bearing mice.9,
pyridylmethanol,

60, 68, 292-294

Among such complexes are Au(III)-2-

Au(III)dichloro(N-ethylsalicylaldiminate),

Au(III)-phosphine,

cyclometalated Au(III), and Au(III)-dithiocarbamates to name a few (Figure 3-1).9, 111, 112,
117, 119, 120, 122, 129, 139, 158, 160, 163, 239, 293, 295-299

Whereas different classes of Au(III) -

dithiocarbamates display promising anticancer activity in vitro and in vivo the mechanism
of action is not well elucidated.122, 300

Examples of C^N Au(III) Complexes
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Figure 3-1. Examples of cyclometalated [C^N] Au(III) complexes.
Herein, we report the synthesis of Au(III) dithiocarbamates that incorporate arylpyridine cyclometalation [C^N] ligands to improve complex stability and different
aryl/alkyl dithiocarbamate ligands for structure activity relationship (SAR). The
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compounds display higher potency in a panel of cancer cells than cisplatin. Using detailed
HPLC, spectrometry, and cyclic voltammetry we identified the active gold(I) cytotoxic
agent. We investigated the mechanism of action using a systems and functional biology
approach that established induction of mitochondria membrane depolarization with
subsequent modulation of oxidative phosphorylation in cancer cells. Altogether, our
studies show that compound 3f exploits cancer cell vulnerability via disruption of
mitochondrial respiration. These compounds exhibit significant depolarization of the
mitochondrial membrane and as such, ROS production is observed as a byproduct. It is
possible that compound 3f reacts with a nucleophilic side chain of its protein target within
the oxidative phosphorylation machinery.
3.3

Synthesis and Characterization
The [C^N]-cyclometalated gold(III) compounds were synthesized from previously

reported methods.301 Treatment of [C^N]Au(III)Cl2 with dithiocarbamate ligands in
methanol for 16 h at room temperature followed by treatment with an aqueous saturated
solution of NH4PF6 gave the desired compounds in respectable yields (Figure 3-2).
A)
O

1. R
Cl

Au

N
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S

S
N
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MeOH, rt, 16h

2. NH4PF6(sat.)

Cl

H

Au

N
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2O
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3a-e (2-benzoylpyridine)
3f-j (2-benzylpyridine)

PF6

N

R

3a-j

B)

R Groups
N

N

N

N

N

Br

N

N

O

Figure 3-2. Synthesis of cyclometalated [C^N] Au(III) dithiocarbamates. Complexes 3ae bear the (2-benzoylpyridine) framework while complexes 3f-j bear the (2benzylpyridine) framework. A) Synthetic scheme to generate [C^N] cyclometalated
Au(III) dithiocarbamate complexes. B) Diversity of dithiocarbamate ligands used in this
study.
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We characterized all 10 compounds (3a-j) by 1H-NMR, 13C NMR, and 19F NMR and
high-resolution mass spectrometry (HRMS). The purity of the compounds was verified by
HPLC (>95%). In this study, we sought to expand the structural architecture of Au(III)
dithiocarbamate complexes to include cyclic and aromatic side chains in addition to
cyclometalation, which provide stabilization by strong sigma-donation to the gold
center.302, 303 We and others have demonstrated that this stabilization strategy has positive
implications on the solution chemistry, biological and electrochemical behavior of
complexes.304 Two different [C^N]Au(III)Cl2 complexes with electronic variations were
used in the synthesis with the aim of establishing structural diversity.
Complexes Used in this Study
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Figure 3-3. SAR library of cyclometalated Au(III) dithiocarbamates used in this study.
Complexes 3a-e possess a carbonyl at the methine bridge of the benzylpyridine
framework, whereas 3f-j do not. Studies from our laboratory show that the difference
impart unique reactivity and kinetics towards nucleophiles. Alternate metal-based drugs to
platinum, the first-line of chemotherapy for several cancer types are desperately needed to
overcome the toxicity and resistance associated with platinum drugs.71,

305-308

Gold

compounds including auranofin have been used in preclinical and clinical trials with great
promise.58, 89, 309-311 A more systematic design and the elucidation of the mechanism of
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action of gold compounds will expand the utility of well-defined gold anticancer drug
candidates with reduced susceptibility to resistance and toxic side effects.
In this work, we developed a small library of gold(III) dithiocarbamate compounds
supported by different cyclometalated and dithiocarbamate ligands to obtain cationic
complexes complemented by hexafluorophosphate ions (Figure 3-3). Structural diversity
was achieved by using two different cyclometalated gold(III) starting materials and five
dithiocarbamate ligands of distinct structural and electronic variety. Consequently, the
library enabled us to explore the biological activity of novel gold(III) dithiocarbamates in
the context of cancer as described in this report.
3.4

Single Crystal X-ray Diffraction
Single crystals of compounds 3c, 3f, 3g, 3h, and 3j (3f depicted in Figure 3-4, all

other crystal structures can be found in Figures S-7-11 through S-7-15, all parameters can
be found in Tables S-4 through S-6), were grown by slow diffusion of Et2O into a
concentrated MeCN solution at room temperature.

Figure 3-4. Single crystal X-ray diffraction of complex 3f. All ellipsoids are drawn at the
50% probability level. Hydrogens are removed for clarity. Full crystallographic
parameters can be found in Table S-4.
Compounds 3f, 3g, 3h, and 3j crystallize out in the solid state with one molecule per
asymmetric unit while compound 3c contains two cation/anions pair. The perchlorate
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analogue ([ClO4]-) of 3g was also synthesized and solved with single crystal X-ray
diffraction (Figure S-7-13); however, due to poorer solubility, the [PF6]- analogues were
pursued. Each cyclometalated ligand, 2-benzylpyridine and 2-benzoylpyridine have a
slightly puckered twist. The bridging methine carbon allows for the formation of a 6membered ring containing the Au atom, leading to a less strained cyclometalated system.
Each molecule is distorted around the Au–C and Au–N bonds resulting in half occupancy
among the two atoms. Analyzing the bonding motif of the [C^N] framework reveals a
significant trans-effect on the binding dithiocarbamate ligand. The Au–S bond trans to the
nitrogen of the [C^N] ligand is significantly shorter (on average 0.156 Å) than the Au –S
bond trans to the carbon (Table 3-1). This results in a slightly distorted square planar
geometry around the Au(III) center in comparison to other Au(III) bis-dithiocarbamate
complexes bearing symmetrical dithiocarbamate ligands which contain four Au–S bonds
equidistant to one another (~2.33 Å).129, 312
Table 3-1. Selected interatomic distances of 3c, 3g, 3h, 3i, and 3j.

Bond (Å)

Compound
3c

3g

3h

3i

3j

Au - C

2.042 (19)

2.043 (3)

2.061 (5)

2.042 (3)

2.045 (19)

Au - N

2.062 (18)

2.071 (2)

2.065 (5)

2.065 (3)

2.069 (17)

Au - S

2.283 (8)

2.280 (7)

2.278 (16)

2.276 (9)

2.298 (5)

2.376 (9)

2.404 (8)

2.392 (14)

2.499 (8)

2.379 (5)

(trans to N)
Au - S
(trans to C)

3.5

Photophysical and Solution Chemistry
We first evaluated the photophysical properties of all ten complexes by scanning

their absorption profile in DMSO (Figure 3-5). A stock solution of each complex was
prepared and diluted to a final concentration of (50 mM). The UV-vis spectra were then
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obtained by scanning from 600 to 200 nm. Each complex displayed similar absorption
profiles with a high-energy transition at 260 nm and a corresponding lower energy
transition at 295– 305 nm. The high-energy transition at 260 nm can be attributed to
intraligand transitions of the 2-benzylpyridine or 2-benzoylpyridine fragments in the [C^N]
ligands. The low-energy transition is attributed to ligand-to-metal-charge transfer from the
donor dithiocarbamate ligand to the electrophilic Au(III) metal center.112 The different

N o r m a liz e d A b s o r b a n c e ( a .u )

dithiocarbamate ligands utilized had minimal effect on the measured absorbance.
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Figure 3-5. Photophysical behavior of 3a-j in DMSO. UV-vis spectra were recorded at a
final concentration of 50 μM.
We next evaluated the stability of all ten complexes in three relevant biological
media, namely, PBS (phosphate-buffered saline), DMEM (Dulbecco's modified eagle
medium), and RPMI-1640 (Roswell Park Memorial Institute-1640). RPMI-1640 contain
several biological nucleophiles such as amino acids and extracellular relevant levels of
GSH, which are common sources of reductants. Development of new drug molecules
require proper characterization of compound stability in solution. To evaluate their
stability, the complexes were prepared as a stock solution in DMSO (5 mM) and diluted
with PBS or DMEM at room temperature to a final concentration of 50 mM. Upon addition
of the stock solution to the aqueous based medium, no precipitation was observed.
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Complex 3f displayed higher stability in PBS, and DMEM at 37 °C in comparison to
RPMI-1640 (Figure 3-6).

Figure 3-6. Solution chemistry of 3f. A) Stability of 3f (50 μM) in PBS over 24 hours, B)
Stability of 3f (50 μM) in DMEM over 24 hours, C) Stability of 3f in RPMI-1640 over 24
hours. All experiments were conducted at 37 °C.
The solution stability of the other 9 complexes can be found in APPENDIX 3
(Figures S-7-31 through S-7-39 (PBS), Figures S-7-40 through S-7-48 (DMEM), and
Figures S-7-49 through S-7-57 (RPMI-1640)). After 24 h, no significant decrease in
absorbance was observed for compound 3f in DMSO, DMEM, or PBS. The cyclic
dithiocarbamate ligands used, especially complexes bearing the phenyl-substituted
piperazine moiety demonstrated reduced stability in comparison to the alkyl substituted
dithiocarbamates over 24 h. Although no deposition of elemental gold was observed, UVvis analysis showed a significant decrease in absorption. We attribute the reduced stability
of these complexes to the longer Au–S bond distances (2.298 Å (5)) trans to the aromatic
nitrogen of the cyclometalated ligand, indicative of a weaker bond. This in addition to the
other electronic factors promote facile reactivity with nucleophiles, hence the instability.
Also, X-ray crystallography reveals the (4-methoxyphenyl)piperazine dithiocarbamate as
an elongated moiety with a puckered square planar geometry. Elongation of the ligand
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likely weakens the Au–S bonds, which reduces stability to nucleophiles in the medium
used. Overall, alkyl substituted gold dithiocarbamates, 3a and 3f show stability in
biologically relevant media over extended periods of time and are promising candidates for
further studies.
3.6

Reactivity of Au(III) Dithiocarbamates with Cysteine Thiols
After establishing the stability of complexes, 3a and 3f in biological buffer, DMEM,

and RPMI-1640 solutions, we investigated the reactivity of 3f with cysteine thiols using Lglutathione (GSH) and L-N-acetyl cysteine as a models (Figure 3-7A). Reactivity of 3a-e
and 3f-j with both GSH and NAC can be found in APPENDIX 3 (Figures S-7-58 through
S-7-67 (GSH) and Figures S-7-68 through S-7-77 (NAC)). Whereas gold dithiocarbamates
are known to react with thiols, detailed studies to unravel the potential mechanism of
activity do not exist.117, 120, 122, 129, 313 HPLC trace of the reaction solution revealed one
distinct band at a different retention time (Rf – 5.00 minutes) from 3f (Rf – 6.03 minutes)
or GSH (Rf – 1.72 minutes) (Figure 3-7B). We subjected the reaction solution of 3f with
GSH to LC-MS analysis (Figure 3-7C and Figure S-7-78), which supported the formation
of a new species with a mass peak at m/z 791, attributable to a gold(I) disulfide species,
[Au(C^N)(DTC)–GSH] (Figure 3-7C), which is short-lived under ESI-MS conditions due
to the labile disulfide bond formed between the thiol of L-GSH and the dithiocarbamate
ligand of the gold complex (Figure 3-7A). Thus, a more dominant mass peak at m/z 485,
attributable to an intact gold complex with liberated L-GSH is observed. 1H NMR
spectroscopy revealed the farthest downfield-shielded peak (δ = 9.03 ppm), which is the
hydrogen located next to the nitrogen in the cyclometalated-ligand, was significantly
shielded upfield in the adduct solution (Figure 3-7A and Figures S-7-79 and S-7-80). We
attribute this to the loss of coordination from the nitrogen of the cyclometalated ligand to
gold, a key signature of the proposed adduct. We then confirmed the formation of the
gold(I) complex by cyclic voltammetry (Figure 3-7C), displaying a reduction potential of
-1.20 V that is consistent with a gold(I) species (see APPENDIX 3, Figures S-7-81
through S-7-84 for controls).15, 314, 315 We evaluated the effect of the 3f-GSH adduct on
breast cancer cells and found similar toxicity (IC50 – 0.53 μM (Figure S-7-85 as reported
in Table 3-2 below)). Taken together, we have further elucidated the reactivity of [C^N]
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gold(III) dithiocarbamates with representative thiols. Interestingly, the reduced gold(I)
compound display high anticancer activity.

Figure 3-7. Elucidation of the Au(III) – thiol adduct. (A) Proposed reaction scheme of
compound 3f and GSH in an equimolar ratio, (B) HPLC chromatograms of 3f, GSH, and
the reaction of 2f + GSH adduct (λ = 240 nm) (C) LC-MS of the 3f + GSH adduct (λ =
280 nm) and cyclic voltammetry of 3f + GSH (I = Au(I) to Au(0), II = oxidation of the
dithiocarbamate ligand, III = oxidation of GSH).
3.7

Cellular Uptake
We next performed cellular uptake studies to determine what percentage of the

compounds were getting into the cell after treatment. Given that most therapeutic targets
are localized receptors on the plasma membrane, quantifying the amount of gold
compounds in cellular fractions and investigating their mode of uptake is crucial. For
whole-cell uptake studies, MDA-MB-231 were treated with all 10 compounds and
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auranofin at 5 μM for 24 h (Figure 3-8A). Auranofin is the only gold-based therapeutic to
be clinically approved, therefor we used this drug as a benchmark for comparison.311 After
treatment, the cells were washed with PBS, centrifuged, and digested with 0.5 mL of conc.
HNO3 and diluted with DI water and subjected to ICP-OES analysis. All ten compounds
exhibited intracellular uptake above 2000 pmol per million cells. In comparison to
auranofin, none of the complexes exhibited higher uptake, however; the complexes 1a and
3f had uptakes (3017 pmol per million cells) and (3267 pmol per million cells) respectively.
Complexes 3c–e and 3h–j, which contain more hydrophobic R groups such as the
piperadine and phenyl substituted piperazine handles, exhibited lower intracellular uptake
than the complexes with the less hydrophobic shorter alkyl (methyl and ethyl) handles.
Further evaluation revealed that >90% of the Au content was found localized in the
cytoplasm (Figure 3-8B) and total membrane fraction (pellet). Given that these complexes
readily react with nucleophilic biological molecules and the lack of accumulation in the
nuclear fraction, it is evident that the mechanism of action of this class of compounds is
differentiated from the clinically available platinum agents.
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Figure 3-8. Cellular uptake and uptake mechanism. Cells were seeded at density of 1 x
106 cells for whole cell uptake, 3 x 105 for pathway dependent cell uptake and 2 x 106 for
cell fraction uptake. A) A) Intracellular uptake of 3a-j as well as auranofin. Cells were
treated for 24 h (5 μM), data are plotted as the mean ± s.e.m. (n=3), B) Cell fraction
uptake of 3f at 5 μM for 24 hours, data are plotted as the mean ± s.e.m. (n=3), ***
denotes value lower than the detection limit of the instrument (5 μg/L), C) whole cell
uptake of 3f for 24 h (5 μM) against pre-treatment with uptake inhibitors, data are plotted
as the mean ± s.e.m. (n=3). Calibration curves can be found in Figures S-7-109 through
S-7-111 in APPENDIX 3.
To understand cell uptake mechanisms, detailed uptake studies using GF-AAS were
conducted whereby MDA-MB-231 cells were incubated with gold compound, 3f after
cellular pretreatment with one of a number of known inhibitors of cellular uptake. Sodium
azide (NaN3), which is known to inhibit mitochondrial oxidative phosphorylation, was
used as a general inhibitor of energy (ATP)-dependent (active) uptake; chlorpromazine
(CL) was utilized as an inhibitor of clathrin-dependent endocytosis (CDE); β-cyclodextrin
(Me-β-CD) and genestein (Gen) were used as inhibitors of clathrin-independent
endocytosis (CIE); and, wortmannin (Wort) was employed as a known inhibitor of
micropinocytosis. We found that the uptake of 3f was significantly decreased with all
inhibitors with the exception of NaN3 (Figure 3-8C). Being an ATP-dependent pathway
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illustrates that these compounds are not dependent on oxidative phosphorylation for
uptake, despite; their ability to modulate OXPHOS. Overall, these ten Au(III) complexes
demonstrate relatively high intracellular uptake which can explain the high in vitro
cytotoxicity as well as the rate at which cellular bioenergetics are affected.
3.8

Anticancer Activity In Vitro
All the gold(III) dithiocarbamate compounds display remarkable cell killing

potential in a panel of breast, ovarian, lung and leukemia cancers. Preliminary studies
focused on different cancer cell lines (MDA-MB-231, MDA-MB-175, and A2780), an
immortalized normal retinal epithelial cell line (RPE-NEO) and human fetal lung
fibroblasts (MRC5) (Figures S-7-96 through S-7-105). These adherent cells were exposed
to a serial-diluted concentration of all ten compounds for 72 h. The cells were subsequently
treated

with

3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium

bromide

(MTT)

solutions, dissolved with DMSO and the absorbance at 570 nm was measured with a platereader. Our initial screen showed promising half-maximal inhibitory concentration (IC50)
values for all complexes across the three cancer cell lines (Table 3-2). Comparison of IC50
values with uptake revealed no significant correlation.
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Table 3-2. In Vitro antiproliferative activity. IC50 values for 3a-j across a panel of cell
lines. Cells were seeded at a density of 2 x 104 cells/well and treated with compounds for
72 h. Data are plotted as the mean ± s.e.m. (n=3). Full dose response curves can be found
in APPENDIX 3 (Figures S-7-86 through S-7-95).

IC50 (μM), 72 hours
MDA-MB-

MDA-MB-

175

231

3a

0.93 ± 0.10

3b

A2780

RPE-NEO

MRC5

0.53 ± 0.10

0.52 ± 0.08

10.29 ± 2.61

>50

1.26 ± 0.31

0.94 ± 0.16

0.92 ± 0.10

25.4 ± 1.98

>50

3c

1.85 ± 0.20

0.95 ± 0.14

1.19 ± 0.13

12.11 ± 1.6

>50

3d

0.84 ± 0.67

1.14 ± 0.08

0.82 ± 0.12

15.13 ± 2.19

>50

3e

01.12 ± 0.43

1.36 ± 0.04

1.13 ± 0.01

14.8 ± 2.15

>50

3f

0.62 ± 0.08

0.77 ± 0.12

0.74 ± 0.09

17.1 ± 1.86

>50

3g

0.83 ± 0.10

2.11 ± 0.10

0.82 ± 0.07

15.1 ± 1.86

>50

3h

1.03 ± 0.10

1.04 ± 0.10

1.20 ± 0.33

21.1 ± 18.6

>50

3i

0.94 ± 0.40

0.85 ± 0.07

2.97 ± 0.71

14.5 ± 2.45

>50

3j

1.17 ± 0.49

1.31 ± 0.09

0.81 ± 0.90

19.2 ± 2.81

>50

Specifically, the complexes exhibited high toxicity (0.5 – 1.5 μM) towards the TNBC
cell line MDA-MB-231 (Figure 3-9A and B). These complexes collectively are more
cytotoxic towards the cell line MDA-MB-231 in comparison to the [C^N]Au(III)DTC
complexes prepared by Bochmann et al.122 The different [C^N] backbone presented here
proves to be a critical component in drug design and overall improvement of cytotoxic
efficacy. The cytotoxicity of complexes 3a and 3f towards TNBC's is quite promising as
these cell lines are typically cisplatin resistant.70 Drug resistance is an ever-increasing
problem in medicine so developing therapeutics for refractory tumors is of great
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importance.316 To test the selectivity of compounds 3a and 3f for cancer cells over normal
cells, we evaluated these complexes in the normal retinal epithelial cells using the MTT
assay. We found up to a >30-fold selectivity for cancer cells over normal cells, indicative
of compounds with potential for reduced side effects.

Figure 3-9. In vitro activity of complexes 3a-j in multiple cell lines. A) IC50 (μM) plot
for complexes bearing the 2-benzoylpyridine framework in MDA-MB-231 (72 hours), B)
IC50 (μM) plot for complexes bearing the 2-benzylpyridine framework in MDA-MB-231
(72 hours), C) extended panel of cell lines for complex 3f, D) Representative bar graph
illustrating that the IC50 values of 3f across a panel of cancer cell lines. The dotted line
indicates a threshold of 1 μM. % Cell survival was determined with MTT (adherent cells)
and CellTiter-Glo (suspended cells). Data are plotted as the mean ± s.e.m. (n=3).
With the completion of preliminary cytotoxicity screening, we set out to explore the
efficacy of compound 3f in different cancer tissue type beyond breast cancer. Both H460
(human large cell lung carcinoma) and K562 (human chronic myelogenous leukemia) were
utilized (Figure 3-9C and D). We found comparable cytotoxicity in these cell lines to those
in our preliminary screen. With 3f displaying IC50 values of 1.5 μM in H460 and 1.0 μM
in K562. With a promising candidate in hand, we pursued further biological testing to gain
mechanistic insight of this class of Au(III) dithiocarbamates.
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3.9

Differential Gene Expression and Biological Pathway Analysis
We investigated the whole-cell effect of compound 3f by analyzing differentially

expressed genes (DEG) from RNA-seq. We treated MDA-MB-231 cells with 1 μM of 3f
for 12 h followed by the isolation of high-purity RNA for Illumina Hi-seq. We found 3019
DEG with 1596 upregulated and 1423 downregulated genes in response to 3f (Figure 310).

Figure 3-10. Representative heat map of differentially expressed genes (DEGs) in
response to exposure to 3f.
Subsequent use of gene ontology (GO) (Figure 3-11A) and Kyoto encyclopedia of
genes and genomes (KEGG) (Figure 3-11B) pathway analysis software led to potential
processes perturbed by 3f.317-321 The pathway analysis software employed are an extensive
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library database capable of integrating chemical and biological pathway perturbation
processes and is well suited for drug development studies. For the identified processes, we
examined the corresponding downstream canonical pathways and corroborated activated
or inhibited pathways with functional biology experiments (vide infra). Notable pathways
identified include, mitotic nuclear division, organelle fission, cell cycle, progesterone
oocyte maturation, and focal adhesion processes. Interestingly, a significant number of
these processes are regulated by the mitochondria. It is well established that a number of
aggressive tumor types including TNBCs exhibit impaired mitochondria function, which
present a vulnerability.322,

323

We therefore, hypothesized that this class of gold(III)

dithiocarbamates disrupt mitochondria function in MDA-MB-231 cells. This was tested by
detailed mitochondrial investigations.

Figure 3-11. A-B) Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes
(KEGG) outlining varying pathways perturbed upon treatment with 3f. For GO; BgRatio
= n/17107. For KEGG; BgRatio = n/5824.
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3.10 Au(III) Dithiocarbamates Disrupt Cancer Cell Metabolism
The RNA-seq showed transcriptional suppression of key genes involved in the
catalytic conversion of long-chain fatty acids such as ACSL4. Further analysis of DEG
revealed the modulation of several genes within the mitochondria respiratory chain or
oxidative phosphorylation. Activated DEG included NDUFS7 [complex I], COX7A1
[complex IV], and ATP5O, ATP5I genes [complex V] whereas the inhibited DEG were
MT-ND4L [complex I], SDHD [complex II], and ATP5C, ATP5F genes, [complex V].
Moreover, an uncoupling protein related gene, UCP3 was found to be upregulated in
response to 3f. These findings prompted functional biology experiments to further
corroborate the effect of 3f or its mechanism of action in TNBC. We examined the effect
of 3f on mitochondrial membrane potential, assayed by JC-1 dye.324 Following an extended
3f treatment and JC-1 staining (Figure 3-12), we found that 3f exhibits strong
depolarization of the MMP (J-monomers) in comparison to the DMSO treatment (Jaggregates) in MDA-MB-231 cells (see APPENDIX 3, Figure S-7-106 for a full FOV
image). We used carbonyl cyanide m-chlorophenyl hydrazine (CCCP), an uncoupler, as a
positive control to validate the experiment. The MMP is a key driving force in ATP
synthesis and overall a key factor in maintaining redox homeostasis throughout the cell.325
Uncoupling of the mitochondrial membrane results in acute cell death as the mitochondrial
become dysfunctional in this aggregative state.
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Figure 3-12. A) DMSO vehicle (1%), B) 3f at 10 μM for 6 hours, C) CCCP as a positive
control (100 μM, 30 minutes), D-F) Corresponding bright field images: DMSO vehicle
(1%), 3f, and CCCP. Compound 3f significantly depolarized the mitochondrial
membrane upon acute treatment in MDA-MB-231. Cells were seeded at 5 x 105 cells per
glass bottom dish with a #1.5 coverslip. Excitation was performed at 488 nm. Jmonomers (green, emission = 520 nm), J-aggregates (red, emission = 580 nm).
3.11 Bioenergetic Modulation Upon Exposure to Au(III) Dithiocarbamates
With the previous biological data pointing towards metabolic changes, we sought to
explore further the effect 3f had on redox metabolism. The ETC is a complicated biological
system that is constantly changing in response to external stress in order to achieve redox
homeostasis within the cell. With the DEG data alluding to involvement of ETC genes
(Figure 3-13), we then decided to look in depth at the effect of complexes on these
biological parameters. We next performed oxygen consumption rate (OCR) experiments
by Seahorse 96XF to quantify the effect of 3f on mitochondrial bioenergetics or stress
(MitoStress) (Figure 3-14A-E).326 A series of known inhibitors of the various parts of the
ETC that allow for the measurement of specific parameters were used.
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Figure 3-13. A) Schematic illustration of the electron transport chain and corresponding
DEGs for 3f.
We conducted a pneumatic injection of 3f into wells containing adhered MDA-MB231 cells followed by subsequent injections of oligomycin, a complex V inhibitor, to view
the basal OCR; FCCP, an uncoupler used to observe the maximum OCR, and rotenone/
antimycin A, a complex I/III inhibitor to completely shut down the ETC. The first step was
to determine the optimal MDA-MB-231 cell density and FCCP concentration, which was
30,000 cells per well and (0.6 μM) FCCP (Figures S-7-107 and S-7-108) respectively. At
a concentration of 3 mM, the basal OCR is diminished by more than 20% after only 17
minutes from time of injection of 3f (Figure 3-14C). We found that at a low concentration
of 3f (1 μM), maximal OCR (Figure 3-14D) is diminished by more than 25% within 50
minutes of treatment compared to the control. The overall decrease in maximal OCR at 1
and 3 μM implies acute depletion of mitochondrial respiration. ATP linked respiration was
also calculated and found to be decreased by more than 80% at 3 μM treatment (Figure 314E). Overall, the rapid decline in OCR suggests that these complexes are severely
impacting the ETC and subsequently OXPHOS, thus causing cell death. Despite the acute
dose-dependent OCR depletion induced by 3f in MDA-MB-231 cancer cells (Figure 314A), 3f did not impact the OCR of human fetal lung fibroblast cells, MRC5 (Figure 314B). These data indicate that 3f causes rapid irreversible inhibition of OXPHOS in the
TNBC, MDA-MB-231 but not in the normal lung epithelial fibroblast, MRC5.
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Figure 3-14. A-E) Bioenergetic monitoring of MDA-MB-231 (green bars) and MRC5
(purple bars) cells following acute in vitro treatment with complex 3f. MDA-MB-231
cells were seeded at a density of 30,000 cells peer well and MRC5 at a density of 50,000
cells per well and analyzed with a Seahorse XF96 Flux analyzer to assess the effect on
key bioenergetic parameters. A-B) Mitochondria stress test was performed with
pneumatic injections of compound 3f at concentrations ranging from (0.1-3 μM) and
response to injections of oligomycin, FCCP, and antimycin A/rotenone. Data are plotted
as the mean ± s.e.m. (8 technical replicates). C-E) Key bioenergetics parameters have
significant statistical response to treatment with compound 3f at concentrations as low as
3 μM within 30 minutes in MDA-MB-231 with high selectivity over MRC5 cells. Data
are plotted as the mean ± s.e.m., * p < 0.05, ** p < 0.01, *** p < 0.001.
3.12 Au(III) Dithiocarbamates Induce Apoptosis in MDA-MB-231
To further assess the mechanistic pathway upon treatment with 3f, we analyzed the
apoptotic effect in MDA-MB-231.
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Figure 3-15. A) Quadrants displaying apoptotic population of MDA-MB-231 within 4
hours of treatment with 3f. Cells were seeded at a density of 5 x 105 per well in a 6 well
plate. Data is representative of three individual experiments. H2O2 was used as a positive
control, B) Bar graph illustrating the early-stage apoptotic cell population. Data are
plotted as the mean ± s.e.m. (n=3), *** p < 0.001, C) Immunoblots of MDA-MB-231
treated with 3f in a concentration dependent manner.
Apoptosis is a common cell death pathway for chemotherapeutics which can be
characterized by distinct morphological features and biochemical mechanisms.327,
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Apoptosis occurs normally in healthy cells to maintain a healthy population of cells during
aging or development of tissues. Some transition metal-based drugs can trigger apoptosis
due to inhibition of p53 dependent pathway (a tumor suppressor gene).329, 330 Populations
of apoptotic cells can be determined by containing cells with Annexin V and PI.331, 332 Cells
undergoing apoptosis contain ample amount of phosphatidylserine (PS) which can be
bound by Annexin V. The Annexin is then labelled with FITC, a green fluorogenic dye
which can be visualized by fluorescence activated cell sorting (FACS). PI is used to stain
damaged DNA to distinguish apoptotic from necrotic cells. Such staining gives four
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separate quadrants upon analysis; (i) lower left, healthy cells which are negative for both
markers, (ii) lower right, pre-apoptotic cells which are positive for FITC but not for PI, (iii)
upper right, apoptotic cells which are positive for both markers, (iv) upper left, necrotic
cells which are positive for only PI. Figure 3-15A illustrates that 3f at 10 μM induced
significant apoptosis of MDA-MB-231 cells. Experimental data shows a 36% increase
(Figure 3-15B, which was extrapolated from Figure 3-15A) in apoptotic cells in
comparison to the control in just 4 h, indicative of apoptosis as a possible mode of cell
death. It is possible that 3f triggers either caspase-dependent or caspase-independent
apoptosis.333, 334 Immunoblotting was used to assess the effect of 3f on proteins involved
in caspase related apoptosis. In a concentration dependent manner, both caspase 3 and
cleaved caspase 3 were found to be upregulated in comparison to the control (Figure 315C). Upregulation of these proteins is indicative of a caspase dependent apoptotic
pathway. Caspase 3 is considered to be an executioner caspase in apoptosis as it coordinates
the destruction of cellular structures including DNA fragmentation and degradation of the
cytoskeleton.335, 336 Immunoblotting of cleaved PARP in response to 3f showed unaltered
protein expression, which is likely due to an uninvolved role of PARP mediated DNA
damage response.337-341
3.13 ROS Analysis
We examined the status of intracellular ROS induced by 3f. For this experiment, we
employed the used 2’,7’ -dichloro-fluoresceindiacetate (DCF-DA), a fluorogenic dye with
an excitation/emission wavelength of 495/525 nm.342 DCF-DA enters into the cell and is
subsequently deacetylated by cellular esterases where it is then oxidized by ROS to produce
a fluorescent compound that can detected with flow cytometry (FACS) using the FITC
channel.343
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Figure 3-16. 3f induces a significant increase in ROS at 10 μM within 1 hour of
treatment. ROS accumulation in MDA-MB-231 were monitored with DCF-DA over 1
hour. Cells were seeded at a density of 5 x 105 and added compounds from a 5 mM stock
in DMSO. H2O2 was used as a positive control (1 hour, 1 mM). Cells were pretreated
with N-acetyl cysteine (10 mM), 2 hours) prior to addition of 3f.
To quantify the amount of ROS produced, we subjected MDA-MB-231 cells to 3f at
10 and 20 μM to assess concentration dependence. Within 1 hour of treatment, we observed
a 1.3 fold increase in ROS in cells treated with 3f versus DMSO (Figure 3-16). At twice
the concentration, 20 μM, we observed a 1.5 fold increase in ROS. This shows a slight
concentration dependence as well as very fast imbalance of the cell homeostasis. When
compared to the H2O2 control, 3f produces similar ROS levels in MDA-MB-231 cells
(Figure 3-16). This suggests that ROS production has a key role in the cell death pathway
of these complexes. To further solidify that the DCF-DA fluorescence is from ROS and
not other reactive species such as RNS, we pre-treated cells with 10 μM N-acetyl cysteine
for 2 h. NAC is a natural ROS scavenger and a key component in the formation of
glutathione (GSH), which is a powerful antioxidant.344, 345 After pre-treatment, the cells
were subjected to the same concentration of 3f (10 μM) for 1 h. We observed using FACS
that there was no increase in ROS levels in comparison to the control. This reveals that
there is a significant amount of ROS being produced in the cells upon treatment and could
be a product of OXPHOS inhibition.
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3.14 Cell Cycle Analysis
The effect of 3f on cell cycle was studied by flow cytometry. We observed a timedependent increase in G0/G1 cell cycle population over 24–72 h period. Analysis of RNAsequencing data revealed the down regulation of several cell cycle related genes including
cyclin D1 and cyclin dependent kinases (CDK1, CDK4, CCND1) (Figure 3-17).

Figure 3-17. DEGs associated with cell cycle response to 3f.
There are several small molecule drug candidates in clinical trials as inhibitors of
CDK and induce G1 cell cycle arrest.346-349 There are several small molecule drug
candidates in clinical trials as inhibitors of CDK4/6 and induce G1 cell cycle arrest. Thus,
our finding is relevant for the design of gold based therapies for refractory tumors such as
TNBC. After 24 h, a 10% increase can be seen for G1 cell population as well as a 6%
decrease in S phase in comparison to the control (Figure 3-18A-C). Over the course of 72
h, there is a significant increase in G1 phase, suggesting that 3f is arresting the cell. The
mitochondria control cellular respiration, it is therefore possible that inhibition of
mitochondrial based respiration and consequently a loss in ATP levels leads to the observed
cell cycle arrest.350-352
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Figure 3-18. A) Representative histograms of the cell cycle; control (DMSO as the
vehicle) vs. 3f. MDA-MB-231 cells were seeded at a density of 2 x 105 cells per well and
treated with 3f at 0.1 μM for 24, 48, and 72 hours. B) Bar graph detailing the change in
G1, G2/M, and S phase over 24, 48, 72 hours. Data are plotted as the mean ± s.e.m.
(n=3), C) Bar graph illustrating the % increase in G1 over a 72 hour time period with 3f
treatment. Data are plotted as the mean ± s.e.m. (n=3), * p < 0.05.
3.15 Conclusion
We have taken advantage of structural diversity of organogold(III) dithiocarbamates
to investigate their anticancer potential and mechanism of action. Solution chemistry reveal
that the active stable specie of these compounds in the presence of biological thiols is a
neutral organogold(I), which was characterized by NMR spectroscopy, mass spectrometry
and electrochemistry. This points to a mode of action that may involve reactivity to cysteine
thiols. These complexes exhibit high in vitro cytotoxicity across a panel of cancer cell lines,
with inhibitory concentration in the range of 500– 2900 nM. The compounds display a 30fold selectivity for cancer cells over the normal RPE-Neo cells. In addition, the compounds
display high cellular uptake in cancer cells of >1000 pmol per million cells. Using wholecell transcriptomics, we explored the global effects of lead compound 3f on MDA-MB231 cells and found that mitochondrial processes related to oxidative phosphorylation, cell
cycle, and organelle fission processes were impacted. We utilized Seahorse XF96, to
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measure oxygen consumption rate of cancer or normal cells in response to 3f and found
selective inhibition of mitochondrial respiration in cancer cells over normal cells (MRC5)
at low concentrations (0.1 – 3 μM). Thus, these agents will be useful as targeted therapy
for cancers that shift metabolism and rely on OXPHOS for proliferation. We further
validate the cell death pathway by investigating key biological markers including, cell
cycle, ROS production, apoptosis, and MMP depolarization. All of these combine to give
a unique outlook on the mechanism of action of Au(III) complexes that has not yet been
reported. Overall, this in-depth study provides key information for a foundation to build
upon in designing future Au(III) drug candidates.
3.16 Experimental Details
3.16.1 General Experimental Details
All reactions were carried under ambient conditions in air unless otherwise noted.
Solvents were of ACS grade (Pharmco-Aaper) and used as is. The starting Au(III)
cyclometalated

complexes;

[2-benzylpyridine]Au(III)Cl2

and

[2-

benzoylpyridine]Au(III)Cl2 were prepared according to a modified procedure from our
lab.301 Sodium dimethyl dithiocarbamate and sodium diethyl dithiocarbamate salts were
purchased

from

Alfa

Methoxyphenyl)piperazine

Aesar.
were

1-(4-bromophenyl)piperazine

purchased

from

Sigma

Aldrich.

and

1-(4-

Ammomium

hexafluorophosphate was purchased from Matrix Scientific. Carbon disulfide was
purchased from Millipore Sigma and distilled prior to use. Sodium hydroxide pellets were
purchased from VWR. Deuterated solvents were purchased from Cambridge Isotope
Laboratories (Andover, MA). 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium
bromide (MTT), 2’,7’ –dichlorofluorescin diacetate (DCF-DA), and JC1 were purchased
from Cayman Chemicals. NMR spectra were recorded on a Bruker Avance NEO 400 MHz
spectrometer and samples calibrated for: 1H NMR (CD3CN δ = 1.94 ppm and DMSO-d6 δ
= 2.50 ppm), 13C NMR (CD3CN δ = 118.26 and 1.32 ppm and DMSO-d6 δ = 49.00 ppm),
and
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F NMR externally referenced to CFCl3 δ = 0.00). Electrospray ionization mass

spectrometry (ESI-MS) was performed on an Agilent Technologies 1100 series liquid
chromatography/MS instrument. High-resolution mass spectra (HRMS) were obtained by
direct flow injection (injection volume = 2 μL) using ElectroSpray Ionization (ESI) on a
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Waters Qtof API US instrument in the positive mode (CIC, Boston University). Typical
conditions are as follows: capillary = 3000 kV, cone = 35 or 15, source temperature = 120
°C, and a desolvation temperature = 350 °C. In addition to spectroscopic characterization,
the purity of all compounds was assessed by RP-HPLC using an Agilent Technologies
1100 series HPLC instrument and an Agilent Phase Eclipse Plus C18 column (4.6 mm 
100 mm; 3.5 µm particle size). All compounds were found to be 97% pure.
3.17 Synthesis of Sodium dithiocarbamate salts
All reactions were carried out under atmospheric conditions. Carbon disulfide was
run through a short silica plug before use. Sonication was performed using a Branson 2800
Series Ultrasonic Cleaner. These dithiocarbamate salts can be stored in a desiccator at room
temperature indefinitely.
3.17.1 Synthesis of Sodium piperazine dithiocarbamate
Prepared from a modified procedure in the literature. A round bottom was charged
with piperazine (850 mg, 10 mmol) and dissolved in 80 mL of ethanol. Sodium hydroxide
pellets (400 mg, 10 mmol) were crushed and added portion wise. The mixture was
sonicated (15 minutes) until all the NaOH was dissolved. The reaction was cooled to 0 °C
using an ice-bath. Carbon disulfide (1.53 g, 20 mmol) was placed in an addition funnel and
added dropwise over 10 minutes. The reaction was allowed to warm to room temperature
naturally and stirred for 12 h. All solvent was removed in vacuo at 50 °C to leave a
yellow/white solid. The solid was dissolved in 20 mL of acetone and 250 mL of ether was
added to precipitate a white solid, which was vacuum filtered, washed with excess ether,
and dried to afford the sodium dithiocarbamate salt. Yield 1.62g, 88%. 1H NMR (400 MHz,
DMSO-d6) δ = 4.27 (t, J = 8 Hz, 4H), 1.52-1.58 (m, 2H), 1.38-1.44 (m, 4H); 13C NMR (101
MHz, DMSO-d6) δ = 213.09, 50.71, 26.22, 24.86.
3.17.2 Synthesis of Sodium 1-(4-bromophenyl)piperazine dithiocarbamate
1-(4-bromophenyl)piperazine (241 mg, 1 mmol) and crushed NaOH pellets (40 mg,
1 mmol) were added in 25 mL of methanol and sonicated for 15 minutes to dissolve the
NaOH pellets. The reaction was cooled to 0 °C. Carbon disulfide (77 mg, 1 mmol) was
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placed in an addition funnel and added dropwise over 5 minutes. The reaction was allowed
to warm up to room temperature naturally and stirred for 2 h. The solvent was removed in
vacuo at 70 °C to leave a white solid. The solid was dissolved in acetone (5 mL) and ether
(75 mL) was added to precipitate a white solid, which was vacuum filtered, washed with
ether, and dried. Yield 200 mg, 59%. 1H NMR (400 MHz, DMSO-d6) δ = 7.35 (d, J = 4
Hz, 2H,), 6.88 (d, J = 4 Hz, 2H), 4.45 (t, J = 8 Hz, 4H), 3.11 (t, J = 8, 4H); 13C NMR (101
MHz, DMSO-d6) δ = 214.73, 150.50, 131.86, 117.56, 48.88, 48.23.
3.17.3 Synthesis of Sodium 1-(4-methoxyphenyl)piperazine dithiocarbamate
Prepared analogously to sodium 1-(4-bromophenyl)piperazine dithiocarbamate. 1(4-methoxyphenyl)piperazine (192 mg, 1 mmol), NaOH (40 mg, 1 mmol), carbon disulfide
(77 mg, 1 mmol). Yield 215 mg, 74%. 1H NMR (400 MHz, DMSO-d6) δ = 6.82 (d, J = 4
Hz, 2H), 6.61 (d, J = 4 Hz, 2H), 4.45 (t, J = 8 Hz, 4H), 3.68 (s, 3H), 2.86 (t, J = 8 Hz, 4H);
13

C NMR (101 MHz, DMSO-d6) δ = 214.49, 153.45, 145.85, 118.03, 114.77, 55.69, 51.31,

50.30, 49.40, 46.12.
3.18 General Procedure for Synthesis of Au(III) Dithiocarbamates
Complexes were prepared following a slightly modified procedure from the
literature.122 For complexes 3a-e, the corresponding Au(III) starting material (2benzoylpyridine)Au(III)Cl2 (50 mg, 0.11 mmol) was suspended in 20 mL of MeOH in a
250 mL Erlenmeyer flask and stirred at room temperature. A separate solution of the
corresponding sodium dithiocarbamate salt (0.13 mmol) was dissolved in 10 mL of MeOH
and added dropwise (500 µL/minute). The mixture gradually turned yellow upon addition
of the dithiocarbamate solution. The reaction was stirred at room temperature for 10-12 h.
A saturated solution of NH4PF6 in DI H2O was made and added to the MeOH mixture.
Excess DI H2O was added until a precipitate was observed. The solution was filtered and
the solid washed with DI H2O (10 mL), excess Et2O and vacuum dried for 30 minutes to
afford the Au(III) complexes 3a-e. Complexes 3f-j were prepared analogously but with the
Au(III) starting material (2-benzylpyridine)Au(III)Cl2 (50 mg, 0.11 mmol).
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3.18.1 3a
Prepared as described in the general procedure. [(2-benzoylpyridine)Au(III)Cl2]
(50 mg, 0.11 mmol) and NaDMDTC (19 mg, 0.13 mmol). Yield 61 mg, 86%. 1H NMR
(400 MHz, MeCN-d3) δ = 9.01 (d, J = 4 Hz, 1H), 8.51 (d, J = 4 Hz, 2H), 7.97 (quint., J = 8
Hz, 2H), 7.58 (sext., J = 12 Hz, 3H), 3.44 (d, J = 8 Hz, 6H); 31C NMR (101 MHz, MeCNd3) δ = 194.11, 190.33, 152.69, 147.60, 145.03, 142.14, 136.13, 131.75, 131.58, 131.36,
130.09, 129.09, 42.18, 41.07;

31

P NMR (162 MHz, MeCN-d3) δ = -131.02, -135.41, -

139.81, -144.20, -148.59, -157.37. HRMS (m/z) calcd. 499.0213, found 499.0212 [MPF6]+ , Purity was demonstrated to be >97% by RP-HPLC: Rf = 6.20 minutes using the
following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1% TFA;
Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min
(40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH) 12 min until end of run (100:0 H2O:MeOH).
3.18.2 3b
Prepared as described in the general procedure. [(2-benzoylpyridine)Au(III)Cl2]
(50 mg, 0.11 mmol) and NaDEDTC (22 mg, 0.13 mmol). Yield 62 mg, 84%. 1H NMR
(400 MHz, MeCN-d3) δ = 9.03 (d, J = 4 Hz, 1H), 8.54 (d, J = 4 Hz, 2H), 8.02 (quint., J = 8
Hz, 2H), 7.60 (sext., J = 12 Hz, 3H), 3.88 (dq, J = 20, 8 Hz, 4H), 1.39 (dt, J = 24, 8 Hz,
6H); 13C NMR (101 MHz, MeCN-d3) δ = 193.47, 190.30, 152.60, 147.61, 145.02, 142.32,
136.12, 131.75, 131.56, 131.35, 130.09, 129.09, 49.02, 47.67, 47.47, 12.31, 12.07, 12.02;
31

P NMR (162 MHz, MeCN-d3) δ = -131.02, - 135.41, -139.81, -144.20, -148.59, -157.37.

HRMS (m/z) calcd. 527.0526, found 527.0516 [M-PF6]+ , Purity was demonstrated to be
>97% by RP-HPLC: Rf = 7.00 minutes using the following method: Flow rate: 1 mL/min;
λ = 260 nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Solvent
Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70
H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of
run (100:0 H2O:MeOH).
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3.18.3 3c
Prepared as described in the general procedure. [(2-benzoylpyridine)Au(III)Cl2]
(50 mg, 0.11 mmol) and sodium piperazine dithiocarbamate (24 mg, 0.13 mmol). Yield 55
mg, 73%. 1H NMR (400 MHz, MeCN-d3) δ = 8.99 (d, J = 4, 1 Hz H), 8.51 (d, J = 4 Hz,
2H), 7.98 (quint., J = 8 Hz, 2H), 7.58 (sext., J = 12 Hz, 3H), 3.90 (dt, J = 16, 4 Hz, 4H),
1.74-1.82 (m, 6H); 13C NMR (101 MHz, MeCN-d3) δ = 191.37, 190.34, 152.64, 147.60,
145.01, 142.37, 136.12, 131.76, 131.64, 131.37, 130.07, 129.09, 52.99, 51.16, 25.97,
24.02; 31P NMR (162 MHz, MeCN-d3) δ = -130.85, -135.24, -139.63, - 144.02, -148.41, 157.20. HRMS (m/z) calcd. 539.0526, found 539.0527 [M-PF6]+ , Purity was demonstrated
to be >97% by RP-HPLC: Rf = 7.12 minutes using the following method: Flow rate: 1
mL/min; λ = 260 nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH with 0.1% TFA;
Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70
H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of
run (100:0 H2O:MeOH).
3.18.4 3d
Prepared as described in the general procedure. 2-benzoylpyridine)Au(III)Cl2] (50
mg, 0.11 mmol) and sodium (4-bromophenylpiperazine) dithiocarbamate (44 mg, 0.13
mmol). Yield 30 mg, 32%. 1H NMR (400 MHz, MeCN-d3) δ = 9.04 (d, J = 4 Hz, 1H), 8.54
(d, J = 4 Hz, 2H), 8.01 (quint., J = 8 Hz, 2H), 7.63 (sext., J = 12 Hz, 3H), 7.44 (d, J = 8 Hz,
2H), 6.95 (d, J = 8 Hz, 2H), 4.12 (t, J = 8 Hz, 4H), 3.48 (t, J = 12 Hz, 4H); 13C NMR (101
MHz, MeCN-d3) δ = 194.06, 152.66, 149.61, 144.92, 136.11, 132.58, 131.67, 131.64,
131.43, 130.05, 129.03, 112.64, 50.78, 49.14, 48.07; 31P NMR (162 MHz, MeCN-d3) δ =
-130.66, -135.05, -139.44, -143.84, -148.23, -152.62. HRMS (m/z) calcd. 693.9897, found
693.9899 [M-PF6]+ , Purity was demonstrated to be >97% by RP-HPLC: Rf = 9.26 minutes
using the following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1%
TFA; Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH),
5 min (40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min
(20:80 H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
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3.18.5 3e
Prepared as described in the general procedure. [(2-benzoylpyridine)Au(III)Cl2]
(50 mg, 0.11 mmol) and sodium (4-methoxyphenylpiperazine)dithiocarbamate (39 mg,
0.13 mmol). Yield 42 mg, 48%. 1H NMR (400 MHz, MeCN-d3) δ = 8.87 (d, J = 8 Hz, 1H),
8.31 (t, J = 8 Hz, 2H), 7.82 (t, J = 12 Hz, 1H), 7.61 (d, J = 8 Hz, 1H), 7.50 (t, J = 8 Hz, 1H),
7.43 (d, J = 8 Hz, 4H), 7.26 (d, J = 10 Hz, 1H), 6.97 (d, J = 8 Hz, 2H), 6.88 (d, J = 8 Hz,
2H), 4.01 (dt, J = 20, 8 Hz, 4H), 3.74 (s, 3H), 3.28 (quint., J = 8 Hz, 4H); 13C NMR (101
MHz, MeCN-d3) δ = 203.55, 155.21, 151.22, 144.80, 134.96, 132.54, 132.36, 128.49,
127.39, 119.54, 115.05, 55.64, 50.69, 50.08, 49.10; 31P NMR (162 MHz, MeCN-d3) δ = 135.41, -139.80, -144.19, -148.58, -152.98, -157.36. HRMS (m/z) calcd. 646.0897, found
646.0896 [M-PF6]+ , Purity was demonstrated to be >97% by RP-HPLC: Rf = 7.14 minutes
using the following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1%
TFA; Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH),
5 min (40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min
(20:80 H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
3.18.6 3f
Prepared as described in the general procedure. [(2-benzylpyridine)Au(III)Cl2] (50
mg, 0.11 mmol) and NaDMDTC (19 mg, 0.13 mmol). Yield 64 mg, 92%. 1H NMR (400
MHz, MeCN-d3) δ = 8.86 (d, J = 8 Hz, 1H), 8.22 (t, J = 8 Hz, 1H), 7.95 (d, J = 8 Hz, 1H),
7.62 (t, J = 8 Hz, 1H), 7.42 (t, J = 8 Hz, 1H), 7.32 (t, J = 8 Hz, 1H), 7.19 (t, J = 8 Hz, 1H),
4.43 (s, 2H), 3.45 (d, J = 4 Hz, 6H); 13C NMR (101 MHz, MeCN-d3) δ = 195.79, 157.04,
152.22, 146.36, 144.17, 13357, 131.11, 129.61, 129.52, 129.23, 127.73, 126.21, 47.31,
42.12, 40.89;

31

P NMR (162 MHz, MeCN-d3) δ = -130.53, -134.92, -139.31, -143.70, -

148.10, -152.48. HRMS (m/z) calcd. 485.0421, found 485.0418 [M-PF6]+ , Purity was
demonstrated to be >97% by RP-HPLC: Rf = 6.26 minutes using the following method:
Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH
with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60
H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
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3.18.7 3g
Prepared as described in the general procedure. [(2-benzylpyridine)Au(III)Cl2] (50
mg, 0.11 mmol) and NaDEDTC (22 mg, 0.13 mmol). Yield 64 mg, 88%. 1H NMR (400
MHz, MeCN-d3)δ = 8.85 (d, J = 8 Hz, 1H), 8.21 (t, J = 8 Hz, 1H), 7.91 (d, J = 8 Hz, 1H),
7.60 (t, J = 8 Hz, 1H), 7.40 (t, J = 8 Hz, 1H), 7.31 (t, J = 8 Hz, 1H), 7.16 (t, J = 8 Hz, 1H),
4.45 (s, 2H), 3.65 (td, J = 24, 16, 8 Hz, 4H), 1.32-1.48 (m, 6H);

13

C NMR (101 MHz,

MeCN-d3) δ = 195.12, 157.03, 152.17, 146.48, 144.16, 133.56, 131.09, 129.60, 129.50,
129.22, 127.75, 126.23, 48.87, 47.37, 47.30, 12.32, 12.04; 31P NMR (162 MHz, MeCN-d3)
δ = -134.25, -138.64, -143.03, -147.42, -151.81, - 160.60. HRMS (m/z) calcd. 513.0734,
found 513.0740 [M-PF6]+ , Purity was demonstrated to be >97% by RP-HPLC: Rf = 7.34
minutes using the following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O
with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50
H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100
H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
3.18.8 3h
Prepared as described in the general procedure. [(2-benzylpyridine)Au(III)Cl2] (50
mg, 0.11 mmol) and sodium piperazinedithiocarbamate (24 mg, 0.13 mmol). Yield 51 mg,
69%. 1H NMR (400 MHz, MeCN-d3) δ = 8.83 (d, J = 8 Hz, 1H), 8.23 (t, J = 8 Hz, 1H),
7.96 (d, J = 8 Hz, 1H), 7.62 (t, J = 8 Hz, 1H), 7.42 (t, J = 8 Hz, 1H), 7.32 (t, J = 8 Hz, 1H),
7.20 (t, J = 8 Hz, 1H), 4.44 (s, 2H), 3.94 (dt, J = 12, 4 Hz, 4H), 1.81-1.85 (m, 6H); 13C
NMR (101 MHz, MeCN-d3) δ = 193.10, 157.05, 152.22, 146.55, 144.14, 133.59, 131.18,
129.60, 129.49, 129.22, 127.74, 126.22, 52.81, 50.80, 47.33, 26.01, 25.78, 24.03; 31P NMR
(162 MHz, MeCN-d3) δ = -128.20, -132.59, -136.98, -141.38, -145.77, -150.16. HRMS
(m/z) calcd. 525.0734, found 525.0731 [M-PF6]+, Purity was demonstrated to be >97% by
RP-HPLC: Rf = 7.48 minutes using the following method: Flow rate: 1 mL/min; λ = 260
nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Solvent Gradient:
0 – 3 min (50:50 H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9
min (0:100 H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of run (100:0
H2O:MeOH).
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3.18.9 3i
Prepared as described in the general procedure. [(2-benzylpyridine)Au(III)Cl2] (50
mg, 0.11 mmol) and sodium (4-bromophenylpiperazine)dithiocarbamate (44 mg, 0.13
mmol). Yield 39 mg, 43%. 1H NMR (400 MHz, MeCN-d3) δ = 8.86 (d, J = 8 Hz, 1H), 8.21
(t, J = 8 Hz, 1H), 7.94 (d, J = 8 Hz, 1H), 7.61 (t, J = 8 Hz, 1H), 7.39-7.45 (m, 4H), 7.33 (t,
J = 8 Hz, 1H), 7.19 (t, J = 8 Hz, 1H), 6.92 (q, J =12 Hz, 2H), 4.42 (s, 2H), 4.06-4.11 (m,
4H), 3.42-3.48 (m, 4H);

13

C NMR (101 MHz, MeCN-d3) δ = 195.05, 156.34, 151.65,

149.05, 145.68, 143.57, 132.87, 131.97, 130.53, 129.04, 128.64, 127.14, 125.60, 118.20,
112.02, 50.07, 48.25, 47.54, 46.65; 31P NMR (162 MHz, MeCN-d3) δ = -131.38, -135.77,
-140.16, -144.55, -148.94, -157.73. HRMS (m/z) calcd. 680.0104, found 680.0104 [MPF6]+, Purity was demonstrated to be >97% by RP-HPLC: Rf = 9.40 minutes using the
following method: Flow rate: 1 mL/min; λ = 260 nm; Eluent A = H2O with 0.1% TFA;
Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min
(40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
3.18.10 3j
Prepared as described in the general procedure. [(2-benzylpyridine)Au(III)Cl2] (57
mg, 0.11 mmol) and sodium (4-bromophenylpiperazine)dithiocarbamate (39 mg, 0.13
mmol). Yield 49 mg, 43%. 1H NMR (400 MHz, MeCN-d3) δ = 8.86 (d, J = 4 Hz, 1H), 8.21
(t, J = 8 Hz, 1H), 7.93 (d, J = 8 Hz, 1H), 7.61 (t, J = 8 Hz, 1H), 7.40 (t, J = 8 Hz, 2H), 7.30
(t, J = 8 Hz, 1H), 7.18 (t, J = 8 Hz, 1H), 6.98 (d, J =12 Hz, 2H), 6.89 (d, J = 8 Hz, 2H),
4.42 (s, 2H), 4.06-4.12 (m, 4H), 3.75 (s, 3H), 3.28-3.33 (m, 4H); 13C NMR (101 MHz,
MeCN-d3) δ = 194.74, 156.43, 154.69, 151.74, 145.79, 144.26, 143.64, 132.98, 130.63,
129.12, 129.01, 128.72, 127.21, 125.67, 119.01, 114.53, 55.13, 50.70, 49.61, 48.83, 46.72;
31

P NMR (162 MHz, MeCN-d3) δ = -130.66, -135.05, -139.44, -143.84, -148.23, -152.62.

HRMS (m/z) calcd. 632.1105, found 632.1100 [M-PF6]+, Purity was demonstrated to be
>97% by RP-HPLC: Rf = 8.48 minutes using the following method: Flow rate: 1 mL/min;
λ = 260 nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Solvent
Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70
80

H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of
run (100:0 H2O:MeOH).
3.19 Physical and Chemical Characterization
3.19.1 X-ray Crystallography
Crystals of all complexes were grown from slow diffusion of Et2O into a
concentrated solution of MeCN at room temperature. All crystals were mounted using
polyisobutene oil on the end of a glass fibre, which had been mounted to a copper pin using
an electrical solder. It was placed directly in the cold gas stream of a liquid nitrogen cryostat
A Bruker D8 Venture diffractometer with graded multilayer focused MoKα X-rays (λ =
0.71073 Å) was used to collect diffraction. Raw data were integrated, scaled, merged, and
corrected for Lorentz-polarization effects using the APEX3 package. Space group
determination and structure solution and refinement were carried out with SHELXT and
SHELXL respectively. All non-hydrogen atoms were refined with anisotropic
displacement parameters. Hydrogen atoms were placed at calculated positions and refined
using a riding model with their isotropic displacement parameters (Uiso) set to either 1.2Uiso
or 1.5Uiso of the atom to which they were attached. Ellipsoid plots were drawn using
SHELXTL-XP. The structures, deposited in the Cambridge Structural Database, were
checked for missed symmetry, twinning, and overall quality with PLATON, an R-tensor,
and finally validated using CheckCIF.
3.19.2 UV-vis Spectrometry of Complexes
All spectra were recorded on a Shimadzu UV-1280 model instrument. All
complexes were prepared as a 1 mM stock in DMSO. The solutions were freshly prepared
prior to use. The solutions were then diluted to a final concentration of 50 µM x 4 mL with
DMSO. Prior to spectra acquisition the instrument was blanked with DMSO. Spectra were
recorded from 600 nm to 200 nm. The spectra were normalized to maximum absorbance
and plotted in GraphPad Prism 6.
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3.19.3 UV-vis Stability in DMEM, PBS, and RPMI-1640
All spectra were recorded on a Shimadzu UV-1280 model instrument. DMEM was
used as purchased from Corning® (4.5 g/L glucose, L-glutamine and sodium pyruvate).
PBS was used as received from Corning® (without calcium or magnesium). RPMI-1640
was purchased from Corning© and used as is. Each medium was warmed to 37 °C prior to
dilution of the complexes. All complexes were freshly prepared prior to use as a 1 mM
stock in DMSO. The solutions were then diluted to 50 µM x 4 mL with the respective
biological medium. The amount of DMSO in each solution was 5%, therefore the
instrument was blanked with either a 5% DMSO/(PBS/DMEM/RPMI-1640) solution prior
to each scan. The solutions were kept in an incubator at a controlled temperature of 37 °C.
Time periods of t = 0 h (after preparation of sample), 1 h, 6 h, 12 h, and 24 h were recorded.
Prior to each time point, the instrument was blanked with corresponding 5% DMSO
solution. The absorbance profile was scanned from 650 nm to 240 nm for each scan. For
each complex, the data were normalized to the highest absorbance at t = 0 h and plotted in
GraphPad Prism 6.
3.19.4 Reactivity with GSH (UV-vis Spectroscopy)
Stock solutions of the complexes were prepared by dissolving enough compound
to achieve 1 mM x 1 mL in DMSO. The stock solutions were diluted down to 50 µM by
taking 50 µL of the stock and diluting to 1 mL with PBS. A separate stock solution of GSH
was prepared as a 1 mM stock x 5 mL. This stock solution was then diluted to 50 µM in
PBS. All spectra were recorded on a Shimadzu UV-1280 model instrument. A blank was
prepared by mixing 50 µL of DMSO and 1.95 mL of PBS. Time intervals of 5 minutes and
12 h were recorded. Prior to each recording the instrument was blanked. The equimolar
solutions of the complex (50 µM) and GSH (50 µM) were mixed in a 1:1 ratio to achieve
a final concentration of 25 µM the UV-vis spectra recorded at the indicated time intervals.
For each reaction, the spectrum was normalized to the highest absorbance and plotted in
GraphPad Prism 6.
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3.19.5 Reactivity with NAC (UV-vis Spectroscopy)
The experimental procedure was performed identically to that of the reaction
involving GSH noted above. For each reaction, the spectrum was normalized to the highest
absorbance and plotted in GraphPad Prism 6.
3.19.6 Reactivity with GSH (HPLC)
All solvents used were of HPLC grade. All spectra were recorded using an Agilent
Technologies 1100 series HPLC instrument and an Agilent Phase Eclipse Plus C18 column
(4.6 mm × 100 mm; 3.5 μm particle size). Compound 3f was prepared as a 5 mM stock in
MeCN. GSH was prepared as a 5 mM stock in H2O. The stocks were diluted to a final
concentration of 2.5 mM with the appropriate solvent and each respective HPLC spectrum
recorded. For the reaction of 3f + GSH, 1 mL from each of the 5 mM stocks were mixed
in a 1:1 ratio to achieve a 2 mL solution with a final concentration of 2.5 mM. The sample
was then subjected to HPLC analysis. All spectra were recorded using the following
method: Flow rate: 1 mL/min; λ = 240 nm; Eluent A = H2O with 0.1% TFA; Eluent B =
MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60
H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH). Data were plotted using
GraphPad Prism 6.
3.19.7 LC-MS Analysis of 3f + GSH Adduct
After performing the reaction of 3f + GSH, a single new peak was observed. The
same solution was then subjected to LC-MS analysis (2.5 mM) using an Agilent 1200
HPLC with a direct flow injection with a HPLC auto sampler without a column, λ = 280
nm, (injection volume: 40 µL, flow rate: 0.2 mL/ min). ESI positive mode was taken with
a source temperature of 120 °C, desolvation temperature of 300 °C, Capillary Vat 3.5 kV
while Cone was set at 35. Data was plotted and analyzed using Mestrenova. The
chromatogram can be found in Figure S-7-78.
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3.19.8 Reactivity with GSH (1H NMR spectroscopy)
Stock solutions comprised of a 1 mL, 20 mM solution of 2a or L-GSH in DMSOd6 was prepared. The solution of GSH was sonicated for 5 minutes to dissolve all of the
reagent. 500 µL of each solution were mixed in a 1:1 ratio to produce a final concentration
of 10 mM in DMSO-d6. The solution was then analyzed by 1H NMR spectroscopy. The
solution was further analyzed at different time intervals, t = 1 h, 6 h, 12 h, and 24 h. Spectra
were plotted using Mestrenova.
3.19.9 Cyclic Voltammetry
All electrochemical measurements were recorded with a scan rate of 0.1 V/s with a
three-segment sweep and a sample interval of 0.001 V. The quiet time was set to 2 seconds
and sensitivity and 1 x10-5 A/V. All solutions were freshly prepared prior to use. All spectra
were recorded using a CH instruments 650E potentiostat. The electrodes used were all 3
mm: glassy carbon working electrode (CHI104), Ag/AgCl reference electrode (CHI111),
and a platinum wire counter electrode (CHI115). Compound 3f (8.8 mg / 7 mL),
NaDMDTC (2 mg / 7 mL), and (2-benzylpyridine)AuCl2 (6.1 mg / 7 mL) were prepared
as a 2 mM solution in anhydrous DMSO using 0.1 M NBu4PF6 (271 mg / 7 mL) as the
electrolyte. The samples were purged with nitrogen for 15 minutes and recorded. GSH (4.3
mg/ 7 mL) was prepared as a 2 mM solution in deoxygenated DI H2O using 0.1 M
anhydrous NaClO4 (85 mg / 7 mL) as the electrolyte. Due to poor solubility of GSH in
DMSO, the reaction between 3f and GSH was performed in a mix of solvents. Compound
3f (8.8 mg / 7 mL) was dissolved in anhydrous DMSO while GSH (4.3 mg / 7 mL) was
dissolved in deoxygenated DI H2O. 3.5 mL of each solution were mixed in a 1:1 ration to
achieve a final concentration of 1 mM x 7 mL. To this was then added 0.1 M NBu4PF6 as
the electrolyte (271 mg). All data were plotted in GraphPad Prism 6. Each graph is
representative of 3 individual experiments.
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3.20 In vitro Biological Assays
3.20.1 Cell Culture
All cell lines were purchased from ATCC and routinely grown in a humidified
incubator at 37 °C with 5-10% CO2. MDA-MB-231, MDA-MB-175, MRC5, RPE-NEO,
H460, and K562 were grown in DMEM supplemented with 10% FBS, 1% amphotericin
and 1% penicillin/streptomycin. A2780 cells were grown in RPMI supplemented with 10%
FBS, 1% amphotericin, and 1% penicillin/streptomycin, and 4 mM glutamine. All
supplements along with PBS and trypsin-EDTA were purchased from Corning Inc. and
used as is.
3.20.2 Cell Viability of the 3f + GSH Adduct
Cells were grown to confluency and added trypsin to collect the cells. The cells
were washed with 2 mL of PBS and suspended in 10 mL of DMEM. The cells were
centrifuged at 2000 rpm for 5 minutes. The pellet was washed with 2 mL of PBS and
suspended in 5 mL of DMEM. The cells were then plated in three separate 96-well clear
bottom plate at a density of 2,000 cells/well. The cells were allowed to adhere overnight.
The adduct was prepared by taking a 10 mM stock of 3f in DMSO and GSH in DMEM
and mixing in a 1:1 ratio to achieve a 5 mM stock of the adduct. The adduct solution was
diluted to 100 µM working concentration with DMEM. The adduct was then added at a 3x
dilution starting at 50 µM for the highest concentration and the cells incubated for 72 h at
37 °C with 5-10% CO2. The medium was removed and a solution of MTT (100 µL,
prepared by dissolving MTT at 5 mg/mL and diluting by 10x with DMEM) was added to
each well and incubated for 4 h at 37 °C with 5-10% CO2. The dye was removed from each
well and 100 µL of DMSO was added to induce cell lysis. The plates were read using a
Genios plate reader (λ = 570 nm). The experiment was performed in triplicate. Data are
plotted as the mean ± s.e.m. (n = 3).
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3.20.3 Cell Viability of 3a-j (Adherent Cell Lines)
The cell viability of all 10 complexes were performed in MDA-MB-231, MDAMB-175, A2780, RPE-NEO and MRC5. The cell viability of compound 3f was also
determined in H460. Cells were grown to confluency and trypsin was added to detach and
harvest cells. The cells were washed with 2 mL of PBS and suspended in 10 mL of the
appropriate media. The cells were centrifuged at 2000 rpm for 5 minutes and the pellet
washed with 2 mL of PBS then suspended in 5 mL of the appropriate media. The cells were
plated at a density of 2,000 cells/well in a 96-well clear bottom plate and allowed to adhere
overnight at 37 °C with 5-10% CO2. The compounds were prepared as a stock in DMSO
and used fresh. The compounds were added at seven concentrations with a 3x serial dilution
starting at 50 µM for the highest concentration and incubated at 37 °C for 72 h with 5-10%
CO2. The medium was removed and a solution of MTT (100 µL, prepared by dissolving
MTT at 5 mg/mL and diluting by 10x with DMEM) was added to each well and incubated
for 4 h at 37 °C with 5-10% CO2. The dye was removed from each well and 100 µL of
DMSO was added to induce cell lysis. The plates were read using a Genios plate reader (λ
= 570 nm). The experiment was performed in triplicate and data are plotted as the mean ±
s.e.m. (n = 3).
3.20.4 Cell Viability of 3a-j (Suspended Cell Lines)
The cell viability of 3f was determined in K562. Cells were grown to confluency
and centrifuged at 2000 rpm for 5 minutes to collect the cell pellet. The cells were washed
with 5 mL of PBS, suspended in 5 mL of DMEM, and centrifuged again at 2000 rpm for 5
minutes to collect the pellet. The pellet was then washed with 2 mL of PBS and suspended
in 5 mL of DMEM. The cells were plated at density of 2,000 cells/well in a 96-well white
bottom plate. 3f was prepared as a stock solution in DMSO and used fresh. The compounds
were added at seven concentrations with a 3x serial dilution starting at 50 µM for the
highest concentration and incubated at 37 °C for 72 h with 5-10% CO2. The cells were
removed from the incubator and allowed to rest at room temperature for 30 minutes. To
each designated well was then added 20 µL of CellTiter-Glo solution and orbitally shaken
for 5 minutes and the luminescence (1000 ms integration and 150 ms gain) acquired on a
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Genios plate reader. The experiment was performed in triplicate. Data are plotted as the
mean ± s.e.m. (n = 3).
3.20.5 Apoptosis
MDA-MB-231 cells were seeded at a density of 5 x 105 cells/well in a 6 well clear
bottom plate with a final media volume of 2 mL. The cells were allowed to adhere
overnight at 37 °C. A stock of 3f was prepared fresh in DMSO and added to the desired
well at a concentration of 1 µM with a final volume of 2.5 mL and incubated for 4 h at 37
°C. A stock of H2O2 was prepared in PBS and the cells treated at a final concentration of 2
mM for 1 hour as a positive control. When ready for analysis, the media were removed and
the wells washed with 5 mL of PBS. The cells were trypsinized (1 mL), 5 mL of DMEM
were added to each well, and total volume collected and centrifuged to pellet the cells. The
cells were resuspended in 2 mL of fresh media, counted, and reconstituted to a
concentration of 1 x 105 cells/mL. The cells were centrifuged again, and the pellet
suspended in 500 µL of Annexin binding buffer. To each sample was added 5
µl of Annexin V-FITC and 5 µL PI and incubated in the dark at room temperature for 5
minutes. The samples were then subjected to FACS analysis. Graphs are representative of
three technical replicates. Percentages are plotted as the mean ± s.e.m. (n = 3).
3.20.6 Immunoblotting
MDA-MB-231 cells were seeded at density of 5 x 105 cells/well in a 6-well clear
bottom plate with a final volume of 2 mL and allowed to adhere overnight at 37 °C.
Compound 3f was prepared as a stock in DMSO and added to the respective wells at the
specified concentrations of 0.1, 1, and 10 µM and treated for 12 h. The cells were washed
with PBS (3 x 3 mL) and were scraped into SDS-PAGE loading bufer (64 mM Tris-HCl
(pH 6.8)/9.6% glycerol/2% SDS/5% β-mercaptoethanol/0.01% bromophenol blue) and
incubated at 95 °C on a heat block for 10 min. The samples were cooled and stored at −20
°C until ready for use. Whole cell lysates were resolved by 4–20% sodium dodecylsulfate
polyacrylamide gel electrophoresis (SDS-PAGE; 100 V for 35 min) followed by electro
transfer to a PVDF (350 mA for 1 h). Membranes were blocked using 3% (w/v) bovine
serum albumin (BSA) in PBST (PBS/0.1% Tween 20) and incubated with specific primary
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antibodies (Cell Signaling Technology) overnight at 4 °C. On the following day, after
washing with PBST (3 ×5 mL), the membrane was incubated with horseradish peroxidaseconjugated secondary antibodies (Cell Signaling Technology) in freshly prepared BSA
blocking solution. Immuno complexes were detected with the ECL detection reagent
(BioRad) and analyzed using a BioRad imager with a chemiluminescence filter.
3.20.7 Cellular Uptake
For whole cellular uptake, MDA-MB-231 cells were seeded at a density of 1 x 106
cells/mL in a 6-well clear bottom plate with a volume of 2.5 mL and allowed to adhere
overnight at 37 °C. Compounds were prepared as a stock in DMSO and added to each well
at a final concentration of 5 µM and treated for 24 h. Auranofin was used as a comparative
control and treated at a final concentration of 5 µM and treated for 24 hours as well. The
cells were then collected by trypsinization and centrifuged at 2000 rpm for 5 minutes to
form a pellet. The pellet was suspended in 1 mL of DMEM, transferred to a 1.5 mL
Eppendorf tube, and centrifuged again at 2000 rpm for 5 minutes. The media were
removed, washed with PBS twice, and the pellet stored at -20 °C until analysis. Prior to
analysis, the pellets were suspended in 0.5 mL of concentrated HNO3 and agitated for 1
minute. The solution was transferred to a 15 mL Falcon tube and then 4.5 mL of DI H2O
was added. The samples were then subjected to analysis with ICP-OES. Data is represented
as the mean ± s.e.m. (n = 3).
Cellular fraction uptake was conducted in a similar manner per the instructions
from the RayBio Nuclear Extraction Kit Protocol (RayBiotech, Inc.). MDA-MB-231
cells were seeded at a density of 2 x 106 in 100 mm petri dishes and incubated overnight at
37 °C. 3f was added at 5 µM for 24 hours. Once the fractions had been isolated, the
concentrate was subjected to GF-AAS analysis. Prior to analysis, a calibration curve using
Au in varying concentrations (0, 10, 20, 50 µg/mL) was performed. Data is represented as
the mean ± s.e.m. (n = 3). The calibration curve for these samples can be found in Figure
S-7-109.
Whole cellular uptake with pre-incubation of uptake inhibitors was performed as
follows. MDA-MB-231 cells were seeded at a density of 3 x 105 in clear-bottomed six88

well plates and incubated at 37 °C overnight. The cells were then pre-treated with the
following inhibitors: NaN3 (1 mM), methyl-β-cyclodextrin (5 mM), chlorpromazine
hydrochloride (28 nM), wortmannin (50 nM), genistein (200 µM), for 1 hour. For the +4
°C sample, the cells were cooled to +4 °C prior to addition of 3f. Following pre-treatment,
the media were removed and washed with PBS (3 x 2 mL). The cells were then incubated
with 3f (5 µM for 24 hours) at 37 °C and the +4 °C sample incubated at the same
concentration at the indicated lower temperature. After treatment, the cells were collected
both, the medium and tryspsinzed cells combined, centrifuged at 2000 rpm for 5 minutes
to form a pellet. The pellet was suspended in 1 mL of DMEM, transferred to a 1.5 mL
Eppendorf tube, and centrifuged again at 2000 rpm for 5 minutes. The media were
removed, washed with PBS twice, and the pellet stored at -20 °C until analysis. Prior to
analysis, the pellets were suspended in 300 µL of 70% HNO3. 100 µL aliquot of this stock
was then diluted to 1 mL and subjected to GF-AAS. A calibration curve using Au in
varying concentrations (0, 10, 20, 50 µg/mL) was performed. After every 10 samples, the
calibration was performed again for quality control assurance. Data is represented as the
mean ± s.e.m. (n = 3). Samples 37 °C, NaN3, methyl-β-cyclodextrin, and chlorpromazine
hydrochloride were calculated using calibration curve Figure S-7-110 and samples
wortmannin, genistein, and +4 °C were calculated using calibration curve Figure S-7-111.
3.20.8 Differential Gene Expression (RNA-sequencing)
MDA-MB-231 cells were seeded on petri dish (100 mm x 15 mm) and allowed to
grow to 85% confluency. The cells were then treated with 3f at a concentration of 1 µM
for 12 h at 37 °C. Cells were harvested and 1 x 107 cells were collected. High quality RNA
was isolated using RNA Qiagen kit following manufacturer’s protocol and subsequently
sent to Novogene® for RNA-sequencing and analysis. Prior to analysis samples were
required to pass three tests before library construction: 1) nanodrop for RNA purity
(OD260/OD280), 2) agarose gel electrophoresis for RNA integrity and potential
contamination, and 3) Agilent 2100 check RNA integrity. Next, the NEB library was
constructed from mRNA enrichment and fragmentation, followed by reverse transcription,
second strand cDNA synthesis, end repair, addition of adaptor, and finally amplification
with PCR. After library construction, qPCR was used to accurately quantify the library
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effective concentration (> 2 nM), in order to ensure the library quality. Raw reads were
removed via the following parameters: 1) remove reads containing adaptors, 2) remove
reads containing N > 10% (N represents bases that could not be determined), 3) the Qscore
(Quality value) of over 50% bases of the read was  5. Novogene® then uses STAR to
accomplish the mapping reads to the reference genome. Gene expression level is then
estimated by the abundance of transcripts (count of sequencing) that mapped to genome or
exon where read counts are proportional to gene expression level, gene length and
sequencing depth. Samples are then subjected to analysis using Pearson’s correlation
coefficient and principal component analysis for statistical significance.
3.20.9 Mitochondrial Membrane Potential
MDA-MB-231 cells were plated at a density of 5 x 105 cells/plate using a glass
bottom petri dish fitted with a #1.5 cover slip with a final volume of 1.5 mL and allowed
to adhere overnight at 37 °C. Compound 3f was prepared as a stock in DMSO and added
at a final concentration of 10 µM. The cells were treated for 6 h at this concentration. CCCP
was prepared as a stock in DMSO and added at a final concentration of 100 µM and the
cells treated for 1 h. This was used as a positive control. After the indicated treatment time,
a working solution of the JC-1 dye (Cayman Chemicals) was prepared by adding 100 µL
of dye into 900 µL of DMEM. Note: the working solution of JC-1 should always be
prepared fresh and not stored for long-term use. Then, 100 µL/mL of DMEM were added
to the cells and incubated at 37 °C for 20 minutes. Prior to imaging, the media was removed
and replaced with room temperature PBS (2 mL). The cells were then visualized using
confocal microscopy on a Nikon A1R Inverted Confocal Microscope. J-aggregates were
imaged

with

(excitation/emission:

510/

590

nm)

and

J-monomers

with

(excitation/emission: 488/525 nm). Each image is representative of three technical
replicates.
3.20.10 ROS Analysis
MDA-MB-231 cells were seeded at a density of 5 x 105 cells/well in a 6-well clear
bottom plate with a final volume of 2 mL and allowed to adhere overnight at 37 °C.
Compound 3f was prepared as a stock in DMSO and added to the desired wells at a final
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concentration of both 5 and 10 µM and treated for 1 h. For the positive control, H2O2 was
used and diluted with PBS and added at a final concentration of 1 mM with a treatment
time of 1 h. For the wells that were pre-treated with NAC, a stock solution of NAC in
DMEM was added at a concentration of 10 mM for 2 h prior to the addition of 3f. Following
treatment, the media were removed, cells were washed with 5 mL of PBS, and collected
via trypsinization by centrifuging at 2000 rpm for 5 minutes. The pellet was then suspended
in 500 µL of a 10 µM DCF-DA solution in PBS and incubated for 30 minutes at 37 °C in
the dark. The cells were then centrifuged again at 2000 rpm for 5 minutes, the pellet washed
with PBS (3 x 1 mL) and suspended in 500 µL of PBS. The cells were then analyzed using
FACS with the FITC channel (excitation, λ = 488 nm). Each data set is representative of
three technical replicates.
3.20.11 Mitochondrial Metabolism (Seahorse XF96)
The initial step of Seahorse XF96 analysis included optimization of the cell density
(Figure S-7-107). In this stage MDA-MB-231 cells were seeded at a range of densities
from 2000 cells/well to 100,000 cells/well, followed by optimization of the FCCP injection
concentration (Figure S-7-108) used (0.6 µM of 1.2 µM). The optimum conditions were
determined to be 30,000 cells/well and an FCCP injection concentration of 0.6 µM. All
Seahorse XF96 experiments with MDA-MB-231 were performed under these conditions.
The cells were seeded the night prior to the experiment with a final volume of 100 µL and
incubated overnight at 37 °C. Compound 3f was prepared as a stock in DMSO and diluted
to a working concentration of 200 µM with Seahorse XF96 assay buffer and then
subsequently serial diluted by 3x to achieve multiple concentrations. The assay was
performed using a pneumatic injection method of 3f, with the final injection concentrations
of 0.1, 1, 3, and 11 µM. This was followed by injection of oligomycin (1.5 µM), FCCP
(0.6 µM) and rotenone/ antimycin A (0.5 µM). The metabolic parameters are calculated as
seen in the supplementary information of the following papers. The Seahorse XF96
analysis for MRC5 was performed in an identical manner to MDA-MB-231 except that
MRC5 cells were seeded at a density of 50,000 cells/well and an FCCP injection
concentration of 0.6 µM was used.

91

3.20.12 Cell Cycle Analysis
MDA-MB-231 cells were seeded at a density of 2 x 105 cells/well in a 6-well clear
bottom plate with a final media volume of 2 mL and allowed to adhere overnight 37 °C.
Compound 3f was prepared fresh as a stock in DMSO and added at a final concentration
of 0.1 µM with a final volume of 2.5 mL. Cells were treated with 3f for time periods of 24
h, 48 h, and 72 h. After the desired treatment period, the medium was removed and added
to a 15 mL Falcon tube. The wells were washed with 5 mL of PBS and added to the Falcon
tube. The cells were trypsinized (1 mL) and added 5 mL of fresh DMEM. All media were
combined, and the tube centrifuged at 2000 rpm for 5 minutes to collect the pellet. The
media were decanted, and the pellet suspended in 1 mL of PBS, which was then transferred
to a 1 mL Eppendorf tube, centrifuged at 2000 rpm for 5 minutes and suspended in 70%
EtOH/PBS solution. These solutions were stored at 4 °C until ready for analysis. Once all
treatments had been collected, the cells were collected by centrifuging at 2000 rpm for 5
minutes. The cells were washed twice with PBS (1 mL) and suspended in a 50 μL of RNase
solution (100 mg/mL) and 200 μL of a 50 mg/mL PI solution. The solutions were then
filtered through a 5 mL polystyrene round-bottom tube fit with a cell-strainer cap. The
samples were then analyzed with FACS. Data are representative of three technical
replicates with percentages plotted as the mean ± s.e.m. (n = 3).
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CHAPTER 4. ORGANOGOLD(III) AGENT INDUCE MITOCHONDRIAL DYSFUNCTION TO
TREAT TRIPLE NEGATIVE BREAST CANCERS

The text and figures within this chapter were adapted from a manuscript in preparation.
4.1

Preface
Cell metabolism is a critical component in the maintenance and proliferation of

cancer cells. Given that recent developments have elucidated the dependence of OXPHOS
for tumorigenesis, targeting cellular metabolism and altering mitochondrial function has
become very prominent in the clinical setting. Metal agents that selectively alter
mitochondrial bioenergetics; however, remain heavily underexplored and developed.
Herein, this chapter presents a continuation of a previously synthesized molecule reported
in Chapter 3, which will be referenced as AuDTC within the context of this chapter of
this dissertation. Further biological evaluation reveals key mechanistic implications to
overall efficacy and targeting modality of this class of compounds (Figure 4-1).

Figure 4-1. Summary of the mechanism of action of the compound AuDTC. Portrayal
includes mitochondrial targeting, localization within mitochondria, G1 cell cycle arrest,
high levels of oxidative damage, and enzymatic profiling illustrating inhibition of
complex V.
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Through intense investigation, bioenergetics were probed through various
applications of the Seahorse XF96 instrumentation. Immunoblots, FACS, and confocal
microscopy reveal significant increase in oxidative stress and damage. Furthermore,
synthetic modulation allowed for the development of a novel Au(III) clickable tool to
visualize localization of this class of compounds in vitro.
4.2

Introduction
Targeting cellular metabolism has become forefront in clinical research as many

cancer types depend on both glycolysis and oxidative phosphorylation (OXPHOS) to meet
the high energy demand for proliferation.353, 354 Conventional thought within the cancer
metabolism field had been that tumor cells robustly rely on glycolysis to provide the
necessary building blocks for macromolecule synthesis, ATP, and NADH, all of which are
essential for high demand of cell proliferation in aggressive cancer types. The first
observation to describe this dependency on glycolysis was by Warburg in the 1920’s,
which illustrated cancer cells as demonstrating high glucose uptake and therefore a heavy
reliance on glycolysis for metabolic activity.274,

275, 355-357

The phenomenon known as

aerobic glycolysis, became what we know today as the Warburg effect.274,

275, 355, 356

Consequently, this led to the belief that mitochondria are defective in tumor cells, thus
there is no dependence on mitochondrial metabolism for growth.358 All of this culminated
to the belief that dysfunctional mitochondria are a hallmark of tumors.279, 358-361
To date, platinum-based drugs still remain the main metal-based therapeutic for the
treatment of cancers; however, given the specific target, certain cancer types including
triple negative breast cancers (TNBCs) are highly resistant to platinum based therapies.65,
69, 71-73, 76, 281, 362-365

Given the high success of cisplatin, others have since been inspired to

develop a variety of metal-based complexes ranging from iridium, ruthenium, rhenium,
osmium, and gold to overcome these challenges.56,

309, 363-373

Our lab has taken such

approach with a motivation to develop novel gold scaffolds for treatment of TNBCs. Given
that auranofin is the only gold(I)-based drug to have found success in a clinical setting,
there exists a high need for more developments in the gold-medicinal field.44-46, 287, 288, 311,
374, 375
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Gold complexes are an ever growing scaffold that have found a broad use for many
pathophysiologies, yet major challenges in gold-based chemical biology are limiting
factors: i) lack of target identification, ii) lack of detailed mechanistic insight, and iii)
incomplete knowledge of localization within biologically relevant systems.60, 159, 248, 376-379
It is typically thought that gold complexes interact with mitochondria given that they can
become delocalized lipophilic cations that accumulate inside the organelle. It has been
illustrated that direct coordination of “gold” to the selenolate domain of the active site of
mitochondrial thioredoxin reductase occurs, further increasing the uptake of gold(I) into
the mitochondria, which results in swelling and an increased inner mitochondrial
membrane potential (IMMP).380 In comparison to platinum complexes, it is known that
gold complexes in either the gold(I) or gold(III) oxidation state have little to zero affinity
for DNA binding. Taken together, there is still a lack of mechanistic investigations of gold
complexes. Not all compounds are created equal, therefore slight modifications and
expansions of ligand systems can change the reactivity and target. We have recently
reported several classes of gold complexes that selectively perturb mitochondrial
respiration, mitochondrial structure and function, as well as alter the mitochondrial electron
transport chain in vivo.67, 111, 112, 163, 381, 382 Given these developments, combined with the
high precedence for gold in medicine, we have focused our efforts into rigorous
investigation of the biological target of these agents through in-depth biological assays.
This notion that all tumors have innately dysfunctional mitochondria was then
challenged in the 1950’s, which elegantly demonstrated that tumor cells can effectively
oxidize palmitate suggesting that tumor cells were also able to utilize OXPHOS
machinery.353,

383, 384

Recent evidence has shown that TNBC models have a high

dependence on both glycolytic and oxidative based pathways, suggesting that these tumors
are heterogeneous.66, 385, 386 Several studies indicate that OXPHOS may be upregulated in
highly metastatic breast cancers. Complex I, II, and IV activity assayed by NADH,
succinate dehydrogenase, and cytochrome oxidase histochemical staining respectively, of
breast cancer tissue reveals that ETC proteins are upregulated in breast cancer cells relative
to adjacent stromal and normal epithelial cells.387 Therefore, a promising strategy to treat
the highly metastatic cell lines is through targeting mitochondrial metabolism and
function.67, 322, 323, 388, 389 For recent small molecules being investigated in the clinic for
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OXPHOS inhibition, (metformin, gboxin, and IACS-010759), their efficacy revealed that
these aggressive tumors rely heavily on functional mitochondrial and that loss of
mitochondrial respiration is an area that can be exploited for therapeutic use.390-396
Herein, we focused primarily on the detailed biological characterization of an
organogold(III) complex bearing dithiocarbamate ligands (Figure 4-2) that demonstrate
selective modulation of mitochondrial respiration. We demonstrate that metabolic
reprogramming towards glycolysis is a direct consequence of the organogold(III)-induced
mitochondrial dysfunction in TNBC. We provide further evidence of mitochondrial
dysfunction through loss of membrane potential and significant ROS production, leading
to a loss of key regulatory proteins and increase in oxidative DNA damage. Further
mechanistic evaluation elucidates a mitochondrial specific cytochrome c release, apoptotic
pathway, and loss of mitochondrial mass. We then show that when MitoTEMPO, a relevant
superoxide scavenger is administered, the observed mitochondrial ROS production is
significantly reduced. These results indicate a potential therapeutic strategy which can be
employed to alleviate adverse effects following exposure to our gold agent.

Au

N

PF6

S

S
N

AuDTC
Compound
(Previously
noted
in
as compound 3f Chapter 3).
Figure 4-2. The compound that is used in this chapter for biological evaluation. This
compound was prepared and reported in Chapter 3 as compound 3f. Herein, it will be
referred to as compound AuDTC.
4.3

Mitochondrial Dysfunction and Metabolic Stress via Loss of OCR
Preliminary investigations on the ability of organogold(III)-dithiocarbamate

complex to disrupt cellular metabolism in MDA-MB-231 was previously reported.67 As
noted earlier, TNBCs are characterized by metabolic heterogeneity which makes it a
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difficult indication to treat. To provide a lot more scientific rigor in gold-based modulation
of cellular metabolism, we expanded the investigation of the effect of AuDTC on a variety
of TNBCs. To do this, we performed a metabolic stress test on mitochondria using the
Seahorse XF96 and measured the subsequent changes of OCR after injection AuDTC
(Figure 4-3A-B). We injected our gold agent pneumatically at varying concentrations
(vehicle (1%DMSO), 0.1, 1 and 3 µM), followed by electron transport chain inhibitors to
shut off various parts of the ETC.

Figure 4-3. Bioenergetic stress test of AuDTC in representative cancerous and normal
breast cell lines. A) Pneumatic injection of AuDTC in TNBC cell lines MDA-MB-468
and 4T1. OCR was normalized per 1,000 cells, B) Pneumatic injection of AuDTC in
normal breast epithelial cells HMEC and MCF-10A. OCR was normalized per 1,000
cells. Data are plotted as the mean ± s.e.m., n = 8.
We were enthusiastic to see a loss of total OCR across these panel of TNBCs upon
treatment with AuDTC in a concentration dependent manner (Figure 4-3A). Despite the
loss in maximal OCR in our TNBC models, AuDTC did not affect the OCR of our two
normal breast epithelial models: MCF-10A and HMEC, even at the same doses used
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(Figure 4-3B). At a concentration of 3 µM (Figure 4-4), a significant loss in maximal
OCR and ATP-linked respiration was observed. Maximal OCR is measured by the area
under the curve between the injection of FCCP and the cocktail of antimycin A/rotenone
(time = 53.11 minutes to 72.57 minutes). In MDA-MB-468, a concentration of 2-times the
IC50 value (1 µM) (Figure 4-4, blue bar), lead to a 39% loss in maximal OCR. Similarly,
we recorded a 42% loss of maximal OCR in 4T1 (Figure 4-4). Furthermore, in MDA-MB468, 4T1, and K562 (leukemia), at a concentration of 3 µM (Figure 4-4, red bar), we
observe a loss in OCR > 50% in comparison to the control (Figure 4-4). The overall
decrease in maximal OCR after a short exposure time across the panel of cell lines implies
acute depletion of mitochondrial respiration. We further evaluated this effect on another
highly proliferative TNBC model, HCC1937 (Figure 4-4), and observed similar effects.

Figure 4-4. Maximal OCR inhibition calculated from the OCR data after pneumatic
injection of AuDTC. The control of each cell line was taken to be 100%. All
concentrations are in comparison to the control. Data for each cell was normalized prior
to calculations per 1,000 cells. Data are plotted as the mean ± s.e.m, n = 8. * p < 0.05, **
p < 0.01, *** p < 0.001. n.s. = not significant, by a Student’s two-tailed t test.
Taken together the data illustrates that this gold agent rapidly perturbs mitochondrial
metabolism regardless of tumor type and it is selective for cancer compared to normal cells.
Further, the data represent an innate capability of AuDTC to rapidly induce mitochondrial
stress through perturbation of OXPHOS. All other bioenergetics OCR plots can be seen in
APPENDIX 4 (Figure S-7-112 (K562) and Figure S-7-113 (HCC1937)).
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4.4

Complex I Mediated Metabolic Stress
We evaluated the underlying mechanism of mitochondrial respiration inhibition by

assessing the effect of AuDTC on specific mitochondrial complex activity. Mitochondrial
metabolism is driven by the transfer of electrons through the ETC.397, 398 The complex
system is made of >100 proteins which form the OXPHOS machinery. The ETC is
comprised of 5 complexes; I-IV and complex V which is a subunit known as F0F1 ATP
synthase which drives respiration through a proton gradient converting ADP to ATP.398-400
Several studies have identified potent small molecules for inhibition of these various
complexes, therefore we sought to explore any possible specific interaction between our
gold agent and complex I.
The effect of AuDTC on mitochondrial complex I-driven respiration was evaluated
using the plasma membrane permeabilizer (XF PMP) assay (Figure 4-5A). Pinpointing the
precise underlying mechanism in disruptions of mitochondrial metabolism typically
involves isolation of mitochondria. Given the complex nature of this experiment and
avoiding low quality and low yielding isolation, we employed the use of the XF PMP assay
to analyze the effect on complex I driven respiration in situ with the critical design of
substrate and inhibitors.401, 402 The assay forms pores in the plasma membrane of the seeded
cells with significantly less mitochondrial outer membrane damage in comparison to
common detergents (i.e. saponin and digitonin). Where these detergents often require
careful titrations to determine optimal permeabilizing times and concentrations, a fixed
concentration of XF PMP provides a sufficient basis for permeabilizing a broad selection
of cell types.

99

Figure 4-5. Complex I-driven respiration measured with Seahorse XF96 in MDA-MB468 using plasma membrane permeabilization and substrates pyruvate (10 mM)/malate (1
mM). A) Bioenergetic stress test using pneumatic injection of AuDTC in a dose
dependent manner. B) Calculated bioenergetic parameters using OCR data from panel A.
Data are plotted as the mean ± s.e.m., n = 8, * p < 0.05, ** p < 0.01, *** p < 0.001, ****
p < 0.0005, by an ordinary one way ANOVA with Dunett’s multiple comparison test.
To measure complex I driven OCR, we subjected MDA-MB-468 cells to pneumatic
injection of AuDTC after the cells had been incubated with MAS buffer containing excess
levels of pyruvate (10 mM) added with 1 mM malate to feed the TCA cycle and thus
NADH linked respiration. In a concentration-dependent manner, we observed a loss in
OCR and respiratory function at 33 µM (Figure 4-5A, purple bar).403, 404 Further analysis
revealed a significant loss in basal respiration and ATP production as well as loss of proton
leak illustrating that complex I driven respiration is affected (Figure 4-5B). Given the high
concentration required to inhibit pyruvate linked respiration, we suspect that overall OCR
loss is due to overall loss in mitochondrial function from an upstream inhibition, rather
than a direct target to complex I. However, given that the effect on complex I respiration
is rapid at 33 µM (Figure 4-5B, purple bar) and there is immediate loss in ATP production
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(Figure 4-5B), it suggests that this deleterious effect is not a product of long exposure and
subsequent cell senescence.
4.5

Perturbation of Mitochondrial Membrane Potential
Following the observations that compound AuDTC decreases cellular respiration,

we wanted to evaluate how AuDTC exposure to cells affects mitochondrial membrane
potential (MMP). Healthy mitochondria are heavily reliant on maintaining a homeostatic
balance within the organelle. The REDOX transfer of electrons through ETC protein
complexes I–IV in the inner mitochondria membrane provides the energy to drive protons
against their concentration gradient across the inner mitochondrial membrane.405-407
Therefore, loss in MMP would subsequently lead to loss in bioenergetic health, which
would result in loss of ETC activity.
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Figure 4-6. FACS analysis of MMP using JC-1 in MDA-MB-468. Loss of PE
fluorescence (J-aggregates) was analyzed. Compensation was performed and held
constant throughout the analysis. A) Dot plots showing loss of PE at both 5 and 10 µM
after treatment with AuDTC (90 minutes). Each plots is representative of 5 samples. B)
CCCP (5 µM, 1 hour) was used as a positive control. The plot is representative of 5
samples. C) Dot plot showing loss of PE (J-aggregates) as a percentage in comparison to
the control (set as 100%). Data are plotted as the mean ± s.d., n = 5. *** p < 0.05, **** p
< 0.01, by an ordinary two way ANOVA for comparison between cancer cell groups
(4T1, MDA-MB-231, and MDA-MB-468) compared to normal cell groups (HMEC and
MCF-10A) and an ordinary one way ANOVA concentrations for each respective cancer
cell line.
Our previous report identified loss of MMP in MDA-MB-231 with the use of
confocal microscopy; however, this experimentation was not quantifiable. Therefore, we
examined the MMP depolarizing effect on our panel of TBNCs and healthy models with
the use of flow assisted cell sorting (FACS) (Figure 4-6A-C). To do so, we used JC-1, a
cationic, fluorometric dye that is dependent on the negative charge of the MMP. It is
represented as J-aggregates (red fluorescence) when it accumulates into the mitochondria
and J-monomers (green fluorescence) when it is located outside the mitochondrial
membrane due to loss of the electrochemical gradient. Following extended treatment with
AuDTC, we observed a large decrease in mitochondrial membrane potential (loss of PE
when analyzed with flow cytometry) in MDA-MB-468 within 90 minutes of treatment
(Figure 4-6A, see APPENDIX 4 for FACS plots of 4T1 (Figure S-7-116) and MDA-MB102

231 (Figure S-7-117)). To validate our results, CCCP (5 µM, 1 hour) carbonyl cyanide mchlorophenyl hydrazine, a classic uncoupler, was used (Figure 4-6B). We were able to
qualitatively assess that this compound rapidly induces MMP in TNBCs, up to 50% loss at
5 µM (MDA-MB-231, MDA-MB-468 and 4T1; Figure 4-6C) and 60 – 95% loss (MDAMB-231, MDA-MB-468 and 4T1; Figure 4-6C) at 10 µM within just 90 minutes of
treatment.

Further investigation revealed a similar trend to the bioenergetic stress

modelling. Even at concentrations as high as 10 µM, there was no significant observable
loss in MMP in both HMEC and MCF-10A (Figure 4-6C, see APPENDIX 4 for FACS
plots; MCF-10A (Figure S-7-114) and HMEC (Figure S-7-115)), illustrating high
specificity towards mitochondrial dysfunction in cancer cell lines. With the MMP being a
key driving force in regulation of mitochondrial metabolism, the perturbation is significant
in further elucidating the mechanistic implications of this gold agent. Evidence suggests
that the uncoupling of the MMP leads to acute cellular stress and cell death.
4.6

Glycolytic Effect and Metabolic Reprogramming
Drawing back to the dependency of cancer cells on both aerobic glycolysis and

cellular metabolism, we wanted to further outline fundamental changes in cellular response
upon exposure to our gold agent. Based on the claim that these agents induce loss of
mitochondrial respiration and subsequently loss of bioenergetics, we sought to analyze the
effect of AuDTC on glycolysis, that is, both direct effects and induced effects after
exposure.
We first performed the glycolytic rate assay in MDA-MB-231, a classic TNBC cell
line which has a higher dependency on glycolysis than OXPHOS for tumorigenesis
(Figure 4-7).386, 408 Cells were incubated with the glycolytic rate assay medium, containing
substrates that are critical for glycolysis (glutamine, glucose, and pyruvate) as well as
HEPES buffer.409 AuDTC was pneumatically injected and the change in basal rates
subsequently recorded. Next, OXPHOS inhibitors were injected to inhibit mitochondrial
oxygen consumption and the rate of proton efflux from respiration (PER) calculated and
removed from total PER to give the glycoPER.
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Figure 4-7. Glycolytic rate of AuDTC after pneumatic injection in MDA-MB-231, a
highly glycolytic cell line, in varying concentrations. PER was normalized per 1,000
cells. Data are plotted as the mean ± s.e.m., n = 8.
This injection is then followed by 2-deoxyglucose (2-DG) to block glycolytic
acidification and confirm pathway specificity. This decrease then provides confirmation
that the PER produced prior to the injection is due to glycolysis. Upon injection with
AuDTC, we observed no change in the basal rate of PER (Figure 4-8A), suggesting that
this compound does not directly inhibit glycolysis. After injection of rotenone/antimycin
A, we observe a significant increase in a concentration-dependent manner, which is
recorded as compensatory glycolysis (Figure 4-8B). At 3 µM, a 1.4-fold increase in
glycoPER can be observed, followed by 1.7-fold increase at 11 µM (Figure 4-8B). This
data suggests that the AuDTC does not directly affect glycolysis; however, a downstream
effect is to shift the cellular metabolism to more glycolytic demand due to the loss in
mitochondrial respiration mentioned before.
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Figure 4-8. Calculated parameters from normalized PER data presented in Figure 4-6.
Data was normalized per 1,000 cells before calculations. A) Basal glycolysis, time period
between AuDTC and rotenone/antimycin a (Rot./AA), B) Compensatory glycolysis, time
period from Rot/AA to 2-deoxyglucose (2-DG), C) mitoOCR/glycoPER ratio. Data are
plotted as the mean ± s.d., n = 8. * p < 0.05, ** p < 0.01, by a Student’s two-tailed t test
in respect to the control.
We were then able to compare the mitoOCR/glycoPER rate (Figure 4-8C), which
exhibited a decrease in ratio as concentration of AuDTC increase. Importantly, we
subjected our normal breast epithelial model, HMEC, to the same glycolytic stress test. We
observed no significant shift in metabolism, suggesting that this compound does not alter
OXPHOS and therefore no observed metabolic shift is observed (Figure 4-9, extrapolated
parameters for basal glycolysis, compensatory glycolysis, and mitoOCR/glycoOCR ratio
can be found in APPENDIX 4, Figure S-7-118). This trend illustrates a metabolic shift to
a more glycolytic dependency once AuDTC inhibits mitochondrial respiration. Taken
together, this data exemplifies modulation of metabolism irrespective of distinct metabolic
phenotype associated with cells and may have transformative outcomes for developing new
therapeutics.
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Figure 4-9. Glycolytic rate of AuDTC after pneumatic injection in HMEC, a normal
human breast epithelial cell line, in varying concentrations. PER was normalized per
1,000 cells. Data are plotted as the mean ± s.e.m., n = 8.
To characterize cellular energy demands upon exposure to AuDTC, we used the
Seahorse XF analyzer to investigate ATP production rates linked to both glycolysis and
mitochondrial metabolism in MDA-MB-468 (Figure 4-10). This technology measures for
the change in OCR and extra cellular acidification rate (ECAR) simultaneously. Basal rates
are first analyzed, followed by injection of AuDTC, to analyze immediate shift in basal
ATP rate production. This is followed by injection of oligomycin to inhibit OCR to allow
characterization of the mitoATP rate. Complete shutdown of mitochondrial respiration
allows for calculations of mitochondrial-related acidification, which when combined with
PER data, allows for the calculation of the glycoATP rate. Upon pneumatic exposure to
AuDTC in MDA-MB-468, within 20 minutes of injection, a decrease in basal mitoATP
(represented by OCR) can be observed (Figure 4-10, solid lines) followed by no change in
glycoATP (represented by ECAR) (Figure 4-10, dashed lines). This again signifies the
selective perturbation of mitochondrial respiration over glycolysis upon exposure to our
gold compound.
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Figure 4-10. Real time ATP rate of AuDTC after pneumatic injection in MDA-MB-468.
Solid lines represent flux in OCR (mitochondrial related ATP – mitoATP). Dashed lines
represent flux in ECAR (glycolytic based ATP – glycoATP). OCR and ECAR rates were
normalized per 1,000 cells. Data are plotted as the mean ± s.e.m., n = 8.
Quantifying these real-time ATP rate results shows a >10-fold induced rate of
glycoATP coupled with loss of mitoATP, illustrating a metabolic shift towards glycolysis;
a result which is indicative of a faulty ETC (Figure 4-11). The data reveals that there while
there is a loss in ATP from mitochondrial respiration, even at a concentration as low as 1
µM (Figure 4-11).
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Figure 4-11. Mitochondrial and glycolytic ATP rates calculated from the real time ATP
rate assay in MDA-MB-468. Red bars represent glycoATP rates and blue bars represent
mitoATP rates. Note, 0 µM represents 1% DMSO as the vehicle control. Normalized
ATP rates induced after injection. ATP rates were normalized per 1,000 cells. Data are
plotted as the mean ± s.e.m., n = 8.
Taken together, the glycolytic rate assay and ATP rate assay confirm in two independent
manners that exposure to AuDTC induces a metabolic shift from mitochondrial
metabolism to a glycolytic pathway (Figure 4-12). This metabolic shift signifies a high
dependence on functional mitochondria for proliferation and function, despite the
acclaimed notion that cancer cells do not rely on OXPHOS for survival. This data gives
strong evidence for gold complexes as selective modulators for bioenergetics, which can
be useful in a clinical setting, given that conventional platinum-based drugs and hormonal
therapies cannot treat these highly aggressive TNBCs.69, 73, 282, 305, 306, 410-412
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Figure 4-12. Bioenergetic map of MDA-MB-468 after treatment with AuDTC. ATP
rates are normalized per 1,000 cells. All rates plotted are induced rates.
4.7

Induced Oxidative Stress and Damage
Reactive oxygen species are an integral part in maintaining cell homeostasis and are

involved in a variety of cell signaling pathways.413-415 Innately, cells do require minimal
amounts of ROS for proper function, however; increased amounts of ROS cause
deleterious effects on cell proliferation and can ultimately lead to programmed cell
death.416-420 With preceding data pointing to a loss of mitochondrial membrane potential
and loss of cellular respiration, we analyzed the effect of compound AuDTC in the context
of ROS production. First, we analyzed the amount of ROS by using DCF-DA, a fluorogenic
dye, which is cleaved by intracellular esterases and subsequently oxidized by ROS species
into a fluorescent molecule (Figure 4-13A). We found a >4-fold shift of ROS upon
treatment with AuDTC for 120 minutes at 5 µM and > 6-fold increase at 10 µM in MDAMB-468 (Figure 4-13A). DCF-DA fluorescence was also measured in MDA-MB-231 and
4T1 to view the effect across a panel of TNBC cells (APPENDIX 4, Figure S-7-120). This
significant increase in ROS is attributed to loss of OXPHOS and a loss of a functional
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mitochondrial system. Second, to solidify the specificity of ROS, we employed the use of
MitoSOX, a mitochondrial targeting dye that specifically reacts with superoxide.
Mitochondrial ROS (mtROS) are a byproduct of the respiratory chain during OXPHOS.421423

Furthermore, superoxide can be produced by a leaky ETC which can then be oxidized

to H2O2, leading to an increase in mtROS fluorescence mentioned above. We then
measured mtROS levels with the use of FACS as well in MDA-MB-468 (Figure 4-13B).
We observed that in all three TNBCs, a significant increase of mtROS was produced at
both 5 and 10 µM within only 120 minutes of treatment time (Figure 4-13B, Figure S-7121 for MDA-MB-231 and 4T1 FACS histograms). Further confirmation of mtROS
production was done with the use of confocal microscopy. MtROS production was detected
with the MitoSOX dye (red) with MitoTracker Green FM (green) and Hoechst (blue) as
counterstains (Figure S-7-119).

Figure 4-13. FACS histograms representing increase in ROS species in MDA-MB-468.
Each histogram if representative of thee replicates. A) ROS measured by DCF-DA after 2
hours treatment (FITC channel). Gated events were kept at 30,000 for each sample. B)
mtROS measured by MitoSOX after 2 hours treatment (PE channel). Gated events were
kept at 30,000 events.
The treatment times adopted were to mimic the pneumatic injection method used
when analyzing metabolic stress. However, we did evaluate the production of mtROS in a
time-dependent fashion, showing that at even a lower concentration of 1 μM, there was
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initial increase in mtROS followed by a steady increase with prolonged exposure (up to 24
hours) (Figure 4-14). Time dependent analysis revealed that TNBCs were unable to
alleviate the mtROS, thus signifying an increase in mitochondrial dysfunction.

Figure 4-14. mtROS levels in a time defendant manner in MDA-MB-468 after treatment
with AuDTC (1 µM). Each histogram is representative of three replicates. Fluorescence
was measured using the PE channel. Gated events were kept at 30,000 for each sample.
Although ROS is required for certain cell signaling pathways, the rapid increase will
have harmful effects on mitochondrial function and overall cell health.415 These ROS
species can directly interact with cellular components and induce deleterious effects
including DNA damage, lipid peroxidation, and protein modifications. To analyze these
downstream effects, we assessed the impact on γH2AX activation, which results from
phosphorylation of the Ser-139 residue of the histone variant H2AX, in response to DNA
damage.424-427 Given that these gold complexes are known to not directly interact with
DNA and arrest cell cycle in the G1 phase, we proposed that an increase of γH2AX is
attributed to an increase in cellular ROS levels.120,

229,

428

With the use of

immunocytochemistry, we observed a persistent and significant increase in γH2AX levels
at both 12 hour and 24 hour time points with upon exposure to AuDTC (5 µM) (Figure 415).
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Figure 4-15. Confocal microscopy of MDA-MB-468 cells measuring increase in γH2AX
foci at 12 and 24 hours of treatment with AuDTC. Left to right: Hoechst stain (nuclear
counterstain), γH2AX (γH2AX primary with fluorescent secondary antibody), merge of
Hoechst and γH2AX channels, and a zoomed view of individual cells from the merged
panel. All images were taken using a 60x oil objective.
Images were taken using a 60x oil objective to visualize individual γH2AX foci within
the nuclei. We counterstained the cells with Hoechst stain to show the overlay of γH2AX
foci within the stained DNA. With the use of the Nikon-Elements software, a random
section of nuclei (>10) were chosen for analysis and quantified. Prolonged exposure to
AuDTC illustrated a significant increase between the 12-hour (18.5 ± 7.5 foci/nucleus)
and 24-hour (33.2 ± 9.2 foci/nucleus) time points compared to the control (4.4 ± 2.4
foci/nucleus) (Figure 4-16). Given the rapid increase of non-specific ROS and specific
mtROS, this result is not surprising.
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Figure 4-16. Measured γH2AX foci/nucleus from confocal microscopy images. 10 cells
were chosen at random. Data are represented as the mean ± s.d. Control (4.4 ± 2.4
foci/nucleus), 12 hours (18.5 ± 7.5 foci/nucleus) and 24 hours (33.2 ± 9.2 foci/nucleus).
** p < 0.01, *** p < 0.001, **** p < 0.0001, by a Student’s two sided t test.
We then analyzed oxidative stress at the protein level by analyzing the loss of mTOR,
a key regulatory protein in maintaining cell homeostasis and proliferation. Researchers
have reported that loss of mTORC1 can be attributed to high levels of ROS and that ROS
activates cytoplasmic ATM and AMPK, which both inhibit mTORC1.429-432 Therefore, it
is worth investigating if exposure to AuDTC results in loss of this key regulatory protein.
Using both confocal microscopy and immunoblotting, we show that exposure to AuDTC
results in a loss of mTOR. Confocal microscopy visually illustrated that MDA-MB-468
treated with AuDTC for 12 hours at 1 µM resulted in loss of mTOR (loss in red
fluorescence) expression (Figure 4-17A). Hoechst and MitoTracker Green FM were used
as a counterstain. We then confirmed this loss of mTOR expression by treating 4T1 in a
concentration-dependent manner and analyzing protein content by immunoblotting
(Figure 4-17B). We found that the loss of mTOR protein expression following exposure
to AuDTC in a concentration-dependent manner occurs 6 hours after treatment.
Altogether, the large effect of oxidative damage to our TNBCs illustrate significant
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changes in the mitochondrial environment. These drastic changes can be attributed to the
alteration of bioenergetics and loss of a functional electron transport chain.

Figure 4-17. Analysis of mTOR levels after treatment with AuDTC. A) Confocal
microscopy of MDA-MB-468 after treatment with compound AuDTC (1 µM, 12 hours).
Top row; merged images of Hoechst (nuclear counterstain), MTG (MitoTracker Green
FM), and mTOR (primary mTOR antibody with secondary fluorescent antibody). Bottom
row; mTOR only. Images show loss of fluorescence suggesting loss in mTOR levels. B)
Western blots of 4T1 after treatment with AuDTC. Treatment time was for 6 hours at
varying concentrations. Β-actin was used as a protein control.
4.8

Mitochondrial Specific Cytochrome C Release
Cytochrome c (Cyt c) is a prominent protein involved in cell regulation including the

apoptotic pathway.433-435 Located in the mitochondrial intermembrane space, its classical
function is to transfer electrons from the cytochrome c complex to cytochrome c oxidase
which is located on the surface of the inner mitochondrial membrane.436, 437 In recent years,
researchers have found that cytochrome c can be released from the mitochondria upon
exposure to apoptotic stimuli: depolarization of the MMP, ROS, and subsequent oxidative
damage.333, 421, 438 Once released, cytochrome c can signal for caspase dependent apoptosis
to promote cell death.325,

334, 335, 398

Seminal work by Korsmeyer gave insights into

mechanistic implications of cytochrome c release which illustrate a BCL-2 regulated
release.439,

440

Further mechanistic insights show that opening of the mitochondrial
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permeability transition pore results in swelling of the mitochondrial matrix, rupture of the
outer membrane, which then results in the release of the intermembrane components.441, 442

Figure 4-18. Mitochondrial specific cytochrome c release in MDA-MB-468 after
treatment with AuDTC (1 µM). An unstained sample, and tagged secondary fluorescent
antibody alone were used as controls. Time dependent cytochrome c release was
measured using FACS (APC channel). Populations left of the control were considered to
be positive for cytochrome c release. All histograms are representative of three replicates.
Bortezomib was used as a positive control.
It is also reasonable to suggest that loss in ETC function and stability would result in
release of this protein as well. Given our findings, we investigated the release of
mitochondrial specific cytochrome c release in a time dependent manner. MDA-MB-468
cells were permeabilized with digitonin, a detergent which permeabilizes the plasma
membrane, keeping healthy mitochondria intact. By doing so, cytosolic cytochrome c is
released and therefore only mitochondrial related cytochrome c will be measured with
immunohistochemistry.443, 444 When MDA-MB-468 cells are exposed to AuDTC at 1 µM,
we observed a 9% release of mitochondrial cytochrome c within 4 hours (Figure 4-18).
Time dependent analysis revealed an increase in release, resulting in > 60% of
mitochondrial cytochrome c being released in just 24 hours (Figure 4-18). We used
bortezomib, a small molecule used to treat multiple myeloma and mantle cell lymphoma,
as a positive control (Figure 4-18).445-447 We then looked to visualize the release of
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cytochrome c using confocal microscopy (Figure 4-19). Using Hoechst as a counterstain,
along with MitoTracker Green FM, we were able to observe a loss in colocalization of
cytochrome c from the mitochondria after the 24 hour treatment (Figure 4-19, right panel)
in comparison to the control (Figure 4-19, left panel). Full individual panels of the cells
analyzed can be found in Figure S-7-122. Furthermore, upon analysis of our images, we
are able to observe rounded, swollen mitochondria with less branching in our 4 hour
treatment sample when compared the vehicle control. This data suggests a loss in
mitochondrial function and a shift towards a profission state, which results in loss of
membrane potential, loss of metabolic activity, and an overall increase in oxidative
stress.448 Previous reports on this compound which illustrate induced apoptosis suggests
that this rapid cytochrome c release may be a critical component for the onset of apoptosis
and high in vitro cytotoxicity.

Figure 4-19. Confocal microscopy of mitochondrial cytochrome c release after exposure
to AuDTC. Blue fluorescence (Hoechst stain for nuclear counter stain), green
fluorescence (MitoTracker Green FM), and red fluorescence (cytochrome c primary
antibody visualized with secondary fluorescent tagged antibody). Left panel, untreated
MDA-MB-468 cells after plasma membrane permeabilization with digitonin. Right
panel, treated MDA-MB-468 cells after permeabilization with digitonin.
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4.9

MitoTEMPO Rescues Oxidative and Bioenergetic Stress
Characterization of chemotherapeutic effects in TNBCs points to widespread

bioenergetics stress and oxidative damage. We then sought to analyze the effect on pretreating these cells with MitoTEMPO, a mitochondrial targeting radical scavenger, as an
antioxidant to see if we could alleviate these deleterious effects upon treatment with our
gold agent. Given the increased levels of mtROS and loss of ETC efficiency, we chose
MitoTEMPO to alleviate mitochondrial based oxidative stress.449, 450 Generally, TNBCs
were pretreated with MitoTEMPO for 2 hours followed by treatment with AuDTC to see
if oxidative stress could be mitigated.
First, we examined the effect of pre-treatment on mtROS production using flow
cytometry. Since MitoTEMPO is a specific scavenger for superoxide, we looked to
investigate the potential to alleviate mitochondrial oxidative damage by scavenging
mtROS once produced. Pretreatment with MitoTEMPO resulted in 1.8-fold decrease in
mtROS versus the non-pretreated group (Figure 4-20). In this experiment, we used
Rotenone, a mitochondrial complex I inhibitor, as a positive control. Having established
that this pre-treatment condition resulted in loss of mtROS, we then evaluated the effect
MitoTEMPO pretreatment had on alleviating other oxidative stresses.
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Figure 4-20. Mitochondrial specific ROS (mtROS) measured with MitoSOX via FACS
(PE channel) in MDA-MB-468. Histograms are representative of three replicates. Red
bar, control; orange bar, pretreatment with MitoTEMPO for 2 hours (1 µM) followed by
treatment with AuDTC (10 µM, 2 hours); blue bar, treatment with AuDTC (10 µM, 2
hours); purple bar, a positive control rotenone (10 µM, 1 hour).
Next, we examined the effect of MMP when pretreated with MitoTEMPO (1 µM, 2
hours) (Figure 4-21). We used the same treatment times and conditions of AuDTC on
MDA-MB-468 (5 and 10 µM) for 90 minutes (Figure 4-21). At a concentration of 5 µM,
we observed an 18% decrease in MMP, and a concentration of 10 µM, we observed a 24%
decrease in MMP. This rescue of MMP suggests that a significant portion of membrane
depolarization is due to mtROS production. When CCCP was used as a control, only a
small decrease from 95% to 84% was observed, suggesting that even though AuDTC and
CCCP induce loss of MMP, it occurs through two distinct mechanisms (Figure 4-21).
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Figure 4-21. Mitochondrial membrane depolarization monitored by loss in PE (loss in Jaggregates) using FACS in MDA-MB-468. Plots are representative of 3 replicates.
Unstained is shown for gating purposes. Cells were treated with AuDTC (5 and 10 µM,
90 minutes) and CCCP (10 µM, 90 minutes). Plots labelled with “MT” indicate
pretreatment with MitoTEMPO (1 µM, 2 hours) prior to addition of AuDTC and CCCP.
Gated events were kept at 30,000 for each sample.
We then looked to analyze the extent to which apoptosis was rescued when pretreated with MitoTEMPO (Figure 4-22A-B). Previous reports combined with data
suggesting high mtROS production and cytochrome C release, we hypothesized that a
significant portion of apoptotic cells were signaled through the mtROS signaling pathway.
We again pretreated MDA-MB-468 cells with MitoTEMPO for 2 hours at a concentration
of 1 µM. Analysis revealed a significant decrease in apoptotic populations at both the 12
and 24 hour treatment conditions when exposed to AuDTC at 10 µM (Figure 4-22A). This
confirms our hypothesis, that the mtROS is a critical factor in cell death. Pre-treatment
with MitoTEMPO was able to alleviate apoptotic stress from a 12 hour incubation period
(Figure 4-22A-B).
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Figure 4-22. Apoptosis of AuDTC in MDA-MB-468. A) Treatment of cells at 10 µM for
12 and 24 hours. Plots labelled with MT indicate pretreatment with MitoTEMPO (1 µM,
2 hours). H2O2 (200 µM, 24 hours) was used a positive control. Plots are representative
of 5 replicates. B) Apoptotic % calculated from FACS analysis. Data are plotted as the
mean ± s.d. (n = 5), * p < 0.05, *** p < 0.001, by an ordinary one way ANOVA with
Dunett’s multiple comparison test. Gates were kept at 30,000 for each sample.
Finally, we wanted to analyze the effect pretreatment with MitoTEMPO had on total
bioenergetic stress. To do this, we subjected plated MDA-MB-468 cells with 2 hours of
with MitoTEMPO pretreatment (1 µM, 2 hours). We pneumatically injected ADTC at
higher concentrations to see if there was a pronounced effect in rescuing bioenergetic
stress. Overall, MitoTEMPO was able to alleviate significant loss in OCR in comparison
to the non-pretreated group (Figure 4-23A). Even at an injection of 11 µM, basal OCR
was rescued near to vehicle treated levels, with significant increase in OCR compared to
the non-pretreated 11 µM (Figure 4-23B). Furthermore, maximal OCR inhibition was
significantly rescued by more than 35% in the 3 µM group and > 20% in the 11 µM group,
illustrating that the functional capacity of the cell could be rescued from mtROS
scavenging (Figure 4-23C). ATP-linked respiration was also significantly rescued in both
pretreated groups, again illustrating the ability to rescue ETC function (Figure 4-23D).
These data represent a key dynamic of cell function upon exposure to AuDTC in that
scavenging mtROS rescues bioenergetic health and ETC function. This provides a potential
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future template in clinical models, given that deleterious side effects of drug treatments can
be mitigated with mtROS scavengers.

Figure 4-23. A) Bioenergetic stress test using Seahorse XF96 in MDA-MB-468 with
pneumatic injection of AuDTC. Solid lines represent normal experimental conditions
with no pretreatment. Dashed lines represent injection of AuDTC after pretreatment with
MitoTEMPO (1 µM, 2 hours). OCR was normalized per 1,000 cells. Data are plotted as
the mean ± s.d., (n = 8). B-D) Bioenergetic parameters calculated from changes in OCR.
Green bars represent the no pretreatment condition, purple bars represent the pretreatment
condition. Data are plotted as the mean ± s.e.m., (n = 8), * p < 0.05, ** p < 0.01, **** p <
0.0001, by a Student’s two-sided t test.
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4.10 In Vitro Click Chemistry and Colocalization

Figure 4-24. Synthetic methodology to achieve an alkyne-functionalized probe of our
gold compound (4-alkyne).
To further elucidate the targeting modality of AuDTC, we developed a synthetic
probe with a free alkyne attached to be used as our clickable probe.451, 452 We chemically
transformed the 2-benzoylpyridine framework of the cyclometalated gold by reacting with
o-2-propynylhydroxylamine hydrochloride to form an alkoxy imine with an alkyne handle.
Replacement of the labile chloride ligands with the sodium salt of dimethyldithiocarbamate
gave us an alkyne modified version of our lead compound (4-alkyne) (Figure 4-24). In
vitro cytotoxicity of 4-alkyne in MDA-MB-468 revealed no loss in efficacy compared to
our original organometallic gold(III) compound (Figure 4-25).

Figure 4-25. Cell viability of 4-alkyne compared to the parent compound (AuDTC), in
MDA-MB-231 over 72 hours. IC50 values are 0.53 ± 0.04 for 4-alkyne and 0.77 ± 0.12
for parent compound AuDTC. Data are plotted as the mean ± s.e.m., (n = 3).
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With this new tool in hand, we sought to perform in vitro click chemistry with an
azide fluorophore and counterstain with MitoTracker Red CM-H2XRos (MTR) to see the
correlation between the two dyes. For this experimental design, we used Alexa488-azide
as the click counterpart and MitoTracker Red CM-H2XRos for mitochondrial tracking
along with Hoechst as a nuclear counterstain (Figure 4-26). Proper control experiments
were performed by using Hoechst/MTR with only Alexa Fluor 488-azide without 4alkyne, as well as Hoechst/MTR treated with 4-alkyne but no Alexa Fluor 488-azide to
ensure that all recorded fluorescence was from the in situ generated click adduct (see
APPENDIX 4 for both sets of control images; Figures S-7-123 and S-7-124). We
performed treatment at varying concentrations (2, 25, and 50 µM (Figure 4-26, 50 µM is
shown); representative images for the 2 and 25 μM concentrations can be found in
APPENDIX 4, Figure S-7-125 (2 µM) and Figures S-7-126 and S-7-127 (25 µM), with
a two hour treatment time, to view what was the direct target of the compound. In Figure
4-26, panels A-C represent the individual laser channels. After treatment with 4-alkyne
and subsequent click chemistry, we were able to clearly visualize the localization of 4alkyne within the intracellular components via confocal microscopy. Panel D represents a
merge of all three respective channels, showing a complete overview of fluorescence. Panel
E illustrates only the nuclear counterstain along with the 4-alkyne - Alexa Fluor 488
adduct. This image shows little to no colocalization between 4-alkyne and the nucleus.
Given that this compound does not directly interact with DNA, this is not surprising.
Finally, panel F represents the 4-alkyne - Alexa Fluor 488 adduct with the MTR stain.
Pleasingly, we found a large amount of orange to yellow fluorescence overlap, which is
indicative of colocalization between the two fluorophores. This prompted us to perform a
Pearson’s Correlation to evaluate the extent of colocalization.
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Figure 4-26. Click chemistry visualized with confocal microscopy in MDA-MB-468.
Cells were treated for 50 µM for 1 hour. Panels: A) Hoechst as the nuclear counterstain,
B) 4-alkyne – Alexa Fluor 488 azide adduct, C) MitoTracker Red CM-H2XRos (MTR)
alone, D) Merge of all three channels, E) Merge of Hoechst and 4-alkyne, F) Merge of 4alkyne and MTR.
Colocalization studies revealed that a large amount of 4-alkyne was colocalized with
the red fluorescence from the MTR dye (Figure 4-27A). Subsequent evaluation with
Pearson’s coefficient gave a correlative value of 0.886 between the green and red channels
(Figure 4-27B). A higher magnification reveals loss in mitochondrial shape and size
coupled with localization of 4-alkyne (Figure S-7-128). Comparison of the blue (Hoechst)
and 4-alkyne (green) channels show no colocalization of our gold compound with the
nucleus. The lack of colocalization within the nucleus suggests that all γH2AX observed is
a result of oxidative DNA damage due to ROS production and dysfunctional ETC. Overall,
this experimental design not only sets a premise for clickable gold agents that can be
monitored in vitro, but also visual proof of interactions between 4-alkyne and the
mitochondria. Combined with the aforementioned data, this helps validate our claim that
this class of gold agents selectively target the mitochondria.
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Figure 4-27. Colocalization of 4-alkyne and the MitoTracker Red dye. A)
Representative confocal image showing a merge of both channels (4-alkyne and MTR).
The orange fluorescence color is a result of overlap “colocalization” of both green and
red fluorescence. B) Pearson’s correlation (PC = 0.886) plot between the green and red
fluorescent channels. 4-alkyne is represented as the x-axis (GFP channel) and MTR is
represented as the y-axis (RFP channel).
4.11 Conclusion
To conclude, we have taken our developed gold agents and further elucidated the
detailed mechanism of action with critical biological evaluation. Mechanistic insights
reveal that this compound directly interacts with bioenergetics through modulation of
OXPHOS and not glycolysis. Further studies illustrated a significant shift to glycolytic
demand once exposed to our compound, signifying a heavy perturbation of the ETC. We
were able to demonstrate that this compound is robust in its effect by showing similar
metabolic effects across a panel of TNBCs as well as other cancer types. Furthermore, this
compound displays a >30-fold selectively towards TNBC models than normal breast
epithelial cells. Significant MMP depolarization, increase in mtROS, and increase in
γH2AX signify that this compound rapidly induces oxidative stress in TNBCs and
subsequent loss in OXPHOS efficiency. The capability of rescuing oxidative stress with
MitoTEMPO further suggests pathway specificity to mtROS induced bioenergetics stress.
All together, these agents will be useful for future development and application to cancer
types that rely heavily on OXPHOS for energy demands. Development of clickable gold
drugs further elucidated the mitochondrial targeting nature of this compound, and provides
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a unique tool for future applications. All of these combine to give a unique outlook on the
mechanism of action of Au(III) complexes that has not yet been reported. Overall, this indepth study provides key information for a foundation to build upon in designing future
Au(III) drug candidates.
4.12 Experimental Details
All synthetic transformations were performed under ambient conditions in ACS
grade solvents which were obtained from Pharmco-Aaper. Compound AuDTC and [2benzoylpyridine]Au(III)Cl2 were prepared according to procedure previously reported in
our lab. o-2-propynylhydroxylamine hydrochloride was purchased from Ambeed, Inc. All
primary and secondary antibodies were purchased from Cell Signaling Technology.
Cellular stains, MitoTracker Green FM, MitoTracker Red CMXros, Hoechst, Alexa Fluor
488-azide, and MitoSOX Red were purchased from ThermoFisher Scientific. DCF-DA,
JC-1 solution, CCCP, MTT, Bortezomib, and MitoTEMPO (hydrate) were purchased from
Cayman Chemicals. A 2 mM solution of rotenone was graciously provided by the Redox
Metabolism Shared Resource Facility (RM SRF) at the University of Kentucky. Hydrogen
peroxide was purchased from MilliporeSigma as 30% (w/w) solution in H2O. Sodium
hexafluorophosphate was purchased from Santa Cruz Biotechnology, Inc. Sodium
dimethyl dithiocarbamate was purchased Alfa Aesar. Deuterated solvents were purchased
from Cambridge Isotope Laboratories (Andover, MA). NMR spectra were recorded on a
Bruker Avance NEO 400 MHz spectrometer and samples calibrated for: 1H NMR (DMSOd6 δ = 2.50 ppm), 13C NMR (DMSO-d6 δ = 49.00 ppm), and 19F NMR externally referenced
to CFCl3 δ = 0.00). The purity of all compounds was assessed by RP-HPLC using an
Agilent Technologies 1100 series HPLC instrument and an Agilent Phase Eclipse Plus C18
column (4.6 mm x 100 mm; 3.5 µm particle size). All compounds were found to be >97%
pure.
Cell viability was assayed using a using a Genios plate reader (λ = 570 nm). Seahorse
XF96 analysis was performed on a Seahorse XF96 Analyzer equipped with an Agilent
Seahorse XF Imaging and Normalization System for post assay normalization of readouts.
Flow cytometry analysis was performed using a BD-LSR II instrument equipped with 3
lasers: 488nm and 633nm lasers and a UV laser. It can simultaneously measure up to 8
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fluorescent antibodies or probes, as well as forward light scatter (cell size) and side light
scatter (cell granularity). Confocal microscopy was performed on a Nikon A1R Inverted
Confocal Microscope equipped with GaAsP detectors for greater sensitivity, and a spectral
detector comprised of 32 individual PMTs allowing for linear unmixing. Images were
processed with Nikon’s NIS-Elements Software.
4.13 Synthetic Procedures
4.13.1 Synthesis of dichloro gold(III)-alkyne ([C^N]-alkyne)
[2-

(100

benzoylpyridine]Au(III)Cl2

mg,

0.22

mmol)

and

o-2-

propynylhydroxylamine hydrochloride (40 mg, 0.42 mmol) were suspended in
DCM/MeOH (1:1) at a total volume of 6 mL and stirred at room temperature for 48 hours.
The resulting mixture was transferred into a centrifuge tube and centrifuged briefly to
separate the precipitate from the filtrate. The filtrate was removed by decanting and the
precipitate was washed by resuspending it in equal volume of DCM/MeOH (1:1),
centrifuged, and the filtrate decanted. The wash step was carefully done three times after
which the precipitate was finally dissolved in DCM and dried under vacuum (40 °C) to
afford an off-white, solid. Yield (46%, 52 mg). 1H NMR (400 MHz, DMSO-d6) δ = 9.34
(d, J = 6.3 Hz, 1H), 8.47 (td, J = 7.8, 1.5 Hz, 1H), 8.32 – 8.27 (m, 1H), 7.97 – 7.89 (m,
1H), 7.54 (d, J = 9.0 Hz, 1H), 7.41 – 7.27 (m, 3H), 5.02 (d, J = 2.4 Hz, 2H), 3.67 (t, J = 2.4
Hz, 1H).
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C NMR (101 MHz, DMSO-d6) δ = 153.25, 143.68, 137.88, 133.77, 130.45,

129.16, 128.91, 128.23, 79.59, 79.37, 63.72.
4.13.2 Synthesis of 4-alkyne
A suspension of [C^N]-alkyne (10 mg, 0.02 mmol) in MeOH (5 mL) was added
dropwise a solution of sodium dimethyldithiocarbamate (4.1 mg, 0.024 mmol) in 2 mL of
MeOH. The suspension slowly turned to a yellow, clear solution and was allowed to mix
for 12 hours at room temperature. A saturated solution of NaPF6 in DI H2O was prepared
and added to the solution to precipitate a beige powder, which was vacuum filtered, washed
with excess water and ether, and left to dry in air. Yield (79%, 10 mg). 1H NMR (400 MHz,
MeCN-d3) δ = 8.87 (d, J = 4 Hz, 1H), 8.32 (t, J = 8 Hz, 2H), 7.69 (q, J = 10 Hz, 1H), 7.59
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(d, J = 8 Hz, 1H), 7.41 (q, J = 9.0 Hz, 2H), 7.27 (d, J = 8 Hz, 1H), 4.78 (s, 2H), 3.36 (d, J
= 4 Hz, 6H), 2.58 (t, J = 10 Hz, 1H). 13C NMR (101 MHz, MeCN-d3) δ = 153.25, 143.68,
137.88, 133.77, 130.45, 129.16, 128.91, 128.23, 79.59, 79.37, 63.72. 19F NMR (376 MHz,
MeCN-d3) δ = -71.8, -73.2. 31P NMR (162 MHz, MeCN-d3) δ = -130.85, -135.24, -139.63,
- 144.02, -148.41, -157.20.
4.14 In Vitro Biological Assays
4.14.1 General Cell Culture and Maintenance
All cell lines were purchased from ATCC and routinely grown in a humidified
incubator at 37 °C with 5-10% CO2. MCF-10A were grown in DMEM/F-12 culture
medium supplemented with 5% horse serum, 0.5 µg/mL hydrocortisone, 20 ng/mL hEGF,
10 µg/mL insulin, 100 ng/mL cholera toxin, 100 µg/ml Penicillin, and 100 µg/ml
streptomycin. HMEC cells were cultured in MEBM supplemented with 5 µg/mL insulin,
6 mM glutamine, 1 µM epinephrine, 5 µg/mL Apo-Transferrin, 5 ng/mL TGF-α, 0.4%
ExtractP, and 100 ng/mL hydrocortisone which were supplied as a kit from ATCC (PCS600-040). MDA-MB-231 and MDA-MB-468 cell lines were grown in DMEM
supplemented with 10% FBS, 1% amphotericin and 1% penicillin/streptomycin. 4T1,
HCC1937, and K562 cell lines were grown in RPMI-1640 supplemented with 10% FBS,
1% amphotericin, and 1% penicillin/streptomycin, and 4 mM glutamine. Horse and fetal
bovine serum, amphotericin, penicillin, streptomycin, PBS, and trypsin-EDTA were
purchased from Corning Inc. and used as is.
4.14.2 Cell Viability
Cell viability of AuDTC was performed in a previous publication. Cell viability of
4-alkyne was performed in MDA-MB-231. Cells were seeded at a density of 2,000
cells/well in a clear bottom 96-well plate and allowed to adhere overnight. Compound 4alkyne was added to the plate starting at 50 µM, following 3x serial dilutions. The cells
were treated for 72 hours, after which the media was removed and replaced with 100 µL
of MTT solution (prepared fresh as a 5 mg/mL solution in PBS) and added to each well at
a final concentration of 0.5 mg/mL in media. The dye was left to incubate for 4 hours, after
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which the media removed, and replaced with DMSO (100 µL) and incubated at room
temperature for 15 minutes before analysis with a Genios plat reader. The plates were
performed in triplicate. Data were process using GraphPad Prism 6 and plotted as the mean
± s.e.m.
4.14.3 Bioenergetic Stress Test (Seahorse XF96)
The seahorse Mitostress test was performed in accordance to Agilent protocols.
Optimal cell seeding density was determined prior to the experimentation. Cell densities
used are as follows: MDA-MB-231, 30,000 cells/well; MDA-MB-468, 30,000 cells/well;
HCC1937, 25,000 cells/well; 4T1, 20,000 cells/well; K562, 30,000 cells/well; MCF-10A,
20,000 cells/well; and HMEC, 30,000 cells/well. Optimal FCCP injection concentration
was also performed prior to each experiment; each cell line used 0.6 µM FCCP injection.
Each Mitostress experiment used injections compound 4 (acute; before the mitochondrial
inhibitors), oligomycin (1.5 µM; comprised of a mixture of oligomycin A, B, and C) and a
mixture of rotenone/antimycin A (1 µM each). AuDTC was diluted with either Seahorse
XF RPMI-1640 (pH 7.4) or Seahorse XF DMEM (pH 7.4) both supplemented with 1 mM
pyruvate, 2 mM glutamine, and 10 mM glucose media prior to pneumatic injection at the
desired concentrations. The last injection contained 20 µM Hoechst stain. Normalization
was performed as follows: brightfield and fluorescently labeled nuclear images were
collected by the XF Cell Imaging and Counting software and the analyzed results were
incorporated to XF analysis data in the Wave software. Cell number per well was measured
by counting fluorescently labeled nuclei from images captured by Cytation 1/5.
For the suspended cell lines, cells were seeded overnight for at least 12 hours prior
to treatment. For the suspended cell line K562, cells were adhered by using Agilent’s
protocol using Cell-Tak (Corning Cell-Tak Cell and Tissue Adhesive, 1 mg, Cat. #
354240). In brief, a 2.5 mL solution of Cell-Tak solution (22 µg/mL, diluted with Seahorse
XF RPMI media) was prepared and 25 µL applied to each well. These wells were incubated
for 20 minutes at room temperature, washed twice with 200 µL of sterile water, and seeded
K562 cells. To seed cells, once plated, the plate was centrifuged for one minute at 200 g
with zero breaking, and transferred to a 37 °C with 5-10% CO2 to incubate for 1 hour. Cells
were checked under a microscope to confirm adhesion before treatment. Data were
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visualized with Agilent’s Wave 2.6.1 software. Data were extrapolated to GraphPad Prism
6 for analysis.
4.14.4 Seahorse XF96 PMP Assay
MDA-MB-468 cells were seeded at 30,000 cells/well and allowed to adhere
overnight. Pneumatic injection was performed as describe earlier. PMP solution was
supplied from Agilent as a 25 µL vial containing 10 µM PMP solution in HNG buffer (50
mM HEPES, pH 7.4, 100 mM NaCl, 10% glycerol (v/v). For the assay, a 3x MAX buffer
was prepared (660 mM mannitol, 210 mM sucrose, 30 mM KH2PO4, 15 mM MgCl2, 6 mM
HEPES, 3 mM EGTA, and 0.6% w/v fatty acid free BSA). This buffer was then used as a
stock buffer to prepare the assay medium. This buffer was combined with DI H2O and
added pyruvate (10 mM final concentration), malate (1 mM), and PMP (1 nM final
concentration). This buffer was also used for dilutions of compound injections. Cell
normalization was performed as previously described and analyzed with Wave 2.6.1. and
GraphPad Prism 6.
4.14.5 Glycolytic Rate Assay (Seahorse XF96)
MDA-MB-231 cells were seeded at a density of 30,000 cells/well and allowed to
adhere overnight. Pneumatic injections were performed as previously described with a
concentration range from 100 µM to 0.1 µM. Assay media was prepared by supplementing
Seahorse XF DMEM (pH 7.4) with 1 mM pyruvate, 2 mM glutamine, and 10 mM glucose.
Compounds were also diluted with this media. Rotenone/anitimycin A injections were both
1 µM final concentration and 2-deoxyglucose injection was 50 mM. Cell normalization
was performed as previously described and analyzed with Wave 2.6.1. and GraphPad Prism
6.
4.14.6 Real Time ATP Rate Assay (Seahorse XF96)
MDA-MB-468 cells were seeded at a density of 30,000 cells/well and allowed to
adhere overnight. Pneumatic injections were performed as previously described. Assay
media was prepared by supplementing Seahorse XF DMEM (pH 7.4) with 1 mM pyruvate,
2 mM glutamine, and 10 mM glucose. Compounds were also diluted with this media.
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Rotenone/anitimycin A injections were both 1 µM final concentration and 2-deoxyglucose
injection was 50 mM. Cell normalization was performed as previously described and
analyzed with Wave 2.6.1. and GraphPad Prism 6.
4.14.7 ROS – DCF-DA
Cell lines were culture to 75-85% confluency and trypsinized, counted, and
aliquoted to 500,000 cells/tube in a 1.5 mL Eppendorf tube. The cells were washed with
PBS (1 x 1 mL) and suspended in a 20 µM DCF-DA solution (200 µL), transferred to 12
x 75 mm FACS tubes, and incubated at 37 °C for 30 minutes. DCF-DA prep (prepare a 5
mM stock in DMSO, dilute to 20 µM with PBS). Compound 4 was then prepared as a 500
µM stock (1% DMSO in media) and diluted to a final concentration of 5 and 10 µM with
a final volume of 250 µL in the suspension of cells that were pre-incubated with DCFDA.
The solutions were incubated with compound for 2 hours and immediately analyzed using
FACS (FITC channel). Cells were gated using live/dead (FSC-H vs. SSC-A) and excluded
aggregates using FSC-H vs. FSC-H. 30,000 events were recorded for each sample. Data
were analyzed with Flowjo 7.6 and GraphPad Prism 6.
4.14.8 Mitochondrial ROS (mtROS)
For FACS analysis, cells were seeded at 700,000 cells/well in a 6-well clear bottom
plate with 2 mL of media and allowed to adhere overnight. Compound AuDTC was added
to the desired wells and treated for the indicated time points. After the treatment condition,
the media was removed and the cells washed with 2 mL of PBS thrice. MitoSOX staining
solution was prepared by dissolving one ampule provided from ThermoFisher to the
appropriate dilution to achieve a stock solution of 5 mM (50 µg x 13 µL DMSO). This
stock solution was then diluted into phenol red free media at a final concentration of 2.5
µM. The cells were suspended into 200 µL of the working MitoSOX solution and incubated
for 30 minutes at 37 °C. The cells were centrifuged, washed with PBS (1 x 1 mL),
suspended in phenol red free media, and analyzed immediately with FACS (PE channel).
Cells were gated using live/dead (FSC-H vs. SSC-A) and excluded aggregates using FSCH vs. FSC-H. 30,000 events were recorded for each sample. Data were analyzed with
Flowjo 7.6 and GraphPad Prism 6.
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For confocal microscopy, cells were seeded at a density of 300,000 cells in glass
bottom dish fitted with a #1.5 coverslip and allowed to adhere overnight. The media was
removed and placed with fresh media containing compound AuDTC at the indicated
concentration and treated for the desired time. After treatment, the media was removed and
the cells washed with PBS (3 x 1 mL) for 5 minutes in between each wash. A staining
solution containing Hoechst (10 µg/mL), MitoSOX (5 µM), and MitoTracker Green FM
(100 nM) was prepared and the cells incubated for 30 minutes at 37 °C. The media was
removed, washed with PBS (3 x 1 mL) and added phenol red free media prior to imaging.
Microscopy was performed immediately after staining.
4.14.9 Mitochondrial Membrane Potential (MMP) (JC-1)
Cells were seeded in a 6 well clear bottom plate at a density of 500,000 cells/well
in 2 mL of media and allowed to adhere overnight. The media was removed and replaced
with fresh media containing compound AuDTC at the desire concentrations and the cells
treatment for the indicated time. Once the treatment was finished, the media was removed
and the cells washed with PBS (3 x 1 mL). JC-1 solution was prepared by completely
thawing the stock JC-1 purchased from Cayman Chemicals to 37 °C (JC-1 is poorly soluble
in aqueous media, therefore it is imperative the media is properly incubated), and diluted
1:100 in fresh media. Cells were collected by trypsinization and washed 1 x 2 mL with
PBS. The cells were then suspended in 100 µL of the working JC-1 solution for 20 minutes.
CCCP was used as a positive control by dissolving pure powder into DMSO as a 10 mM
stock and dilution with media for treatment. Samples were analyzed immediately after
staining using FACS (FITC channel for J-monomers and PE channel for J-aggregates).
Cells were gated using live/dead (FSC-H vs. SSC-A) and excluded aggregates using FSCH vs. FSC-H. 30,000 events were recorded for each sample. Compensation for PE was
performed using the unstained control and positive control and held constant throughout
analysis. Different cell lines required different compensation values. Loss of PE
fluorescence was analyzed as an indicator of loss of J-aggregates. Data were analyzed with
Flowjo 7.6 and GraphPad Prism 6.
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4.14.10 γH2AX (Confocal Microscopy)
MDA-MB-468 cells were seeded at a density of 300,000 cells/dish in glass bottom
dish fitted with a #1.5 coverslip and allowed to adhere overnight. The media were replaced
fresh media containing AuDTC at a concentration of 5 µM and treated for 12 and 24 hour
time periods. After treatment, the media was removed, washed with PBS (3 x 1 mL) and
fixed in the dish with 4% paraformaldehyde in PBS (MeOH free) for 20 minutes at room
temperature. The cells were washed with PBS (3 x 1 mL) to remove the paraformaldehyde.
Post-fixation, cells were permeabilized/blocked with ice cold 5% BSA, 0.3% triton X-100
in TBS (1X TBS; 50 mM Tris-Cl, 150 mM NaCl, pH 7.5 in DI H2O) for 1 hour. γH2AX
(Ser139)(20E3) rabbit mAb (Cell Signaling #9718) was added to a final concentration of
1:400 and incubated overnight at +4 °C. The cells were washed with TBS (3 x 1 mL) and
added a solution of secondary anti-rabbit Alexa Fluor 647 conjugate (Cell Signaling #4414)
at a final concentration of 1:200 and incubated at room temperature for 1 hour. The media
was removed, washed with TBS (3 x 1 mL) and the cells covered with a Hoechst solution
(10 μg/mL) in TBS. Cells were imaged using a Nikon A1R confocal microscope. Images
were analyzed using NIS-Elements and data plotted using GraphPad Prism 6.
4.14.11Mitochondrial Specific Cytochrome C Release
For FACS, cells were seeded at a density of 750,000 cells/well in a 6 well clear
bottom dish and allowed to adhere overnight. The media was removed and replaced with
fresh media containing AuDTC at a concentration of 1 µM. Cells were treated for different
time points to get a time dependent response. To do so, cells were treated for the longer
incubation times first so all samples were collected at the same time. Bortezomib was used
as a positive control (500 nM). After treatment, cells were collected via trypsinization and
washed with 1 mL of PBS. The supernatant was combined with the adherent cells to collect
all populations. Cells were permeabilized with 100 µL of a freshly prepared ice cold
digitonin solution (200 μg/mL, 100 mM KCl, in PBS) and placed in the +4 °C for 4.5
minutes in 1.5 mL Eppendorf tube. The cells were analyzed by trypan blue exclusion
(approximately 95%). It is important to note: 1) digitonin is difficult to dissolve, we
prepared a stock solution 1 mg/mL by sonication using a Branson CPX2800H sonicator
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for a few minutes until all digitonin powder was dissolved, 2) digitonin responds differently
to cell types therefore it is necessary to experimentally determine the optimal concentration
for each cell type, 3) 100 mM KCl is necessary to the experiment as a high concentration
of KCl is present in the cytoplasm and is therefore needed for dissociation of cytochrome
c from membranes. After permeabilization, 200 µL of 4% paraformaldehyde was added to
the digitonin solution to dilute the digitonin and start the fixation process. The cells were
centrifuged and the supernatant removed. The cells were then suspended in 200 µL of 4%
paraformaldehyde and incubated at room temperature for 20 minutes. The cells were
washed with 1 mL of PBS thrice. Cells were then suspended in blocking buffer (0.05%
saponin, 3% BSA in PBS) and incubated while rocking for 1 hour at room temperature.
The cells were again washed with 1 mL of PBS thrice. The cells were suspended in a
cytochrome c rabbit mAb (Cell Signaling #4272) solution (1:200) in blocking buffer and
incubated overnight with rocking at +4 °C. The cells were washed with PBS (3 x 1 mL)
and suspended in a solution of secondary anti-rabbit Alexa Fluor 647 conjugate (Cell
Signaling #4414) at a final concentration of 1:200 and incubated for 1.5 hours. The cells
were washed twice with PBS (1 mL) and suspended in fresh PBS and analyzed with FACS
(APC channel). For all washing steps, 2500 rpm for 5 minutes was used. Note,
permeabilized/fixed cells do not pellet as tightly, therefore it is important to carefully
pipette the supernatant off. All cell populations were used for analysis to included apoptotic
populations. Cellular debris was gated way. 50,000 events were recorded for each sample.
Populations was differentiated by a negative and positive APC population, with the
negative population being cells that have lost cytochrome c from mitochondria. Unstained,
secondary only, and vehicle samples were used as controls. Cells were gated using
live/dead (FSC-H vs. SSC-A) and excluded aggregates using FSC-H vs. FSC-H. 30,000
events were recorded for each sample. Data were plotted using Flowjo 7.6.
For confocal microscopy, a similar procedure was used. Cells were seeded at a
density of 300,000 cells/dish in a glass bottom dish fitted with a #1.5 coverslip and allowed
to adhere overnight. The media was removed and replaced with fresh media containing
AuDTC at a concentration of 1 µM and treated for 24 hours. After treatment, the media
was removed, cells washed with PBS (1 x 2 mL) and incubated with MitoTracker Green
FM (200 nM) in media for 1 hour at 37 °C. The cells were then washed with PBS (3 x 1
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mL) and fixed, permeabilized, blocked, and incubated with both same primary and
secondary antibodies as described earlier. For our confocal dishes, 600 µL of solution was
sufficient to ensure all cells on the coverslip were completely covered. After this
preparation, the cells were washed with PBS (3 x 1 mL) and incubated with Hoechst stain
(10 µg/mL) for 20 minutes. The media was removed and replaced with fresh PBS. The
cells were imaged using a Nikon A1R confocal microscope. Images were analyzed using
Nikon-Elements. Images are representative of three technical replicates.
4.14.12 Quantification of mTOR
Cells were seeded at 1 x 106 cells in a 100 mm petri dish and allowed to grow to
80% confluence. Cells were treated with compound AuDTC at concentrations of 0.2, 0.5
and 1 µM for 6 hours. After treatment, cells were washed with PBS and lysates were
prepared by scraping cells lysed with RIPA lysis buffer into a 1.5 mL Eppendorf tube. The
mixture was centrifuged for 15 minutes at 14,000g to separate supernatant (protein) from
debris. The cell lysates were separated by 4–20% SDS-polyacrylamide gel electrophoresis
(35 min, 100V). This was followed by transfer of the proteins contained in the gel to PDVF
membrane (1 hour, 350 mA) after which the membrane was blocked with (5% BSA in
PBST) followed by incubation of the membranes overnight with primary antibodies in
blocking buffer (Cell Signaling Technology) overnight (+4 °C). The next day, membranes
were washed with (PBST) and incubated with appropriate secondary antibodies
(horseradish peroxidase-conjugated) prepared in BSA blocking solution. Visualization of
blots was done with a LI-COR C-Digit western blot scanner.
For confocal microscopy, cells were seeded at a density of 300,000 cells/dish in a
glass bottom dish fitted with a #1.5 coverslip and allowed to adhere overnight. The media
was removed and replaced with fresh media containing AuDTC at a concentration of 5
µM for 12 hours. After treatment, the media was removed, cells washed with PBS (1 x 2
mL) and incubated with MitoTracker Green FM (200 nM) in media for 1 hour at 37 °C.
The cells were washed with PBS once with 2 mL. The cells were fixed with 4%
paraformaldehyde at room temperature for 20 minutes and washed with PBS (3 x 1 mL).
Cells were blocked with blocking buffer (1X PBS, 5% FBS, and 0.3% Triton X-100) for 1
hour at room temperature. Primary mTOR antibody (mTOR (7C10) Rabbit mAb #2983
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from Cell Signaling) was then diluted in blocking buffer to a final concentration of 1:200
and incubated overnight at +4 °C. The cells were washed with PBS (3 x 1 mL) and covered
in a solution of secondary anti-rabbit Alexa Fluor 647 conjugate (Cell Signaling #4414) at
a final concentration of 1:200 and incubated for 1.5 hours. After this preparation, the cells
were washed with PBS (3 x 1 mL) and incubated with Hoechst stain (10 µg/mL) for 20
minutes. The media was removed and replaced with fresh PBS. The cells were imaged
using a Nikon A1R confocal microscope. Images were analyzed using Nikon-Elements.
Images are representative of three technical replicates.
4.14.13 Pretreatment Assays (MitoTEMPO)
For all pretreatment assays, MitoTEMPO was prepared as a fresh solution in DI
H2O (solubility 10mg/mL). For flow cytometry (mtROS, JC-1, and apoptosis), the cells
that were seeded (750,000 cells/well) were added fresh media containing MitoTEMPO at
a final concentration of 1 µM and incubated for 2 hours, after which the media was
removed, cells washed with PBS, and then added a solution of fresh media containing
AuDTC at the indicated concentration and treated for the desired time. Staining procedures
remained unchanged. For the seahorse assay, cells were seeded in the Agilent Seahorse
XF96 cell culture microplate and adhered overnight in 100 µL of solution. The next day,
100 µL of MitoTEMPO (2 µM in media) was added 2 hours prior to the assay. The plate
was then analyzed in accordance to the Mitostress test procedure described above.
4.14.14 Apoptosis
Cells were seeded at a density of 1 x 106 cells/well and allowed to adhere overnight.
The cells were treated with AuDTC at a concentration of 10 µM for 12 hours and 24 hours.
For the MitoTEMPO pretreatment conditions, cells were incubated with 1 µM
MitoTEMPO, washed, and added compound AuDTC in accordance to the above
procedure. Hydrogen peroxide (200 μM, 24 hours) was used as a positive control. After
treatment, cells were harvested via trypsinization and washed with PBS (1 x 2 mL). The
cells were suspended in 500 µL of Annexin binding buffer and added PI (10 µg/mL) and
Annexin-FITC (0.9 µg/mL), then incubated for 25 minutes at +4 °C. Cells were gated to
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include all populations excluding debris. Cell counts of 30,000 were used for each sample.
Data were plotted using Flowjo 7.6 and GraphPad Prism 6.
4.14.15 In Vitro Click Chemistry
Cells were seeded at a density of 300,000 cells/ml on a glass bottom dish fitted with
a #1.5 glass coverslip and incubated overnight in appropriate growth medium at 37 °C.
After adhering overnight, the media was removed and cells were washed with PBS twice
(1 mL) before treatment with test compound at (2, 25, and 50 µM) for 1hr. Controls
included no stains, compound AuDTC only, and Alexa Fluor 488-azide only to ensure
fluorescence was a product of the click-chemistry adduct. After treatment with test
compound, cells were washed three times with PBS followed by treatment with
MitoTracker Red CMXRos (200 nM) for 45 minutes after which the cells were washed
three times with PBS (1 mL) and fixed with 4% PFA for 20 minutes at room temperature.
After fixation, cells were washed three times with PBS (1 mL) and permeabilized with 0.2
% Triton X-100 in PBS for 1 hour at room temperature. Cells were washed three times
with PBS (1 mL) after permeabilization. In a 15 ml centrifuge tube, Alex Fluor 488-azide
(final concentration of 100 µM) and amino guanidine (final concentration of 1 mM) were
mixed in PBS, (total reaction volume of 3 ml) and placed on ice. To this mixture was added
CuSO4 and tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) (molar ratio of 1:5). A
stock solution of sodium ascorbate (100 mM) was prepared fresh and added to the mixture
for a final ascorbate concentration of (2.5 mM) in the mixture. The reaction mixture was
placed on ice for 10 minutes after which it was added to the cells for 30 minutes and
incubated at +4 °C. After 30 minutes, cells were washed three times and stained with
Hoechst (10 µg/mL) for 20 minutes at room temperature. Cells were washed with PBS (1
x 1 mL) and imaged with a Nikon A1R confocal microscope. Images were analyzed with
NIS-Elements.
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CHAPTER 5. SYNTHETIC CONTROL OF MITOCHONDRIAL DYNAMICS: DEVELOPING
THREE-COORDINATE AU(I) PROBES FOR PERTURBATION OF MITOCHONDRIA
STRUCTURE AND FUNCTION
The text and figures within this chapter were reproduced by permission of The American
Chemical Society. Reference: R. Tyler Mertens, William C. Jennings, Samuel Ofori, Jong
Hyun Kim, Sean Parkin, Gunnar F. Kwakye, and Samuel G. Awuah JACS Au 2021 1 (4),
439-449. https://pubs.acs.org/doi/10.1021/jacsau.1c00051
5.1

Preface
Mitochondrial structure and organization is integral to maintaining mitochondrial

homeostasis and an emerging biological target in aging, inflammation, neurodegeneration,
and cancer. The study of mitochondrial structure and its functional implications remains
challenging in part because of the lack of available tools for direct engagement, particularly
in a disease setting. Here, we report a gold-based approach to perturb mitochondrial
structure in cancer cells. Specifically, the design and synthesis of a series of tricoordinate
Au(I) complexes with systematic modifications to group 15 nonmetallic ligands establish
structure−activity relationships (SAR) to identify physiologically relevant tools for
mitochondrial perturbation. The optimized compound, 5i selectively disrupts breast cancer
mitochondrial structure rapidly as observed by transmission electron microscopy with
attendant effects on fusion and fission proteins. This phenomenon triggers severe
depolarization of the mitochondrial membrane in cancer cells. The high in vivo tolerability
of 5i in mice demonstrates its preclinical utility. This work provides a basis for rational
design of gold-based agents to control mitochondrial structure and dynamics.
5.2

Introduction
Mitochondria are dynamic organelles that control ATP production, biosynthesis of

macromolecules, and signaling. Often referred to as the powerhouse of the cell, the
mitochondria have a well-defined but complicated structure with important functional
implications. The outer membrane envelops the inner-membrane energy hub, which
protects a dense protein-rich matrix.453 The large surface area of the inner membrane is
characterized by a macromolecular folding, known as cristae. There exists an intimate
relationship between mitochondria morphology and cellular bioenergetics.454 A key
dynamic parameter of regulated mitochondria function is fusion and fission.455 A balanced
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cycle of fusion and fission is critical for physiology and the loss thereof has adverse
implications on cell function, leading to inflammation, aging, neurodegeneration, and
cancer (Figure 5-1).456, 457 Thus, tools to study mitochondrial structure is an unmet need
and an attractive approach for developing new therapeutics.
As part of a large research program in our laboratory to develop mitochondrial probes
and targeting approaches, we are particularly interested in the synthetic control of
mitochondrial homeostasis. We recently reported the development of gold agents, which
have interactions with the mitochondrial OXPHOS machinery and cellular metabolism.

Figure 5-1. Mitochondrial biogenesis is a key component in maintaining cell
homeostasis.
We and others have shown that gold compounds can be tuned for mitochondrial
localization.67 Increasing evidence suggests that mitochondrial biological processes
participate in acquired drug resistance. Specifically, loss of the mitochondrial protein
CLPB compromises mitochondrial structural and functional integrity leading to AML
sensitization to apoptosis.458 Thus, we envisioned that developing small-molecules to
disrupt mitochondrial structure will be of therapeutic benefit. However, synthetic alteration
of oxidation states or ligand environment of gold compounds for direct mitochondria
interaction or targeting of distinct locales is unknown.
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The development of gold-based small-molecules for biological use received a major
boost following the FDA approval of auranofin for the treatment of rheumatoid arthritis.45,
46

Over the past decade, several gold compounds have been synthesized as potential

therapeutic agents for a plethora of diseases.57, 89, 111, 112, 142, 143, 163, 378, 459 Their unique
properties have alluded to unique behavior both in vivo and in vitro in comparison to other
transition metal-based alternatives.10,

105, 106, 146, 147, 460-463

Despite the breadth of gold

complex libraries developed thus far, the unique geometry of tricoordinated Au(I)
complexes are uncommon and their therapeutic potential left untapped.219,

246, 464-470

Bourrisou and co-workers have demonstrated catalytic capability with tricoordinate
complexes due to their distinct reactivity.192, 199, 469, 471, 472 We sought to explore the effect
of these geometrically unique gold complexes on mitochondria morphology and functional
consequences in normal or cancerous epithelial cells.
Our approach included the diversification of compounds using different N^Nbidentate ligands to tune lipophilicity and monodentate arsine or phosphine ancillary
ligands to define a unique degree of asymmetry for interaction with biomolecules in a
manner distinct from other transition metal complexes. The SAR enabled the selection of
a potent candidate that rapidly perturbed the structure of mitochondria after 1 hour as
observed using transmission electron microscopy. The phenotype observed was sharply
different from other agents of known mode of action. Additionally, immunoblotting,
respirometry, and quantitative proteomics studies corroborate the discovery of a novel gold
compound with specificity for mitochondrial structure. We explored the anticancer
potential of the compounds and found that they possess an appreciable selectivity to kill
cancer cells compared to normal ones. Preliminary toxicity studies in mice demonstrate
that 5i can be tolerated safely at 10 mg/kg, highlighting the potential of metal-based
compounds for mitochondrial biology.
5.3

Rationale, Synthesis, and Characterization of Tricoordinate Complexes
The quest to develop chemical tools that target distinct aspects of the mitochondrion

prompted investigations into reagents that can perturb mitochondrial structure. Given
previous reports in the literature of cationic gold complexes directly affecting
mitochondrial damage and mitochondrial permeabilization, we were intrigued to see the
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effect of cationic tricoordinate complexes in mitochondrial biological systems.92, 291, 473-478
Tricoordinate compounds can assume an unsymmetrical structure with one longer metalheteroatom bond length, which is weak enough to act as a coordination site upon bond
breakage. This deviation from the use of leaving groups bonded to metal centers was the
motivation for our work. We hypothesized that unsymmetrical gold compounds would
provide a distinct labile character to interact with biomolecules (vide infra). Therefore, we
designed and synthesized a class of novel compounds to enable SAR studies. Tricoordinate
gold(I) complexes were achieved by a facile synthetic protocol (Figure 5-2).
Commercially available phosphine and arsine ligands were treated with either
HAuCl4·3H2O or AuCl(tht) to afford the neutral gold(I) precursors. These precursors were
subjected to silver transmetalation by adding to a suspension of the gold(I) precursor in
dichloromethane, the corresponding silver salt, and N^N bidentate ligand of choice to
afford a library of cationic tricoordinate gold(I) complexes 5a-j in good-to-excellent yields.
The synthetic feasibility allows for a vast library of complexes to be developed in a short
amount of time. In further development of these complexes and continuing along the group
15 block by adding antimony (Sb) derivatives. Although we were able to isolate the
ClAuSbh3 analogue, it is highly unstable in solution and decomposes to elemental gold
within 10 minutes in a CDCl3 solution. Thus this substrate was not suitable for further
synthetic applications. The crystal structure for this compound can be found in the
supporting information as compound 5k (Figure S-7-24 and Table S-8).
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Figure 5-2. Synthetic approach to developing a tricoordinate gold(I) library with SAR.
All 10 complexes (5a-j) used in this study are depicted above.
5.4

X-ray Crystallography
To further elucidate the unique geometry, the structures of six complexes were solved

by X-ray diffraction techniques. Structure of 5f (Figure 5-3A) demonstrates a clearly
unsymmetrical three coordinate geometry around the gold center. The NN-bidentate ligand
shows heavy distortion with one Au−N bond length significantly longer than the other as
exemplified by compound 5f (Au1−N1 = 2.187(2) Å and Au1−N2 = 2.374(2) Å).67, 381
Consequently, the bite angle between N1−Au−N2 (71.89°(9)) is significantly smaller than
observed in gold(III) phenanthroline complexes, which are typically between 81 and 83°.
Additionally, we were able to confirm the structure of our lead compound, 5i, with the help
of X-ray crystallography (Figure 5-3B).
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Figure 5-3. X-ray crystallography of structures 5f and 5i. Ellipsoids are drawn at the 50%
probability level. Hydrogen atoms are omitted for clarity.
Again, the symmetric distortion between Au−N bonds can be observed with Au−N1
(2.1636(17) Å) and Au−N2 (2.5046(17) Å). All further crystallographic parameters, as
well as structures, for complexes 5d, 5h, and 5i can be found in APPENDIX 1 (Figures
S-7-16 through S-7-21 and Tables S-6 through S-8). We propose that the unique geometry
of these complexes would impart unexplored reactivity in vivo in comparison to the typical
linear d10 gold complexes.
5.5

In Vitro Cell Viability
Once we had established a library of the tricoordinate gold(I) complexes, we then

explored their anticancer efficacy in vitro by initially testing the complexes in a cisplatin
resistant breast cancer cell line, MDA-MB-231 (Table 5-1).66, 70, 322
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Table 5-1. Cell viability of 5a-j in TNBC cell line MDA-MB-231 over a 72 hour
treatment period. Data are plotted as the mean ± s.e.m., (n = 3).
MDA-MB-231
Compound

IC50 value (µM)

Compound

IC50 value (µM)

5a

8.65 ± 0.122

5f

11.75 ± 0.492

5b

2.51 ± 0.151

5g

5.41 ± 0.245

5c

6.56 ± 0.354

5h

1.12 ± 0.095

5d

3.98 ± 0.359

5i

0.501 ± 0.03

5e

0.825 ± 0.065

5j

1.12 ± 0.423

1,10-phenanthroline

7.21 ± 1.68

4,7-

14.08 ± 2.58

dimethylphenanthroline
bathophenanthroline

7.48 ±1.64

2,2’-bipyridine

17.54 ± 0.354

cisplatin

34.56 ± 0.783

auranofin

1.31 ± 0.15

NaSbF6

> 50

Over 50% of cancer patients worldwide receive some type of platinum based drug.72,
309, 479

These drugs have been used to treat testicular, ovarian, cervical, and non-small-cell

lung cancers effectively; however, the success of these drugs are limited by resistance from
long exposure times to the drugs.73, 412, 480 Moreover, platinum-based drugs have been used
in breast cancer cell lines such as BRCA-1 deficient and triple negative breast cancer
(TNBC) cell lines; however, their efficacy is short-lived due to resistance from alteration
to multiple cellular pathways. With this in mind, our initial screening of the tricoordinate
complexes in MDA-MB-231 proved to be a crucial first step in evaluating the cellular
toxicity. All the compounds were more cytotoxic in MDA-MB-231 cells in comparison to
cisplatin (IC50 = 34.56 ± 0.783 μM, Table 5-1; see APPENDIX 5, Figures S-7-129
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through S-7-138 for % survival curves). Next, we evaluated cellular selectivity by testing
the ten complexes in MRC5, a normal lung fibroblast cell line (Figure 5-4A).

Figure 5-4. Cell proliferation assays. (a) Cell viability of all 10 complexes (5a-j) in
MRC5 over 72 h. (b) Cell viability of 5a-j in MDA-MB-231 over 72 h. (c) Cell viability
of 5i in a panel of cell lines over 72 h. (d) SAR of Sphos-based derivatives in MDA-MB231 over 72 h. Control or compounds were treated to ensure a final concentration < 1%
DMSO. Data are plotted as the mean ± s.e.m, (n = 3).
Interestingly, these complexes all exhibited IC50 values over 50 μM. This selectivity
is key, as toxicity to healthy cells is a main source of harmful side effects with regards to
traditional platinum based chemotherapeutics. Overall, complexes bearing the Sphos
ancillary ligand (i.e., 5g-j) were more effective than PPh3 and AsPh3. To establish that the
observed cytotoxicity was due to the gold(I) complex itself and not the bidentate
framework, all four bidentate ligands were evaluated in MDA-MB-231. The cytotoxicity
of the ligands were ≥7 μM (Table 5-1, see APPENDIX 5, Figure S-7-139 for % survival
curves), indicating that the observed cytotoxicities of the tricoordinate gold(I) complexes
are not attributed solely to the bidentate backbone. We, then, evaluated the effect of the
[SbF6]− counterion. Common counterions used in biologically relevant transition metal
complexes are [BF4]− and the most common being [PF6]−. We used NaSbF6 as the source
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of the counterion, and to our delight, there was no cytotoxicity observed (IC50 > 50 μM,
Table 5-1 and Figure S-7-139). Furthermore, SAR considering the different bidentate
ligands revealed that the derivatives of bathophenanthroline (bphen) were more toxic than
their counterparts (Figure 5-4B). This is attributed to improved stability and lipophilic
character of the bphen ligand. The combined SAR gave us our lead compound, 5i, as the
most promising candidate moving forward, with an IC50 value of 0.501 ± 0.03 μM (Table
5-1). To evaluate the efficacy of our lead compound further, we compared it to known FDA
approved drug, auranofin. Given the observed IC50 value of auranofin (1.31 ± 0.15 μM,
Table 5-1), 5i proved to be a potent candidate for extensive biological characterization.
We then explored the efficacy of 5i in an array of cell lines in an attempt to validate the
effect across a broad range of cell lines (Figure 5-4C). 5i demonstrated competitive
cellular toxicity across a panel of cell lines. Additionally, a comparison of the free ligand
(Sphos) and gold(I) precursor (ClAuSphos), reveal that the observed cellular toxicity is a
result of the unified tricoordinate gold(I) complexes and not the ligands (Figure 5-4D).
5.6

Solution Stability and Reactivity
Solution stability of metal complexes is a critical factor in the development of

effective transition metal based therapeutics. The longevity of the complex in biological
systems determines important parameters including but not limited to cytotoxicity,
maximum tolerated doses, and pharmacokinetics. To assess the stability of these gold
complexes, we initially subjected them to time dependent stability studies in the
biologically relevant media: Dulbecco’s modified essential medium (DMEM, see Figure
5-5A for 5i). We monitored changes in the absorption spectra of AuTri-1−10 over the
course of a 24-h time period, incubating the solutions at 37 °C (figures for all complexes
5a-h and 5j can be found in APPENDIX 5, Figures S-7-140 through S-7-148). We
observed that the PPh3 derivatives were relatively stable over the 24-h period, with the
exception of the bipyridyl analogue (5c). The extra electronics of the more conjugated phen
and bphen derivatives provide enhanced stability to the gold metal center. Not surprisingly,
the AsPh3 analogues were not stable, rapidly reducing to elemental gold after the 12-h
mark. The increased bond length observed between Au−As, in complexes 5d-f, confirms
the lability of those compounds and may explain their relatively rapid reduction.
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Figure 5-5. UV−vis assessment of 5i stability and reactivity: (a) UV−vis stability of 5i
(50 μM) in DMEM at 37 °C over 24 h, (b) UV− vis stability of 5i (50 μM) in DMSO at
37 °C over 24 h, (c) UV−vis stability of 5i (50 μM) in PBS at 37 °C over 24 h, (d)
reactivity of 5i (50 μM) with NAC at 37 °C over 1 h, and (e) reactivity of 5i (50 μM) with
GSH at 37 °C over 1 h.
Complexes 5g-j proved to be very stable over the 24-h period due to the stronger
Au−P bonds. Our lead compound 5i, was exceptionally stable over the 24- h time period
(Figure 5-5A-C) with no alterations to the UV−vis spectra. We further evaluated the
solubility and stability of 5i in DMSO (Figure 5-5B) and PBS (Figure 5-5C) using UV−vis
spectroscopy. All complexes are readily soluble in both DMSO and MeCN, however; we
wanted to evaluate the stability of 5i in DMSO and PBS solutions over an extended time
period. When evaluated over a 24-h time period, the complex exhibits minimal changes in
its absorption profile, indicative of suitable stability and solubility of the compound in
solution. Further, we explored the reactivity of 5i with common thiol reductants including
N-acetyl cysteine (NAC) and L-glutathione (GSH). We monitored the reaction by UV− vis
spectroscopy. We incubated a PBS solution of 5i with both NAC (Figure 5-5D) and LGSH (Figure 5-5E) at varying equivalents over 1 h. The reaction involving NAC did not
impact the absorption band of 5i, suggestive of no reaction with NAC. Conversely, when
5i was exposed to L-GSH, a decrease in the absorbance spectrum was observed, indicating
reactivity with this nucleophile. Given that intracellular thiols are common binding targets
of gold(I) complexes, this interaction is not surprising. Of note, there was no reduction to
elemental gold.
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5.7

Direct Effect on Mitochondrial Structure and Function
To examine the direct effect of the geometrically distinct gold agents on

mitochondria, we selected our lead compound, 5i. Morphological changes to mitochondria
are associated with different cell phenotypes or cell death mechanisms.361, 439, 453, 481-484
Targeting mitochondrial processes is a fruitful arena for metallodrug discovery.90, 92, 106, 279,
353, 369, 391, 393, 394, 423, 449, 450, 458, 473, 480, 485-487

We employed the use of transmission electron

microscopy (TEM) to look at the exact morphological changes in mitochondria of cells
exposed to 5i. We treated MDA-MB-231 with 5i (Figure 5-6A), staurosporine (STS) an
apoptosis inducer (e.g., chromatin condensation and margination) (Figure 5-6A);
hydrogen peroxide (Figure 5-6B), which induces necrosis (e.g., cytoplasmic and organelle
swelling, plasma membrane rupture); rapamycin (Figure 5-6B) for cellular induced
autophagy (e.g., formation of double-membrane enclosed vesicles) and erastin (Figure 56B), a known ferroptosis inducer.482 When comparing 5i with our vehicle control, clear
rupture of mitochondrial membranes can be observed along with fragmented cristae (green
arrow). Healthy mitochondria (yellow arrow) show distinct intact outer membrane and
cristae, thus we suspect that our compound is directly effecting the structure of
mitochondria. Comparing 5i treatment with H2O2, the distinct cytoplasmic swelling and
membrane rupture (white star) is observed; however, the mitochondrial structure remains
intact. Comparison to erastin showed opposite effects, 5i demonstrated fragmentation and
destruction of mitochondria structure, whereas erastin showed mitochondrial shrinkage
(orange arrow). Furthermore, comparison of mitochondrial features with both rapamycin
and staurosporine revealed dissimilar morphological changes. Both rapamycin (yellow
arrow) and staurosporine (pink arrow) showed no distinct morphological changes to
mitochondria. Mitochondrial cristae play a pivotal role in overall cell health. Under normal
biological conditions, mitochondria undergo fusion/fission and cristae form junctions
throughout the mitochondria. This allows for the redistribution of cytochrome C from the
cristae lumen to the intermembrane space.484
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Figure 5-6. Transmission electron microscopy of known cell death inducers, vehicle
control, and 5i (10 µM) in MDA-MB-231, 1% DMSO was added to the control wells. A)
left to right: control, 5i, and staurosporine, B) left to right: H2O2, erastin, and rapamycin.
Depicted in the panels as follows: healthy mitochondria (yellow arrows), fragmented
cristae (green arrow), cytosolic swelling (white star), shrunken mitochondria (orange
arrow and orange box), double membrane vesicle (purple arrow).
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As earlier noted, mitochondrial bioenergetics and normal mitochondrial structure are
crucial to maintaining MMP, the driving force of ATP production. Using Velox digital
micrograph software, we measured the cristae width within each treatment condition to
quantify and compare the morphological change (Figure 5-7).

Figure 5-7. Maximal cristae width. Data are representative of 10 cells chosen at random
n = 10, where mitochondria were also chosen at random, and a maximum of 3 cristae
measured per individual mitochondrion. Total number of cristae measured per each cell,
n = 100, data are then plotted as mean ± s.e.m.
We found that treatment with 5i resulted in significantly increased maximal cristae
width in comparison to the vehicle control, implicating dysfunctional cristae and decrease
in mitochondrial biogenesis. This phenomenon may be exploited to develop therapeutics
and study mitochondrial dynamics. Overall, a distinct profile to mitochondrial structure
disruption can be achieved in a rapid manner using 5i.
To investigate the consequence of mitochondrial structure perturbation, we
performed immunoblotting of critical proteins involved in maintaining mitochondrial
structure homeostasis. We examined TOM20, a protein located on the outer membrane as
a component of the import receptor complex, MFN1, a key protein responsible for
mitochondria fission, MFF, a protein primarily responsible for mitochondrial division, and
OPA1, a critical protein involved in maintaining mitochondrial structure (Figure 5-8A).481,
486, 488-490

Immunoblotting in MDA-MB-231 as well as our normal cell model, RPE,
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revealed a decrease in protein content of all four structure proteins in MDA-MB-231 (full
uncropped blots can be seen in APPENDIX 5, Figures S-7-149 through S-7-153. ANOVA
Tables for OPA1, TOM20, and Mitofusin1 can be found in Table S-10). Notably, there
was no change in protein levels in the healthy cell model. Normalized protein levels
confirmed the noted changes (Figures 5-8B-C). It is worth noting that rapid protein
changes were observed within 30 min of treatment. The downregulation of OPA1 by
immunoblotting and quantitative proteomics, suggests that this protein is a potential direct
target of 5i. Recently, a study demonstrated that in HeLa cells, loss of OPA1 leads to
fragmentation of the mitochondrial network in conjunction with loss of mitochondrial
membrane potential thus causing fragmentation and disorganization of mitochondrial
cristae, which resulted in caspase-dependent apoptotic death. With this knowledge, we can
state that disruption of mitochondrial structure is just as pertinent to cell homeostasis as
any other biological system.

Figure 5-8. A) Immunoblots of OPA1, MFF, MFN1, and TOM20 over varying treatment
times with 5i. B) Representative quantitative protein content of OPA1, MFN1, and
TOM20, respectively; n = 4, *p < 0.05, and ***p < 0.001.
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5.8

Generation of Intracellular ROS
Given the recent reports of gold-based chemotherapeutics inducing apoptosis as a

result of ROS generation, we investigated the ability of 5i to generate intracellular ROS.92,
294, 461, 476, 491-493

Using 2′,7′-dichlorofluorescin diacetate (DCF-DA) a fluorogenic dye,

which has its fluorescence activated upon oxidation by ROS species, MDA-MB-231 cells
were stained and subjected to 5i treatment at 5 μM. ROS levels were measured using flow
cytometry (ex. FITC channel) at different time points (15 min, 30 min, and 1 h) (Figure 59). Tert-butyl hydroperoxide was used as a positive control (50 μM, 1 h). After a 15 minute
treatment time with 5i, significant increase in ROS levels was observed in comparison to
the untreated control group. However, after 30 min and furthermore at 1 h, there was no
difference in the ROS increase observed earlier for the 15 minute treatment. We attribute
the phenomenon to initial oxidative stress on the cells upon exposure to 5i. However, since
ROS levels do not drastically increase over exposure time, we posit that ROS may not be
a major contributor to cell cytotoxicity.

Figure 5-9. Intracellular ROS accumulation in MDA-MB-231 monitored by DCF-DA
fluorescence using FACS. 5i was used at a concentration of 5 μM for the designated time
points. TBHP was used as a positive control. 1% DMSO was used as the vehicle control.
Data are plotted as the mean ± s.d., n = 3, n.s. = not significant, and * p < 0.01.
5.9

Quantitative Proteomics
Considering previous effects of gold molecules on intracellular thiols, we sought to

use quantitative proteomics to deepen our understanding of the potential targets or
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pathways impacted by 5i. We subjected 5i-treated MDA-MB-231 cells to TMT-labeled
quantitative proteomics and analyzed for differential protein changes compared to vehicletreated MDA-MB-231 cells. The raw MS files were analyzed and searched against
HUMAN protein database based on the species of the samples using Maxquant. Only high
confident identified peptides were chosen for downstream protein identification analysis.
A quantitative ratio over 1.5 was considered upregulation while quantitative ratio less than
1/1.5 was considered as downregulation. The data revealed significant down regulation of
RAS family proteins, specifically GTPases and RAB proteins. More specifically, 5i
downregulated mitochondria structural proteins (e.g., OPA1, MFN1, and TOM20) without
affecting protein content of the OXPHOS machinery and cell metabolism based proteins
(including SOD1, SOD2, and NRF2) (Figure 5-10).
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Figure 5-10. Quantitative proteomics in MDA-MB-231 upon treatment with 5i (1 μM,
for 12 h).
Other proteins of interest were also found to be downregulated, such as TXLN-1
(Figure 5-10), a sulfur containing thioredoxin like protein. Unsurprisingly, downregulation
of these proteins is common given the affinity of a soft polarizable metal like gold and the
softer nature of sulfur atoms. However, after compilation of significant protein
concentration changes, our findings indicated that these compounds could potentially be
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attacking mitochondria structure rather than cell metabolism. Together, protein studies
corroborate the rapid disruption of mitochondrial structure induced by 5i.
5.10 Effect on Cellular Metabolism
To fully understand the mechanism of action, knowing that mitochondrial based
proteins were modulated, we sought to analyze the effect of 5i treatment on metabolism.
Compounds that disrupt the electron transport chain (ETC) are potent inhibitors of cell
metastasis as cancer cells hijack OXPHOS machinery to support growth.393 First, we
treated cells with 5i via pneumatic injection in a Mitostress assay using Seahorse XF96 and
analyzed the changes in OCR (oxygen consumption rate) over time. Next, known
OXPHOS inhibitors were injected: oligomycin, a complex V inhibitor, to view the basal
OCR; FCCP, an uncoupler used to observe the maximum OCR, and rotenone/antimycin
A, a complex I/III inhibitor to completely shut down the ETC (Figure 5-11A).

Figure 5-11. A) Mitostress test performed in MDA-MB-231 with 5i (injected
pneumatically). Data are plotted as mean ± s.d., n = 8. B) Metabolic parameters derived
from the Mitostress test. Data are plotted as mean ± s.d., n = 8.
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To our surprise, at concentrations 6 times the IC50 of 5i, no significant change in
OCR was observed after the 90 minute experimental protocol. Often, pneumatic injection
is preferred over pretreating cells with the agent under investigation to better recapitulate
direct metabolic effects instead of cell-death associated events. For example, gboxin, a
known small molecule inhibitor of OXPHOS, induces rapid and irreversible inhibition of
overall OCR to demonstrate specificity for mitochondrial respiration.396 Further evaluation
of key metabolic parameters including basal OCR, maximal OCR, spare respiratory
capacity, and non-mitochondrial dependent oxygen consumption remain unaltered (Figure
5-11B). Although OXPHOS is critical for cancer cell proliferation and survival, it is clear
that other cell pathways involving mitochondria can be a target for cell death. Next, we
treated MDA-MB-231 cells with 5i to analyze the mitochondrial membrane polarization
(MMP), using a known uncoupler carbonyl cyanide m-chlorophenyl hydrazine (CCCP) as
a positive control (Figure 5-12). The mitochondrial specific dye JC-1 was used, where
green fluorescence represents J-monomers and red fluorescence represents J-aggregates.494
Interestingly, a stark change in MMP was observed upon treatment in 1 h.

Figure 5-12. JC-1 fluorometric determination of MMP in MDA-MB-231 using 5i.
Images are representative of 3 separate replicates.
This drastic change in MMP suggests that the structural changes observed contribute
to depolarization. We then performed immunoblotting of key proteins involved in the
OXPHOS machinery (full uncropped blots can be found in APPENDIX 5, Figures S-7149 through S-7-153). These included SOD1, SOD2, NRF2, and cytochrome C (Figure 513A). These proteins were chosen because SOD1/SOD2 reduces intracellular ROS and
their inhibition induces cell death by oxidative stress. Increased NRF2 activity provides
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defense against mitochondrial toxins. Furthermore, down regulation of NRF2 is found in
several mitochondrial based diseases, such as Parkinson’s disease.495 Finally, we evaluated
cytochrome c levels as it is released into the cell when a cell receives apoptotic stimuli.
Given the key roles, these proteins play in maintaining redox homeostasis, immunoblotting
provides concrete evidence of protein level upon treatment. In contrast, upon treatment of
both RPE cells and MDA-MB-231 cells, no change in protein levels could be observed.
Measurements of integrated density of protein bands was performed using Image Studio
Software (version 5.2.5), with background correction calculated using a signal ratio error
model. To quantify the protein content (Figures 5-13-B-E), the bands were analyzed with
LI-COR and normalized by β-actin levels. Calculations of relative signal were normalized
to untreated sample for each set, as indicated (full ANOVA tables for SOD1 can be found
in Table S-10 and SOD2, NRF2, and cytochrome C found in Table S-11) . Analysis of the
immunoblots showed no significant changes in the proteins examined, suggesting that 5i
does not interact directly with OXPHOS machinery or key cytosolic proteins that maintain
cell redox homeostasis.

Figure 5-13. A) Immunoblotting of SOD1, SOD2, NRF2, and cytochrome C, B-E)
Representative quantitative protein content of SOD1, SOD2, NRF2, and cytochrome c
respectively, n = 4.
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5.11 Intracellular Uptake of Tricoordinate Complexes
We, then, sought to understand the uptake mechanism of 5i in cells. Understanding
the target and uptake pathway is crucial when developing new therapeutic agents or probes.
Subcellular localization of therapeutic agents to better understand specific target binding
and the affinity a therapeutic has toward certain parts of the cell. This insight helps further
elucidate the mechanism of action of therapeutic agents as one can pinpoint the specific
binding target. We analyzed gold content in specific cellular fractions including, nucleus,
cytoplasm, membranes, and mitochondria. This data revealed that localization of 5i was
found to occur in the cytoplasm of the cell (Figure 5-14A). This can be attributed to the
lipophilicity associated with 5i.

Figure 5-14. Cellular uptake of 5i using GF-AAS in MDA-MB231. A) Subcellular
uptake of 5i in MDA-MB-231 at 1 μM for 6 h. Data are plotted as the mean ± s.d., n = 3.
B) Uptake inhibition using known inhibitors 1 h prior to treatment with 5i (1 μM, 6 h).
Data are plotted as the mean ± s.d., n = 3. GF-AAS standard curves can be found in
APPENDIX 5, Figures S-7-154 and S-7-15.
We observed relatively lower gold uptake in both the nucleus and cellular
membranes. The gold compound localized within the mitochondria at >2 pmol/million
cells. To determine the potential mechanism of cellular uptake, we first treated MDA-MB231 with 5i to determine the whole cell uptake. Next, we pretreated cells with known
uptake inhibitors: sodium azide (NaN3), which is known to inhibit mitochondrial oxidative
phosphorylation and was used as a general inhibitor of energy (ATP)-dependent (active)
uptake; chlorpromazine (CL) was utilized as an inhibitor of clathrin-dependent endocytosis
(CDE); β-cyclodextrin (Me-β-CD) and genestein (Gen) were used as inhibitors of clathrin157

independent endocytosis (CIE); and wortmannin (Wort) was employed as a known
inhibitor of micropinocytosis (Figure 5-14B). The high cellular uptake of Au with respect
to our control when pretreated with NaN3 shows that OXPHOS is not a key factor in uptake
of the compound. This further confirms our hypothesis that these compounds do not
directly affect OXPHOS machinery in cancer cells. Other inhibitors collectively show a
reduction in Au uptake, indicative of a broad uptake mechanism. Overall, this study
illustrates a new way of targeting mitochondria via structural perturbation, rather than
direct interaction of OXPHOS machinery.
5.12 Preliminary In Vivo Studies
To determine preliminary in vivo tolerance, we treated female athymic Nu/nude mice
with 5i at a dose of 10 mg/kg based on gold (every other day, three-times per week, 7×).
With known gold agents having a MTD (maximum tolerated dose from 3 to 10 mg/kg and
auranofin (12 mg/kg based on gold), 10 mg/kg provided us with a more accurate estimation
of overall in vivo toxicity.46, 60, 496, 497 We compared our treatment group to a separate
control group of mice that were administered with 85% Kolliphor, 1% DMSO, and 4%
PBS (n = 2 mice per group) (Figure 5-15). We monitored the weight and behavior of the
mice every 2 days for signs of toxicity. After a 14-day treatment time, all mice were
recorded with no significant change in body weight. This preliminary data suggests that
the compound is tolerable in mice, a critical component in further drug/probe development.
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Figure 5-15. In vivo toxicity as determined by mouse body weight. Female athymic
Nu/Nude mice were treated with 5i or vehicle control at 10 mg/kg twice a week via
intraperitoneal injection, n = 2.
5.13 Conclusion
All together, we have taken advantage of a facile synthetic strategy to access a small
library of unique tricoordinate gold(I) complexes. We have demonstrated that this
geometry seems to play a critical role in cellular toxicity due to the increase in toxicity over
traditional linear gold(I) complexes. These complexes exhibit high in vitro cytotoxicity
with a clear improvement based on SAR. Furthermore, the compounds display a >35 times
selectivity toward TNBC’s over normal lung fibroblasts. Our best candidate displayed
promising cytotoxicity in multiple cell lines. With the use of quantitative proteomics, we
were able to gather critical information which signaled a mitochondrial driven mechanism.
Combined bioenergetics studies revealed no significant effect on bioenergetics; however,
a direct change in overall MMP, which suggests a change in mitochondrial dynamics
independent from OXPHOS. Electron microscopy revealed significant morphological
changes, which are different from traditional cell death pathways, which was further
confirmed by immunoblotting of mitochondrial structure proteins. Cellular uptake was
then quantified and revealed that 5i was taken up into the cell via a broad mechanism and
gold content found to be localized in mitochondria. Finally, preliminary in vivo studies
suggest that these compounds are potential candidates for further evaluation as 5i was
tolerated in mice at 10 mg/kg over a two-week period. All of these factors illustrate for the
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first time, biological utility of tricoordinate gold(I) complexes as mitochondrial probes and
anticancer agents.
5.14 Experimental Details
5.14.1 General Experimental Details
All reactions were carried under ambient conditions in air unless otherwise noted.
Solvents were of ACS grade (Pharmco-Aaper) and used as is. The starting Au(I) complexes
(ClAu(tht), ClAuPPh3, ClAuAsPh3, and ClAuSphos) were prepared from procedures in the
literature.498-501 Triphenylphosphine, triphenylarsine, and tetrahydrothiophene were
purchased from Alfa Aesar. Sphos and AgSbF6 were purchased from Strem Chemicals and
stored under N2. Phenanthroline (phen), 4,7-dimethylphenanthroline (dmphen),
bethophenanthroline (bphen), and bipyridine (bpy) were all purchased from Matrix
Scientific. Deuterated solvents were purchased from Cambridge Isotope Laboratories
(Andover, MA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
and JC-1 were purchased from Cayman Chemicals. NMR spectra were recorded on a
Bruker Avance NEO 400 MHz spectrometer and samples calibrated for: 1H NMR (CD3CN
δ = 1.94 ppm and DMSO-d6 δ = 2.50 ppm), 13C NMR (CD3CN δ = 118.26 and 1.32 ppm
and DMSO-d6 δ = 49.00 ppm), and 31P NMR externally referenced to H3PO4 δ = 0.00).
High-resolution mass spectra (HRMS) were obtained by direct flow injection (injection
volume = 2 µL) using ElectroSpray Ionization (ESI) on a Waters Synapt G2 HDMS
instrument in the positive mode with a quadripole/TOF analyzer (UC Boulder). In addition
to spectroscopic characterization, the purity of all compounds was assessed by RP-HPLC
using an Agilent Technologies 1100 series HPLC instrument and an Agilent Phase Eclipse
Plus C18 column (4.6 mm x 100 mm; 3.5 µm particle size). All compounds were found to
be ≥97% pure.
5.15 General Procedure for the Preparation of Compounds 5a-j
To 5 mL of DCM was added 1 equivalent of the corresponding N^N bidentate ligand
and 1.1 equivalents of AgSbF6 in a 20 mL screw cap vial wrapped in aluminum foil. This
mixture was stirred for 5 minutes at room temperature where it was then added to a solution
of 1 equivalent of corresponding XAu(I)Cl (X = PPh3, AsPh3, and Sphos). The mixture
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was then stirred for 30 minutes at room temperature under the exclusion of light. The
solution was then placed in 1.5 mL Eppendorf tubes and centrifuged at high RPM to pellet
the AgCl solid. The supernatant was decanted into a round-bottom flask (cleaned with aqua
regia) and concentrated in vacuo at 40 °C. Excess Et2O was added to precipitate the
corresponding tri-coordinate complex, which was further washed with excess Et2O and
vacuum dried under the exclusion of light. All complexes except 5d-f are benchtop stable
indefinitely. 5d-f will slowly degrade into a purple looking solid at room temperature,
indicating reduction of the gold metal center. In solution phase, (DMSO and MeCN), 5d-f
will rapidly decompose and deposit elemental gold on the glass vial in both air and under
nitrogen atmosphere. Storage at +4 °C significantly improves the longevity of the
complexes 5a-c and 5g-j.
5.15.1 5a
1

H NMR (400 MHz, MeCN-d3) 9.25 (d, J = 4 Hz, 2H), 8.92 (d, J = 8 Hz, 2H), 8.30

(s, 2H), 8.20 (q, J = 8 Hz, 2H) 7.86 – 7.80 (m, 6H), 7.72 – 7.65 (m, 9H); 13C NMR (101
MHz, DMSO-d6) δ = 152.35, 142.29, 140.43, 134.42, 134.28, 132.74, 132.71, 130.20,
130.08, 129.40, 128.06, 126.18;

31

P NMR (162 MHz, DMSO-d6) δ = 31.27. Purity was

demonstrated to be >97% by RP-HPLC: Rf = 5.09 minutes using the following method:
Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH
with 0.1% TFA; Solvent Gradient: 0 – 3 min S4 (50:50 H2O:MeOH), 5 min (40:60
H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
5.15.2 5b
1

H NMR (400 MHz, DMSO-d6) 8.13 (d, J = 8 Hz, 2H), 8.05 (s, 2H), 7.79 – 7.66

(m, 25H); 13C NMR (101 MHz, DMSO-d6) δ = 152.00, 151.53, 143.04, 136.30, 134.40,
132.73, 132.71, 130.21, 130.09, 129.58, 127.50, 126.35, 125.53;

31

P NMR (162 MHz,

DMSO-d6) δ = 39.12. Purity was demonstrated to be >97% by RP-HPLC: Rf = 10.15
minutes using the following method: Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2O
with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50
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H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100
H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
5.15.3 5c
1

H NMR (400 MHz, MeCN-d3) 8.81 (bs, 2H), 8.51 (d, J = 8 Hz, 2H), 8.27 (bs, 2H),

7.81 (bs, 2H) 7.60 – 7.51 (m, 15H); 13C NMR (101 MHz, MeCN-d3) δ = 142.29, 134.83,
133.84, S5 132.64, 132.46, 132.39, 131.61, 131.15, 130.77, 130.54, 127.50, 124.40,
124.10; 31P NMR (162 MHz, DMSO-d6) δ = 30.75. Purity was demonstrated to be >97%
by RP-HPLC: Rf = 4.77 minutes using the following method: Flow rate: 1 mL/min; λ =
280 nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Solvent
Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70
H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of
run (100:0 H2O:MeOH).
5.15.4 5d
1

H NMR (400 MHz, DMSO-d6) 8.82 (d, J = 8 Hz, 2H), 8.59 (d, J = 8 Hz, 2H), 8.23

(t, J = 8 Hz, 2H), 7.77 (t, J = 8 Hz, 2H) 7.68 – 7.62 (m, 15H).
5.15.5 5e
1

H NMR (400 MHz, DMSO-d6) 9.29 (d, J = 4 Hz, 2H), 8.14 (d, J = 4 Hz, 2H), 8.07

(s, 2H), 7.76 (t, J = 4 Hz, 5H) 7.75 – 7.63 (m, 20H).
5.15.6 5f
1

H NMR (400 MHz, DMSO-d6) 8.81 (d, J = 8 Hz, 2H), 8.59 (d, J = 8 Hz, 2H), 8.23

(t, J = 8 Hz, 2H), 7.77 (t, J = 8 Hz, 2H) 7.68 – 7.62 (m, 15H).
5.15.7 5g
1

H NMR (400 MHz, DMSO-d6) 8.91 (d, J = 8 Hz, 4H), 8.30 (s, 2H), 8.20 (t, J = 8

Hz, 2H), 7.95 (t, J = 8 Hz, 1H), 7.55 (quint., J = 16 Hz, 2H), 6.96 (t, J = 4 Hz, 2H), 5.72 –
5.61 (m, 3H), 3.38 (s, 6H), 2.14 (bs, 2H), 1.85 (bs, 4H), 1.73 (bs, 4H), 1.46 – 1.34 (m,
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10H); 13C NMR (101 MHz, DMSO-d6) δ = 156.13, 151.89, 151.54, 143.36, 143.23, 140.01,
139.04, 132.85, 132.34, 131.03, 127.82, 127.75, 125.76, 122.55, 105.64, 70.23, 32.02,
29.99, 26.24, 22.86, 21.87;

31

P NMR (162 MHz, DMSO-d6) δ = 39.09. Purity was

demonstrated to be >97% by RP-HPLC: Rf = 5.22 minutes using the following method:
Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2O with 0.1% TFA; Eluent B = MeOH
with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60
H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
5.15.8 5h
1

H NMR (400 MHz, DMSO-d6) δ = 8.71 (d, J = 8 Hz, 4H), 8.39 (s, 2H), 8.02 (t, J

= 8 Hz, 2H), 7.94 (t, J = 8 Hz, 1H), 7.55 (quint., J = 16 Hz, 2H), 6.96 (t, J = 4 Hz, 1H), 5.76
– 5.61 (m, 3H), 3.39 (s, 6H), 2.95 (s, 6H), 2.16 (bs, 2H), 1.84 (bs, 4H), 1.72 (bs, 4H), 1.48
– 1.27 (m, 10H);

13

C NMR (101 MHz, DMSO-d6) δ = 157.88, 151.11, 149.87, 142.87,

133.61, 133.53, 133.01, 132.97, 131.46, 129.75, 128.78, 128.16, 128.08, 126.23, 123.90,
103.32, 55.46, 32.03, 30.35, 26.80, 19.14;

31

P NMR (162 MHz, DMSO-d6) δ = 39.13.

Purity was demonstrated to be >97% by RP-HPLC: Rf = 6.01 minutes using the following
method: Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2O with 0.1% TFA; Eluent B =
MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60
H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
5.15.9 5i
1

H NMR (400 MHz, DMSO-d6) 8.93 (bs, 2H), 8.18 – 8.12 (m, 6H), 7.98 (t, J = 8

Hz, 2H), 7.94 (t, J = 8 Hz, 1H), 7.70 (t, J = 4 Hz, 11 H), 7.58 (quint., J = 16 Hz, 1H), 7.00
(t, J = 4 Hz, 1H), 5.86 – 5.67 (m, 3H), 3.44 (s, 6H), 2.20 (bs, 2H), 1.86 – 1.76 (m, 8H), 1.49
– 1.37 (m, 10H);

13

C NMR (101 MHz, DMSO-d6) δ = 156.12, 152.47, 150.81, 143.28,

143.15, 140.39, 132.86, 132.78, 132.35, 132.31, 131.19, 128.80, 128.65, 127.83, 127.75,
126.46, 124.23, 122.61, 122.54, 106.15, 70.19, 31.88, 31.79, 29.80, 26.12, 22.72, 21.90;
31

P NMR (162 MHz, DMSO-d6) δ = 40.74. HRMS (m/z) calcd. 939.3354, found 939.3346

[M - SbF6]+ , Purity was demonstrated to be >97% by RP-HPLC: Rf = 10.87 minutes using
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the following method: Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2O with 0.1% TFA;
Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min
(40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
5.15.10 5j
1

H NMR (400 MHz, DMSO-d6) 8.58 (bs, 2H), 8.49 (d, J = 8 Hz, 2H), 8.24 (bs, 2H),

7.91 (quint., J = 16 Hz, 1H), 7.80 (bs, 2H), 7.54 (d, J = 8 Hz, 2H), 6.99 (t, J = 8 Hz, 1H),
6.46 (bs, 1H), 6.02 (d, J = 8 Hz, 2H), 3.43 (s, 6H), 2.03 (bs, 2H), 1.80 – 1.63 (m, 8H), 1.47
– 1.18 (m, 10H);

13

C NMR (101 MHz, MeCN-d3) δ = 157.97, 133.63, 133.56, 133.04,

133.01, 131.67, 130.31, 130.14, 129.62, 128.20, 128.13, 126.77, 126.04, 135.60, 103.80,
55.53, 31.69, 30.06, 26.87, 26.77, 26.63, 26.32; 31P NMR (162 MHz, DMSO-d6) δ = 38.46.
Purity was demonstrated to be >97% by RP-HPLC: Rf = 4.82 minutes using the following
method: Flow rate: 1 mL/min; λ = 280 nm; Eluent A = H2O with 0.1% TFA; Eluent B =
MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min (50:50 H2O:MeOH), 5 min (40:60
H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100 H2O:MeOH), 10 min (20:80
H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
5.16 Physical and Chemical Characterization
5.16.1 X-ray Crystallography
Crystals of all complexes were grown from slow diffusion of Et2O into a
concentrated solution of MeCN at room temperature. All crystals were mounted using
polyisobutene oil on the end of a glass fibre, which had been mounted to a copper pin using
an electrical solder. It was placed directly in the cold gas stream of a liquid nitrogen
cryostat.258, 259 A Bruker D8 Venture diffractometer with graded multilayer focused MoKα
X-rays (λ = 0.71073 Å) was used to collect diffraction. Raw data were integrated, scaled,
merged, and corrected for Lorentz-polarization effects using the APEX3 package.260, 262, 264
Space group determination and structure solution and refinement were carried out with
SHELXT and SHELXL respectively.263-265, 502 All non-hydrogen atoms were refined with
anisotropic displacement parameters. Hydrogen atoms were placed at calculated positions
164

and refined using a riding model with their isotropic displacement parameters (Uiso) set to
either 1.2Uiso or 1.5Uiso of the atom to which they were attached. Ellipsoid plots were drawn
using SHELXTL-XP. The structures, deposited in the Cambridge Structural Database,
were checked for missed symmetry, twinning, and overall quality with PLATON, an Rtensor, and finally validated using CheckCIF.266, 267 Complete X-ray structures can be
found in Figures S-7-16 through S-7-21 and corresponding complete crystallographic
parameters in Tables S-6 through S-8.
5.17 In Vitro Biological Assays
5.17.1 Cell Culture
All cell lines were purchased from ATCC and routinely grown in a humidified
incubator at 37 °C with 5-10% CO2. MDA-MB-468, MDA-MB-231, MDA-MB-175,
MRC5, RPE-NEO, HCT116, and K562N were grown in DMEM supplemented with 10%
FBS, 1% amphotericin and 1% penicillin/streptomycin. A2780 cells were grown in RPMI
supplemented with 10% FBS, 1% amphotericin, and 1% penicillin/streptomycin, and 4
mM glutamine. All supplements along with PBS and trypsin-EDTA were purchased from
Corning Inc. and used as is.
5.17.2 Cell Viability of 5a-j (Adherent Cell Lines)
The cell viability of all 10 complexes were performed in MDA-MB-231.
Additionally, 5i was evaluated in the following: MDA-MB-175, MDA-MB-468, A2780,
HCT116, OVCAR8 and MRC5. Cells were grown to confluency and trypsin was added to
detach and harvest cells. The cells were washed with 2 mL of PBS and suspended in 10
mL of the appropriate media. The cells were centrifuged at 2000 rpm for 5 minutes and the
pellet washed with 2 mL of PBS then suspended in 5 mL of the appropriate media. The
cells were plated at a density of 2,000 cells/well in a 96-well clear bottom plate and allowed
to adhere overnight at 37 °C with 5-10% CO2. The compounds were prepared as a stock in
DMSO and used fresh. The compounds were added at seven concentrations (< 1% DMSO)
with a 3x serial dilution starting at 50 µM for the highest concentration and incubated at
37 °C for 72 h with 5-10% CO2. 1% DMSO were added to control wells as the vehicle
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control. The medium was removed and a solution of MTT (100 µL, prepared by dissolving
MTT at 5 mg/mL and diluting by 10x with DMEM) was added to each well and incubated
for 4 h at 37 °C with 5- 10% CO2. The dye was removed from each well and 100 µL of
DMSO was added to induce cell lysis. The plates were read using a Genios plate reader (λ
= 570 nm). The experiment was performed in triplicate and data are plotted as the mean ±
s.e.m. (n = 3). Full sigmoidal plots of 5a-j, phenanthroline, bathophenanthroline,
bipyridine, dimethylphenanthroline, auranofin, cisplatin, and NaSbF6 in MDA-MB-231
can be found in Figures S-7-129 through S-7-139.
5.17.3 Cell Viability of 5i (Suspended Cell Lines)
The cell viability of 5i was determined in K562. Cells were grown to confluency
and centrifuged at 2000 rpm for 5 minutes to collect the cell pellet. The cells were washed
with 5 mL of PBS, suspended in 5 mL of DMEM, and centrifuged again at 2000 rpm for 5
minutes to collect the pellet. The pellet was then washed with 2 mL of PBS and suspended
in 5 mL of DMEM. The cells were plated at density of 2,000 cells/well in a 96-well white
bottom plate. 5i was prepared as a stock solution in DMSO and used fresh. The compound
was added at seven concentrations (< 1% DMSO) with a 3x serial dilution starting at 50
µM for the highest concentration and incubated at 37 °C for 72 h with 5-10% CO2. The
cells were removed from the incubator and allowed to rest at room temperature for 30
minutes. To each designated well was then added 20 µL of CellTiter-Glo solution and
orbitally shaken for 5 minutes and the luminescence (1000 ms integration and 150 ms gain)
acquired on a Genios plate reader. The experiment was performed in triplicate. Data are
plotted as the mean ± s.e.m. (n = 3).
5.17.4 Solution Stability 5i
All media were warmed to 37 °C prior to use. DMEM was supplemented with 10%
FBS, 1% amphotericin and 1% penicillin/streptomycin, PBS (1X) was purchased from
Fischer Scientific and used as it, and DMSO was purchased as ACS grade was purchased
from Sigma Aldrich and used as is. All absorption spectra were recorded on a Shimadzu
UV-1280 model instrument. Prior to each run, the instrument was blanked with the
corresponding buffer/solvent. The solutions were incubated at 37 °C until used for
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absorption measurement. For DMEM, 5a-j were prepared as a 1 mM stock in DMSO and
diluted down to 50 µM with the corresponding medium. No precipitation was observed.
The absorption spectra were recorded at each listed time interval. For DMSO and PBS, 5i
was prepared as a 1 mM stock in DMSO and diluted to 50 µM. No precipitation was
observed. The absorption spectra were recorded at each listed time interval.
5.17.5 Reactivity of 5i with NAC and GSH
All media were warmed to 37 °C prior to use. DMEM was supplemented with 10%
FBS, 1% amphotericin and 1% penicillin/streptomycin, PBS (1X) was purchased from
Fischer Scientific and used as it, and DMSO was purchased as ACS grade was purchased
from Sigma Aldrich and used as is. All absorption spectra were recorded on a Shimadzu
UV-1280 model instrument. 5i was prepared as a 1 mM stock in DMSO and diluted to 100
µM. Both NAC and GSH were dissolved in PBS (1 mM) and diluted to 100 µM with PBS.
The solutions were added in the stated stoichiometric amounts and the absorption spectra
recorded after 1 hour of incubation.
5.17.6 Immunoblotting
Equal numbers of RPE and MDA-MD-231 cells were seeded and treated with 5i
for the indicated time points. Whole cell lysates were prepared using RIPA buffer, 1x
protease inhibitor cocktail (Sigma), and 1x phosphatase inhibitor cocktails I and II (Sigma)
and loaded by equal protein for SDS-PAGE. Protein concentrations in the cell lysates were
determined with the Bradford protein assay reagent. Cell lysates containing equal amounts
of protein were separated on a 4 – 20% SDS-polyacrylamide gel. Post separation, proteins
were transferred to a nitrocellulose membrane and non-specific binding sites were blocked
by treating with 5% nonfat dry milk. The membranes were incubated overnight with the
primary antibodies directed against OPA1, MFF, MFN1, TOM20, SOD1, SOD2, NRF2,
cytochrome c, and beta-actin. Appropriate secondary antibodies were used accordingly.
Blots were visualized with Thermo Scientific Pierce Supersignal West Dura Extended
Duration Chemiluminescent Substrate on the LI-COR C-DiGit Chemiluminescent Western
Blot Scanner (Lincoln, NE). Measurement of integrated density of protein bands was
performed using ImageStudioLite software (LI-COR). Full immunoblots can be found in
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Figures S-7-140 through S-7-153. The full ANOVA table can be found in Tables S-10
and S-11.
5.17.7 Whole Cellular Uptake of 5i
For whole cellular uptake, MDA-MB-231 cells were seeded at a density of 1 x 106
cells/mL in a 6-well clear bottom plate with a volume of 2.5 mL and allowed to adhere
overnight at 37 °C. Compounds were prepared as a stock in DMSO and added to each well
at a final concentration of 1 µM (< 1% DMSO) and treated for 6 h. The cells were then
collected by trypsinization and centrifuged at 2000 rpm for 5 minutes to form a pellet. The
pellet was suspended in 1 mL of DMEM, transferred to a 1.5 mL Eppendorf tube, and
centrifuged again at 2000 rpm for 5 minutes. The media were removed, washed with PBS
twice, and the pellet stored at -20 °C until analysis. Prior to analysis, the pellets were
suspended in 0.5 mL of concentrated HNO3 and agitated for 1 minute. The solution was
transferred to a 15 mL Falcon tube and then 4.5 mL of DI H2O was added. The samples
were then subjected to analysis with ICP-OES. Data is represented as the mean ± s.e.m. (n
= 3). The standard curve can be found in Figure S-7-154.
Whole cellular uptake with pre-incubation of uptake inhibitors was performed as
follows. MDA-MB-231 cells were seeded at a density of 1 x 106 in clear-bottomed sixwell plates and incubated at 37 °C overnight. The cells were then pre-treated with the
following inhibitors: NaN3 (1 mM), methyl-β-cyclodextrin (5 mM), chlorpromazine
hydrochloride (28 nM), wortmannin (50 nM), genistein (200 µM), for 1 hour. For the +4
°C sample, the cells were cooled to +4 °C prior to addition of 5i. Following pre-treatment,
the media were removed and washed with PBS (3 x 2 mL). The cells were then incubated
with 5i (5 µM for 24 hours, < 1% DMSO) at 37 °C and the +4 °C sample incubated at the
same concentration at the indicated lower temperature. After treatment, the cells were
collected both, the medium and tryspsinzed cells combined, centrifuged at 2000 rpm for 5
minutes to form a pellet. The pellet was suspended in 1 mL of DMEM, transferred to a 1.5
mL Eppendorf tube, and centrifuged again at 2000 rpm for 5 minutes. The media were
removed, washed with PBS twice, and the pellet stored at -20 °C until analysis. Prior to
analysis, the pellets were suspended in 300 µL of 70% HNO3. 100 µL aliquot of this stock
was then diluted to 1 mL and subjected to GF-AAS. A calibration curve using Au in
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varying concentrations was performed. The same standard curve was used for data analysis
as the previous experiment (Figure S-7-154).
5.17.8 Subcellular Uptake of 5i
The subcellular uptake of 5i was conducted in a similar manner per the instructions
from the RayBio Nuclear Extraction Kit Protocol (RayBiotech, Inc.). MDA-MB-231 cells
were seeded at a density of 10 x 106 in 100 mm petri dishes and incubated overnight at 37
°C. 5i was added at 1 µM (< 1% DMSO) for 6 hours. Once the fractions had been isolated,
the concentrate was subjected to GF-AAS analysis. Prior to analysis, a calibration curve
using Au in varying concentrations was performed. Data is represented as the mean ± s.e.m.
(n = 3). The same standard curve was used for data analysis as the previous experiment
(Figure S-7-154).
5.17.9 Mitochondrial Uptake of 5i
The localization of Au content in mitochondria were performed by using
Mitochondria Isolation Kit for Cultured Cells from ThermoFisher ScientificTM. MDA-MB231 cells were plated at a density of 20 x 106 in 100 mm petri dishes and incubated
overnight at 37 °C. 5i was added at a concentration of 1 µM (< 1% DMSO) for 6 hours.
Once the fractions had been isolated, the concentrate was subjected to GF-AAS analysis.
Prior to analysis, a calibration curve using Au in varying concentrations was performed.
Data is represented as the mean ± s.e.m. (n = 3). The standard curve was used for data
analysis as the previous experiment (Figure S-7-155).
5.17.10ROS accumulation of 5i using DCF-DA
DCF-DA was purchased from Cayman Chemicals, stored at -20 °C, and used
without light. DCF-DA was prepared as a 1 mM stock in DMSO and diluted to a working
concentration of 20 µM with PBS. 5i was prepared as a 1 mM stock in DMSO and diluted
to a working concentration of 25 µM with PBS. MDA-MB-231 cells were grown to 85%
confluency at 37 °C with 5-10% CO2. The cells were trypsinized, washed with PBS, and
aliquoted to a density of 3 x 105 cells, centrifuged, and suspended in 200 µL of a 20 µM
DCF-DA solution prepared above. The cell suspensions were incubated at 37 °C for 30
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minutes. 5i was added (50 µL) to achieve a final volume 250 µL and a final concentration
of 5 µM of 5i and analyzed using FACS (FITC channel, excitation 488 nm) at the given
time intervals. After 4 hours, no response was observed as the population were dead (>
90%). Tert-butyl hydroperoxide was used as the positive control. Data were analyzed using
BD CellQuest Pro and plotted using GraphPad Prism 6.
5.17.11Quantitative Proteomics-Differentially Expressed Proteins (DEP)
MDA-MB-231 cells were seeded on petri dish (100 mm x 15 mm) and allowed to
grow to 85% confluency. The cells were then treated with 5i at a concentration of 1 µM
for 12 h at 37 °C. Cells were harvested and sent to Creative Proteomics (Shirley, NY).
Chemicals and Instrumentation used are as follows: TMT10plex Isobaric Label Reagent
Set, Pierce Quantitative Colorimetric Peptide Assay, was purchased from Thermo Fisher
Science. Triethylammonium bicarbonate buffer (1.0 M, pH 8.5 ± 0.1), tris(2carboxyethyl)phosphine hydrochloride solution (0.5 M, pH 7.0), iodoacetamide (IAA),
formic acid (FA), acetonitrile (ACN), methanol, were purchased from Sigma (St. Louis,
MO, USA). Trypsin from bovine pancreas was purchased from Promega (Madison, WI,
USA). Ultrapure water was prepared from a Millipore purification system (Billerica, MA,
USA). An Ultimate 3000 nano UHPLC system (Thermo Scientific, Waltham, MA) coupled
online to a Q Exactive HF mass spectrometer (Thermo Scientific) equipped with a
Nanospray Flex Ion Source (Thermo Scientific). Cell pellets were lysed by using 200 uL
of RIPA lysis buffer including protease inhibitors, centrifuged at 12000 rpm for 15 min at
4 °C and transfer the supernatant to a new EP tube and protein concentration determined
by using BCA kit. Transfer 200 µL sample into a new microcentrifuge tube. To each
sample tube, reduced by 10 mM TCEP at 56°C for 1 h, then alkylated by 20 mM IAA at
room temperature in dark for 1 h. Next, samples were added free trypsin into the protein
solution at a ratio of 1:50, and the solution was incubated at 37°C overnight and lyophilized
the extracted peptides to near dryness. Re-dissolve the sample with 100 mM TEAB.
Samples were then labelled with peptide and fractionated. Samples were then analyzed by
Nano LC-MS/MS. Nanoflow UPLC: Ultimate 3000 nano UHPLC system (ThermoFisher
Scientific, USA); Nanocolumn：trapping column (PepMap C18, 100 Å , 100 µm × 2 cm,
5 µm) and an analytical column (PepMap C18, 100 Å, 75 µm × 50 cm, 2 µm); Loaded
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sample volume: 5 µL Mobile phase: A: 0.1% formic acid in water; B: 0.1% formic acid in
80% acetonitrile. Total flow rate : 250 nL/min LC linear gradient: a linear gradient from 5
to 7% buffer B in 2 min, from 7% to 20% buffer B in 80 min, from 20% to 40% buffer B
in 35 min, then from 40% to 90% buffer B in 4 min. Q Exactive HF mass spectrometer
(Thermo Fisher Scientific, USA) Spray voltage: 2.2 kV Capillary temperature: 270°C MS
parameters: MS resolution: 120000 at 200 m/z MS precursor m/z range: 300.0-1650.0
www.creativeproteomics.com 45-1 Ramsey Road, Shirley, NY 11967, USA Tel:1-631275-3058

Fax:1-631-

614-7828

www.creative-proteomics.com

info@creative-

proteomics.com MS/MS parameters: Product ion scan range: start from m/z 100 Activation
Type: CID Min. Signal Required: 1500.0 Isolation Width: 3.00 Normalized Coll. Energy:
40.0 Default Charge State: 6 Activation Q: 0.250 Activation Time: 30.000 Data dependent
MS/MS: up to top 15 most intense peptide ions from the preview scan in the Orbitrap.
5.17.12Mitochondrial Membrane Potential (MMP with JC-1)
MDA-MB-231 cells were plated at a density of 5 x 105 cells/plate using a glass
bottom petri dish fitted with a #1.5 cover slip with a final volume of 1.5 mL and allowed
to adhere overnight at 37 °C. Compound 5i was prepared as a stock in DMSO and added
at a final concentration of 10 µM (< 1% DMSO). The cells were treated for 1 h at this
concentration. CCCP was prepared as a stock in DMSO and added at a final concentration
of 5 µM and the cells treated for 15 minutes. This was used as a positive control. After the
indicated treatment time, a working solution of the JC-1 dye (Cayman Chemicals) was
prepared by adding 100 µL of dye into 900 µL of DMEM. Note: the working solution of
JC-1 should always be prepared fresh and not stored for long-term use. Then, 100 µL/mL
of DMEM were added to the cells and incubated at 37 °C for 20 minutes. Prior to imaging,
the media was removed and replaced with room temperature PBS (2 mL). The cells were
then visualized using confocal microscopy on a Nikon A1R Inverted Confocal Microscope.
J-aggregates were imaged with (excitation/emission: 510/590 nm) and J-monomers with
(excitation/emission: 488/525 nm).
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5.17.13 Mitochondrial Metabolism Analysis with Seahorse XF96
The optimum conditions for cell density and FCCP injection concentration were
determined to be 30,000 cells/well and an FCCP injection concentration of 0.6 µM. All
Seahorse XF96 experiments with MDA-MB-231 were performed under these conditions.
The cells were seeded the night prior to the experiment with a final volume of 100 µL and
incubated overnight at 37 °C. Compound 5i was prepared as a stock in DMSO and diluted
to a working concentration of 200 µM with Seahorse XF96 assay buffer and then
subsequently serial diluted by 3x to achieve multiple concentrations. The assay was
performed using a pneumatic injection method of 5i, with the final injection concentrations
of 0.1, 1, and 3 µM (< 1% DMSO). This was followed by injection of oligomycin (1.5
µM), FCCP (0.6 µM) and rotenone/ antimycin A (0.5 µM). The metabolic parameters are
calculated as seen in the supporting information of the following papers.
5.17.14 Transmission Electron Microscopy
MDA-MB-231 cells were seeded in 6 well plates and allowed to grow to 85%
confluency. The cells were then treated with 5i at a concentration of 10 µM (< 1% DMSO)
for 1 h at 37 °C. Growth media were removed and immediately and added 3%
glutaraldehyde at 4°C in 0.1 M Sorenson’s or Cacodylate Buffer. After 5 minutes remove
fix and replace with fresh fixative, leave for 45 min to 1 h at 4°C, washed in 0.1 M buffer
w/5% sucrose 4x, 5 minutes each. Post fix, the cells were stained with 1% OsO4 in 0.1 M
buffer for 1 h at 4°C and washed in 0.1 M buffer 1x. The cells were dehydrated in graded
ethanols, 5 minutes each, from 50% through 100% and absolute ethanol (2x) at 4°C. After
the last alcohol wash remove the residual alcohol with a small pipette and immediately add
straight resin (14.5 g Eponate 12, 8.0 g DDSA, 7.15 g NMA, and 0.85 gm BDMA) to the
dish. Swirl the dish and then remove as much of the resin, (which may contain residual
alcohol), with a plastic pipette being careful not to disturb the cell layer. Then add straight
resin 2x for 1-2 hours and place under the lamp, on a shaker. Pour off the 2nd straight resin
wash, let the plate drain well (leaving a layer of resin on the bottom) and invert labeled
beem capsules into each well that have had the conical ends removed. Place the smooth
factory end down in the wells being careful not to move the capsules around too much and
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disturb the cell layer and polymerize overnight at 60°C. The following morning fill the
beem capsules with fresh resin and polymerize for another 24 hours at 60°C. With the aid
of a metal chemical spatula snap the capsules off the dishes when cool. The capsules were
then sectioned using a fresh microtome. Transmission electron microscopy (TEM) and
scanning transmission electron microscopy (STEM) were performed on a Thermo
Scientific Talos F200X microscope, operated at an accelerating voltage of 200 kV or/and
80 kV. Velox digital micrograph software was used to record TEM/STEM images, measure
cell size, and measure changes in mitochondrial morphology.
5.18 In Vivo Biological Assays
5.18.1 Animal Facility and Standard of Care
Mice were placed in a facility accredited by the Institutional Animal Care and Use
Committee (IACUC ID#: 2019-3183). Treatments were administered by intraperitoneal
injection. The amount of anticancer agent was calculated on the basis of the average animal
body weight. The Division of Laboratory Animal Resources of the University of Kentucky
approved all animal protocols.
5.18.2 In Vivo Maximum Tolerated Dose of 5i
Six-week-old female Nu/Nu Nude mice were purchased from the Charles River
Laboratories (Shrewsbury, MA) and quarantined for seven days. Animals were randomized
into two treatment groups (n = 3) and given either PBS or 5i at an equivalent dose of 10
mg/kg body weight through intraperitoneal injection (every other day, three-time per week,
7x). Mice were weighed every other day to monitor potential side effects and stress.
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CHAPTER 6. RATIONALLY DESIGNED AIR-STABLE AU(I) CATALYSTS FOR REDOX
NEUTRAL C-H FUNCTIONALIZATION WITH IODOARENES
Data and figures presented in this Chapter have been submitted for publication and is
currently under peer review.
6.1

Preface
The development of oxidant-free gold-catalyzed cross coupling reactions involving

aryl halides have been hamstrung by the lack of gold catalysts capable of performing
oxidative addition at Au(I) centers under mild conditions. Expanding gold-catalyzed C-H
functionalization with readily available aryl halides complements widely used palladium
(Pd) catalysis in the construction of complex organic structures containing biaryl scaffolds.
Herein, we report the development of novel tricoordinate gold(I) catalysts supported by
N,N-bidentate ligands and ligated by phosphine or arsine ligands for C-H functionalization
without external oxidants to form biaryls with no homocoupling. The catalytic method is
insensitive to air or moisture. Computational investigation into the mechanism suggest an
oxidative addition step followed by a C(sp2) – H auration and reductive elimination to
afford C – H functionalized products in high yields. The unsymmetrical character of the
air-stable gold(I) catalyst is critical to facilitating this necessary orthogonal transformation.
This study unveils yet another potential of Au(I) catalysis in biaryl synthesis. This work
was inspired by recent works in the literature which employ a hemilable bidentate P-N
ligand to promote oxidative addition. This generated catalyst in situ had a similar
tricoordinate gold(I) geometry. While developing these tricoordinate complexes for
biological activity (see Chapter 5), we also explored the catalytic capabilities of these
frameworks given the unique tricoordinate geometry. To our delight, we were successful
after probing several catalytic transformations. The work presented herein this chapter is
representative of our first discovery.
6.2

Introduction
The biaryl framework is a common structural motif found in prescribed

pharmaceuticals, agrochemicals, pigments, and organic materials including light emitting
diodes (LED), polymer conductors, and liquid crystals.503, 504 Significant gains have been
made in biaryl synthesis primarily using metal-catalyzed strategies that employ aryl halides
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(Ar1-X) and aryl organometallic compounds (Ar2-M).95, 505-511 Direct arylation methods
involving cross-coupling of arenes (Ar1-H) and activated coupling partner (Ar2-M) or the
use of two non-functionalized arenes (Ar1-H) have been engaged in biaryl synthesis.14, 199,
211, 512-515

Drawbacks to these oxidative direct arylation include the formation of

homocoupled side-products, low reactivity, poor selectivity, high catalyst loading, and the
synthesis of specialized pre-activated coupling partners for use in the construction of
complex biaryl-containing compounds. To circumvent these challenges, for example,
selectivity is achieved by using excess of coupling partners and the use of directing groups.
Seminal work by Lloyd-Jones and Russell paved the way for oxidative direct
arylation that invoked AuI/AuIII catalysis for biaryl synthesis using simple arenes and
electron-deficient arylsilanes as coupling partners.200,

513, 514, 516

The use of gold(I)-

catalyzed oxidative arylation of arenes with electron-deficient arylboronic acids further
expanded the scope of oxidative direct arylation.18, 517, 518 Other gold(I)-catalyzed crosscoupling methods employing the combined strength of electron-deficient arenes and/or
activated arenes with strong bases or silver salts have emerged as important routes to C –
C bond formation.19, 519-522 In all these methods, the use of external oxidants stifles catalytic
development.211, 513, 514, 523-529
The challenge of redox-neutral gold catalysis is largely because Au(I) is sluggish in
undergoing oxidative addition due to the high redox potential. Gold catalyzed crosscoupling methods that are redox-neutral is an attractive and burgeoning area of research
with great promise. Pioneering work by Bourissou and Toste stimulated the pursuit of
oxidative addition at gold(I) centers. Gold(I) compounds with tricoordinate configurations
were shown to be activated towards oxidative addition by aryl halides and pi systems.144,
148, 192, 507, 516, 518, 530-532

The use of hemilabile gold(I) catalysts efficiently promote cross-

coupling reactions of electron-rich arenes with aryl iodides (Figure 6-1A).199,

531, 533

Subsequent variations using this catalyst have been advanced in other cross-coupling
reactions without external oxidants. A remarkable study by Russell et al. led to the
establishment of elementary organometallic transformations (oxidative addition,
transmetalation, reductive elimination) using bipyridine gold(I) complexed to homoleptic
gold ethylene in stoichiometric amounts.200 Patil et al. demonstrated gold catalyzed 1,2175

heteroarylation of alkenes (Figure 6-1B) using ligand enabled DalphosAuCl catalyst,
which was further applied to C(sp2)-N cross coupling transformations (Figure 6-1C and
6-1D).14,

515,

534

Also

within

the

last

year,

a decarboxylative cross-

coupling of iodoarenes was detailed by Topczewski and co-workers (Figure 6-1E).535 All
together, these recent efforts on oxidative addition to gold(I) have opened new
opportunities for gold in cross-coupling reactions. The development of catalysts capable of
direct arylation without external oxidants is an unmet need in gold-catalysis
toward biaryl synthesis.
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Figure 6-1. Representation of recent gold(I) catalyzed cross coupling reactions.
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We report herein the synthesis of novel three coordinate gold(I) catalysts that are
shelf-stable for the direct arylation of simple arenes (Ar’-H) with aryl iodides (Ar-X) to
afford biaryls (Ar- Ar’) (Figure 6-1F). The reactions are of good yield and can be carried
out in air/moisture (see Figure S-7-156 for reaction setup). The tolerability of the reaction
to other functional groups makes this strategy particularly useful. The catalyst makes use
of bipyridyl ligands coordinated to Au(I) center and ligated to phosphine or arsenic
ancillary ligands. Notably, degree of distortion imposed by phosphine or arsenic affects
catalyst stability and performance with isolated yields up to >80%. Computational insights
revealed that oxidative addition and iodide abstraction are key steps in the direct arylation
methodology described in this report.
6.3

Synthesis and Characterization
We sought to develop an air-stable three coordinate gold(I) catalyst for direct

arylation (C(sp2) – C(sp2) cross-coupling) due to their significantly unsymmetrical
character that facilitate oxidative addition to aryl halides. Earlier work by Uson et al. and
recently by Russell et al. and Hashmi et al provided impetus to investigate the stability and
catalytic performance of bipyridyl gold(I) ligated by Group 15 ligands based on arsenic or
phosphorus.200, 467, 469 We rationalized that these elements vary in sigma-donor strength and
size, which are capable of distorting the tricoordinate geometry and influence trans effects
for oxidative addition to gold(I). The improved stability of the overall complex will
subsequently deliver a catalytic outcome without external oxidants or photoredox catalysis
as commonly seen with gold(I) arylations. The synthesis of compounds 6a and 6b were
achieved using ligand substitutions that included chloride abstraction by silver. Briefly,
gold(I) compounds bearing triphenylarsine or triphenylphosphine ligands (ClAuAsPh3 and
ClAuPPh3) were reacted with 4,7-dimethylphenanthroline (4,7-dmp) and silver
hexafluoroantimonate in dichloromethane at room temperature for 30 minutes. After
centrifugation of the silver chloride generated, the target complexes were precipitated by
the addition of diethyl ether as off-white solids. The compounds were fully characterized
by 1H NMR, 13C NMR, 31P NMR, HPLC, and HRMS.
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6.4

X-ray Crystallography
Single crystals of 6a and 6b were grown by vapor diffusion of diethyl ether into a

solution of concentrated gold complex in acetonitrile for analysis by X-ray diffraction to
determine the molecular structure.

Figure 6-2. Ellipsoid plots of X-ray crystal structures of compounds 6a and 6b.
Hydrogen atoms are omitted for clarity. All ellipsoids are drawn at the 50% probability
level.
The crystal structures of 6a and 6b reveal a three coordinate gold complex in trigonal
planar orientation with unsymmetrical character (Mercury generated ellipsoid plots can be
seen in Figures S-7-23 and S-7-24; crystallographic parameters can be found in Tables S8 and S-9). The Au-N bond length in 6a and 6b differed from each other, with 6a displaying
a shorter bond length (2.400(2) Å) than that of 6b (2.511(12) Å). This is indicative of a
weaker Au-N bond strength in 6b due to the weaker sigma-donating character of the
triphenylarsine (Au-As bond length (2.275(6) Å) moiety trans to the nitrogen.
Furthermore, the N1-Au-N2 bond angle in complex 6b (72.26(9) °) was greater than that
of 6a (71.68(7) °), alluding to an overall less stable framework. Overall, complex 6b is less
stable in solution over time, exhibiting rapid deposition of elemental gold on glassware.
The observed bond angles and lengths were consistent with other three coordinate
complexes prepared by different methods. We hypothesized that the unsymmetrical
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character due to the weaker Au-N2 bond length relative to Au-N1, coupled with the
stronger Au-P bond (2.2179(6) Å) in 6a will promote oxidative addition and enhance
catalytic performance in direct arylation reactions.
6.5

Reaction Optimization
We explored the feasibility of a direct C(sp2) – C(sp2) cross-coupling using simple

arenes and aryl iodides by investigating the model reaction between iodobenzene (6c) and
2’,4’,6’-trimethoxybenzene (TMB, 3) under various experimental conditions. Preliminary
investigations based on a previous arylation protocol using a catalytic mixture of [Au(4,7dmp)PPh3][SbF6] (6a) and additive AgSbF6 in CH3CN, which yielded low conversion, was
very exciting and compelled us to use other conditions. Initially, biaryl 6c was obtained in
moderate yields using 1,2-dichloroethane (DCE) and by adding a base, K3PO4 (Table 6-1,
entry 1) with 10 mol% catalyst loading (62%). When 6b was used as catalyst, the formation
of 6c was possible but in trace yields (Table 6-1, entry 2).
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Table 6-1. Reaction optimization of biaryl cross-coupling. Notes: a reactions run at 90 °C
under aerobic conditions, b all yields were isolated yields unless otherwise noted, c yields
based on GC-MS using dodecane (0.022 mmol) as an internal standard, d n.d. = not
detected upon GC-MS analysis, e trace = < 5% detected by GC-MS.

Entrya

[Au(I)] cat,
mol%

Ar-I : Ar’-H

Additive, eq.

Base

% Yieldb

1

1a, 10%

1:1

AgSbF6, 1

K3PO4

62%

2

1b, 10%

1:1

AgSbF6, 1

K3PO4

trace c,e

3

1a, 5%

1.5:1

AgSbF6, 1

K3PO4

88%

4

1a, 5%

2:1

AgSbF6, 1

K3PO4

73%

5

1a, 5%

1.5:2

AgSbF6, 1

K3PO4

21%

6

1a, 5%

1.5:1

AgSbF6, 0.5

K3PO4

62%

7

1a, 5%

1.5:1

AgSbF6, 0.20

K3PO4

31%

8

1a, 5%

1.5:1

no additive

K3PO4

n.d.c,d

9

1a, 5%

1.5:1

K3PO4

n.d.c,d

10

no cat.

1.5:2

AgSbF6, 1

K3PO4

n.d.c,d

11

1a, 5%

1.5:1

AgBF4, 1

K3PO4

73%

12

1a, 5%

1.5:1

AgNO3, 1

K3PO4

trace c,e

13

1a, 5%

1.5:1

NaOAc, 1

K3PO4

n.d.c,d

14

1a, 5%

1.5:1

NH4OTf, 1

K3PO4

n.d.c,d

15

1a, 5%

1.5:1

AgSbF6, 1

Cs2CO3

73%

16

1a, 5%

1.5:1

AgSbF6, 1

NaOtBu

71%

17

1a, 5%

1.5:1

AgSbF6, 1

Et3N

34%

4,7-dmp, PPh3 (1
eq. each)
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The substantial increase in yields between 6a and 6b is as a result of the change in
ancillary ligands from PPh3 to AsPh3, suggesting that the role of the donor ligand in
stabilizing the gold center or the degree of distortion of the Au-N bond that lead to
unsymmetrical gold catalyst may be critical for catalytic performance. This is a subject of
intense investigation within our laboratory. We then sought to lower the catalyst loading
and subsequently optimize ratios between coupling partners 6c and aa. To our delight,
when 1.5 equivalents of aryl-iodide was used, we were able to improve overall yield of
6caa even at 5 mol% catalyst loading (Table 6-1, entry 3). It is of note, the reaction will
still proceed even with 1 mol% Au(I) catalyst; however, at reduced yield (41%, Table S12, entry 3). Subsequent optimizations proved that the ratio of aryl-iodide to Ar-H (1.5:1)
were crucial, as excess aryl-iodide (Table 6-1, entry 4) and excess TMB (Table 6-1, entry
5) resulted in loss of yield of the biaryl product 6caa (see Table S-13, entries 1-7 for
complete optimization of stoichiometric equivalents of Ar-I and Ar’-H). Next, changing
stoichiometric amounts of AgSbF6 afforded the biaryl product; however, in less yield than
when using 1 equivalent (Table 6-1, entries 6-7). Control experiments regarding the role
of silver, gold catalyst, and ligands were also performed (Table 6-1, entries 8-10) to ensure
the catalytic transformation was not due to trace metal contamination or the organic
framework alone. The reactions did not proceed without AgSbF6 or the gold catalyst
present (Figures S-7-157 and S-7-158). Further experimentation revealed that even when
ligands; 4,7-dmp and PPh3, were used, the reaction does not proceed without the presence
of the gold(I) complex, 6a (Figure S2).
AgBF4 produced yields comparative to that of AgSbF6 (Table 6-1, entry 11). Of note,
silver salts with less stabilizing anions, like AgNO3, did not facilitate formation of 6caa
(Table 6-1, entry 12). Subsequent optimization of additive was performed by changing
amounts of AgSbF6 used. Overall, decreasing the amount of AgSbF6 reduced the yield of
6caa when either 1.5 or 2 equivalents of Ar-I were used (Table S-14, entries 1-7).
Furthermore, doubling the amount of AgSbF6 to 2 equivalents significantly decreased the
overall yield of 6caa to 22% (Table S14, entry 8). Other additives used did not produce a
reaction (Table 6-1, entries 13-14; Table S-15, entries 1-6, and 9.). The role of base was
then investigated, and we found the use of Cs2CO3 and NaOtBu to be good, resulting in
yields slightly above 70% (Table 6-1, entries 15-16). Other bases, such as triethylamine, a
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common organic base used in palladium-based cross coupling reactions was less optimal,
with low yields of 34% (Table 6-1, entry 17). Other inorganic bases were screened;
however, all were found to be sub-optimal (Table S-16, entries 1-7). Although the yields
for reactions employing different bases were low, the compatibility of diverse array of both
inorganic/organic bases with our catalyst is promising. Of note, no desired product could
be obtained in the absence of a base. Overall, a high-yielding arylation using novel gold(I)
catalysts without external oxidants has been developed. The reactions can be conducted in
an open-air environment in a relatively short period of time (2 h).
6.6

Substrate Scope – Aryl Iodides
We first investigated the substrate scope of the aryl iodides as shown in Table 6-2.

The use of TMB and iodobenzene gave rise to 6caa in excellent isolatable yield (88%).
Similarly, the use of substituted iodoarenes bearing electron donating or electron
withdrawing groups gave good to excellent yields. Functional groups such as phenols and
ethyl benzoates afforded respectable yields, giving rise to functional group tolerance. The
reaction did not discriminate on the position of the iodo substituents on the benzene ring;
ortho, meta, and para substituents all gave acceptable yields. Analysis of the reaction in
the presence of bromides and chlorides, suggest that the initial oxidative addition is
chemoselective for iodoarenes. Reactions with bulkier groups such as naphthalene and
biphenyl also afforded the cross-coupled products in moderate yields. Further exploration
resulted in successfully cross coupling two TMB moieties with 1,2-diiodobenzene,
confirmed by GC-MS (Figure S-7-159) and isolated with column chromatography.
Altogether, the reaction presented allows for a diverse use of aryl-iodides to afford unique
biaryls (6caa-6paa) on moderate to high yields.
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Table 6-2. Substrate scope of aryl iodides used in this study.
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O
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3laa (80%)

6.7

3maa (64%)

3naa (62%)

3oaa (51%)

Substrate Scope – C-H Coupling Partners
Next, we investigated the scope of classes of arenes to undergo an oxidant free, gold-

catalyzed C-H activation with iodobenzene (Table 6-3). Given that previous reports of
gold catalyzed C-H activation used TMB and other electron rich compounds including
indoles as substrates, we sought to expand the arenes with our catalytic system.199 This will
enable a broader library of biaryls to be generated.
We screened a variety of electron rich arenes and found the electron donor character
of the substituents influenced the rate of reaction. The use of a derivative of TMB, 3,5dimethoxyphenol underwent C-H functionalization with iodobenzene to afford the target
compound (6cab) in moderate yield. Upon analysis, only the carbon ortho to the phenol
underwent substitution and was subsequently isolated and well characterized. The stronger
para-directing methoxy substituent may contribute to the observed regioselectivity. Given
the success with 3,5-dimethoxyphenol, we examined the outcome of C-H activation using
2-n-propylresorcinol as a coupling partner. To our delight, this transformation worked
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across 4 different aryl-iodides tested, illustrating the robust capability of the catalytic
reaction (ab-ad). Lastly, we sought to use 2’,3’,4’-trimethoxyacetophenone, as another CH partner. We found that this framework undergoes C-H activation with multiple aryliodides bearing different substituents ranging from electron donating to electron
withdrawing ones (6cad-6fad). We further confirmed selective arylation to the carbon
which is meta to the acetyl group with the use of HMBC (Figures S-7-160 through S-7162).
Table 6-3. Substrate scope of Ar’-H partners used in this study.
[Au(I)] 5 mol%, AgSbF6
K3PO4, 90 oC, 2 h

I
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O

O

HO

OH

HO

OH

OH

F
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6cac (75%)

O
HO

OH

HO

OH

O

O

O
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6fac (82%)
O

O
O

6cad (97%)

O

O

O

F
6dad (88%)

O

O

O
O

O

O

6ead (53%)

6fad (57%)

Interestingly, fluoro-substituted arenes can undergo C-H functionalization under
these conditions. Thus, the scope of biaryl products accessible by this oxidant free Ar–
I/Ar′–H coupling strategy is complementary to that of the redox neutral approaches put
forth by Bourrissou and coworkers, Topczewski et al., Neufeldt and coworkers and the
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oxidative coupling reactions described by Lloyd-Jones, Russell and coworkers, Nevado
and coworkers, and Larrosa and coworkers.
6.8

Proposed Reaction Mechanism and Computational Insight
Given the success of gold catalysis over the years, direct oxidative addition to Au(I)

to form Au(III) species in catalytic transformations have been scarce and questioned.189, 536
Work done recently by Bourrisou and co-workers have demonstrated that direct oxidative
addition is possible, given the success behind the DalphosAuCl complex.144, 148, 192, 530, 531,
533

The reaction presented in this work differs from the pre-ceding reports in the literature

by using a preformed Au(I) catalyst with no need for in situ generation. The unique
tricoordinate geometry of the complex provides a designed hemi-labile framework that we
report as a “swing-door” mechanism versus the DalphosAuCl which helps generate a
hemilabile Au(I) complex via halide abstraction with silver (Figure 6-3). Notably, we are
able to promote oxidative addition to Au(I) with a simple 4,7-dimethylphenanthroline
backbone simply by tuning the geometry from a classic linear Au(I) system to a
tricoordinate Au(I) distorted system.
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Figure 6-3. Proposed catalytic cycle for gold(I) catalyzed C(sp2)-C(sp2) cross-coupling.
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The oxidative addition of iodobenzene and subsequent proposed catalytic steps were
investigated computationally using the triple-ζ quality and low-cost method B97-3c from
Grimme and co-workers (Figure 6-4).537 The method is based on the B97 functional with
dispersion correction and a short-range basis, as implemented in Orca 4. This approach has
proved to be very efficient on large benchmark sets including metal organic reactions
(MORs), and brings considerable speedup. It has been tested on a set of 41 MORs and
performed better (MADs to DLPNO-CCSD(T) = 4.2 kcal/mol) than both B97-D3 and the
(too) popular B3LYP-D3 DFT functionals (MADs of 6.0 and 5.0 kcal/mol,
respectively).537 The phenyl groups on the phosphine were replaced by methyl for obvious
computational reasons. The data obtained here indicate that formation of a (4,7dmp)Au(PMe3)ArI σ-complex (6t2) precedes through oxidative addition by a concerted
mechanism and the oxidative addition of Ar-I (TS1), to form the classical 4-coordinate
square planar Au(III) intermediate 6t2.

Figure 6-4. Calculated free energy profile for the oxidative addition and C-C coupling at
the B97-3C level of theory in the gas phase. The catalytic cycle proceeds through four
consecutives transition states (TS1-TS4).
Subsequent C-H activation and di-aryl coupling was found to proceed through three
transition states with the first demonstrating binding of the electrophilic Au(III) center to
the aromatic carbon, resulting in C-H activation on TMB (TS2), with an out-of-plane
deformation of the C(sp2)-H bond (i.e., increased sp3 character), while the concomitant
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release of iodine leads to the formation of 6t4. Next, the C-H proton is transferred to the
iodine (TS3), producing the intermediate square planar complex 6t5, which will finally
progress to TS4 to form the di-aryl product 6t6 and restore the starting Au(I) catalyst with
an overall free energy change of around -7 kcal mol-1. The highest energy barrier was
calculated to be 25.2 kcal mol-1 and the reaction should indeed proceed easily at the reaction
temperature (90 °C).
6.9

Conclusions
In conclusion, we report the first use of air-stable, pre-formed tricoordinate Au(I)

complexes to catalyze the formation of biaryls through C(sp2)-C(sp2) coupling under
aerobic conditions. This work expands upon previous reports of gold-catalyzed C(sp2)C(sp2) cross-coupling. We are able to demonstrate functional group tolerance, a broad
scope of acceptable iodoarenes which vary in donor properties, and are able to expand the
scope of C-H activation partners. We further elucidate the mechanistic pathway through
detailed computational studies. Taken together, this work provides fundamental
experimentation that can be further developed and applied to different catalytic cycles and
applications.
6.10 Experimental Details
6.10.1 General Experimental Details
All reactions were carried under ambient conditions in air unless otherwise noted.
Solvents were of ACS grade (Pharmco-Aaper) and used as is. The starting gold(I)
precursors ClAuPPh3 and ClAuAsPh3 were prepare from procedures reported in the
literature.382,

467

Aryl iodides and C-H coupling partners were purchased from Sigma

Aldrich, TCI chemicals, Santa Cruz Biotechnology, Acros Organics, Alfa Aesar, and
Oakridge chemicals. Deuterated solvents were purchased from Cambridge Isotope
Laboratories (Andover, MA). NMR spectra were recorded on a Bruker Avance NEO 400
MHz spectrometer and samples calibrated for: 1H NMR (CDCl3 δ = 7.26 ppm, CD3CN δ
= 1.94 ppm, and DMSO-d6 δ = 2.50 ppm), 13C NMR (CDCl3 δ = 77.36 and DMSO-d6 δ =
49.00 ppm),

19

F NMR externally referenced to (CFCl3 δ = 0.00 ppm) and

31

P NMR

externally referenced to (H3PO4 δ = 0.00 ppm). All reactions were carried out in
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borosilicate glass test tubes (VWR) in a heating block apparatus (BDProbeTecET Lysing
Heater, REF 440483). Silica gel for column chromatography (Silicycle, P/N: R10030B
SilicaFlash F60, Size: 40-63 µm, Canada) was purchased from Silicycle. Aluminum
backed silica-gel plates (20 x 20 cm2) were purchased from Silicycle (TLA-R10011B-323)
and utilized for analytical thin-layer chromatography (TLC). Electrospray ionization mass
spectrometry (ESI-MS) was performed on an Agilent Technologies 1100 series liquid
chromatography/MS instrument. High-resolution mass spectra (HRMS) were obtained by
direct flow injection (injection volume = 2 μL) using ElectroSpray Ionization (ESI) on a
Waters Qtof API US instrument in the positive mode (CIC, Boston University). Removal
of solvents in vacuo was performed using a Büchi rotary evaporator and further drying was
achieved via a Schlenk line at ~120 mTorr using a dynamic vacuum pump.
6.11 X-ray Crystallography
Crystals of all complexes were grown from slow diffusion of Et2O into a
concentrated solution of MeCN at room temperature. All crystals were mounted using
polyisobutene oil on the end of a glass fibre, which had been mounted to a copper pin using
an electrical solder. It was placed directly in the cold gas stream of a liquid nitrogen
cryostat.258, 259 A Bruker D8 Venture diffractometer with graded multilayer focused MoKα
X-rays (λ = 0.71073 Å) was used to collect diffraction. Raw data were integrated, scaled,
merged, and corrected for Lorentz-polarization effects using the APEX3 package.260-262
Space group determination and structure solution and refinement were carried out with
SHELXT and SHELXL respectively.263, 264, 502 All non-hydrogen atoms were refined with
anisotropic displacement parameters. Hydrogen atoms were placed at calculated positions
and refined using a riding model with their isotropic displacement parameters (Uiso) set to
either 1.2Uiso or 1.5Uiso of the atom to which they were attached. Ellipsoid plots were drawn
using SHELXTL-XP.264 The structures, deposited in the Cambridge Structural Database,
were checked for missed symmetry, twinning, and overall quality with PLATON, an Rtensor, and finally validated using CheckCIF.266, 267
6.12 Quantum Mechanical Calculations
All calculations have been achieved using Orca 4.2.1. Geometries were fully
optimized with the triple-ζ quality and low-cost method B97-3c from Grimme and co188

workers. Potential energy surface minima found upon optimization were confirmed by
frequency calculations and free energies were corrected to account for the zero-point
energy. Optimized geometries were verified as minima (i.e. no imaginary frequencies). The
nudged elastic band (NEB) method was used for locating transition structures. These
structures were further verified as saddle points by frequency calculations (i.e. one
imaginary frequency).
6.13 Synthesis of Gold Catalysts
6.13.1 Synthesis of 6a
Prepared according to a procedure in the literature.382, 467 A round bottom was
charged

4,7-dimethylphenanthroline

(143

mg,

0.69

mmol)

and

silver

hexafluoroantimonate (260 mg, 0.76 mmol) were combined in 10 mL of DCM. A separate
solution of ClAuPPh3 (340 mg, 0.69 mmol) was dissolved in 1.5 mL of DCM. The
solutions were mixed together and stirred at room temperature for 30 minutes. The solution
was centrifuged to pellet AgCl formed during the reaction. The supernatant was decanted,
concentrated in vacuo to a volume around 1-1.5 mL and added excess Et2O to precipitate
a white solid which was further dried over vacuum in air. Yield 220 mg, 74%. 1H NMR
(400 MHz, CD3CN) δ = 9.04 (d, J = 4 Hz, 2H), 8.35 (s, 2H), 7.99 (d, J = 4 Hz, 2H), 7.81
(q, J = 20 Hz, 6H), 7.64-7.71 (m, 9H), 2.95 (s, 6H); 13C NMR (101 MHz, DMSO-d6) δ =
151.87, 150.16, 134.37, 134.23, 132.67, 132.65, 130.24, 130.18, 130.06, 129.63, 129.18,
126.63, 124.10, 19.36;

31

P NMR (162 MHz, CD3CN) δ = 31.60. Purity was determined

>97% by RP-HPLC: Rf = 4.95 min.; HPLC Flow rate: 1 mL/min; λ = 240 nm; Eluent A =
H2O with 0.1% TFA; Eluent B = MeOH with 0.1% TFA; Solvent Gradient: 0 – 3 min
(50:50 H2O:MeOH), 5 min (40:60 H2O:MeOH), 7 min (30:70 H2O:MeOH), 9 min (0:100
H2O:MeOH), 10 min (20:80 H2O:MeOH), 12 min until end of run (100:0 H2O:MeOH).
HRMS (m/z) calcd. 667.16; found: 667.10.
6.13.2 Synthesis of 6b
Prepared according to a procedure in the literature.382,
charged

with

4,7-dimethylphenanthroline
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(143

mg,

467

0.69

A round bottom was
mmol)

and

silver

hexafluoroantimonate (260 mg, 0.76 mmol) were combined in 10 mL of DCM. A separate
solution of ClAuAsPh3 (371 mg, 0.69 mmol) was dissolved in 1.5 mL of DCM. The
solutions were mixed together and stirred at room temperature for 30 minutes. The solution
was centrifuged to pellet AgCl formed during the reaction. The supernatant was decanted,
concentrated in vacuo to a volume around 1-1.5 mL and added excess Et2O to precipitate
a white solid which was further dried over vacuum in air. *This compound is not benchtop stable for more than a few months. It will decompose to a purple colloidal solid in air
over time. The compound cannot be stored in solution for extended periods of time as well
due to the high lability of the Au-As bond. Yield 334 mg, 68%. 1H NMR (400 MHz,
CD3CN) δ = 9.04 (d, J = 4 Hz, 2H), 8.35 (s, 2H), 7.99 (d, J = 4 Hz, 2H), 7.74 (t, J = 8 Hz,
6H), 7.65 (d, J = 4 Hz, 9H), 2.90 (s, 6H);

13

C NMR (101 MHz, DMSO-d6) δ = 151.77,

149.60, 141.63, 133.44, 132.16, 131.96, 130.48, 128.89, 126.47, 123.88, 19.33.
6.14 General Procedure for the Preparation of Biaryls
All reactions were carried under ambient conditions in wet solvents. Aryliodide (0.33
mmol), C-H coupling partner (0.22 mmol), K3PO4 (70 mg, 0.33 mmol), AgSbF6 (76 mg,
0.22 mmol), and gold catalyst (5 mol%, 10 mg, 0.011 mmol) were added to a 13 mL glass
test tube and dissolved in 3 mL of 1,2-dichloroethane and briefly sonicated (~ 1 minute)
and added to a heating block apparatus (BDProbeTecET Lysing Heater, REF 440483)
and heated at 90 ˚C for 2 hours. After the reaction was completed, the mixture was placed
in a 15 mL centrifuge tube and centrifuged at 2000 rpm for 1-2 minutes to pellet the
inorganics. The supernatant was decanted into a round bottom flask and the crude mixture
separated on a silica gel flash chromatography (eluent was a gradient from 1% EA/hexanes
to 20% EA/hexanes). The fractions were combined, solvent removed in vacuo, and dried
on a rotary evaporator to dryness to afford the products in moderate to high yields.
6.15 Control Reaction Without Gold Catalyst
All reactions were carried under ambient conditions in wet solvents. Iodobenzene
(37 μL, 68 mg, 0.33 mmol), 2’,4’,6’-trimethoxybenzene (37, mg0.22 mmol), K3PO4 (70
mg, 0.33 mmol), AgSbF6 (76 mg, 0.22 mmol), and were added to a 13 mL glass test tube
and dissolved in 3 mL of 1,2-dichloroethane and briefly sonicated (~ 1 minute) and added
to a heating block apparatus (Figure S-7-156) and heated at 90 ˚C for 2 hours. The reaction
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mixture was centrifuged, and the supernatant analyzed with GC-MS using dodecane as an
internal standard. No formation of 6caa was observed.
6.16 Control Reaction With No Additives
All reactions were carried under ambient conditions in wet solvents. Iodobenzene
(37 μL, 68 mg, 0.33 mmol), 2’,4’,6’-trimethoxybenzene (37 mg, 0.22 mmol), K3PO4 (70
mg, 0.33 mmol), AgSbF6 (76 mg, 0.22 mmol), 4,7-dimethyl phenanthroline (46 mg, 0.22
mmol), and triphenylphosphine (58 mg, 0.22 mmol) were added to a 13 mL glass test tube
and dissolved in 3 mL of 1,2-dichloroethane and briefly sonicated (~ 1 minute) and added
to a heating block apparatus and heated at 90 ˚C for 2 hours. The reaction mixture was
centrifuged, and the supernatant analyzed with GC-MS using dodecane as an internal
standard. No formation of 6caa was observed.
6.17 Characterization of Biaryls
6.17.1 6caa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and iodobenzene (37 µL, 0.33 mmol) as a white solid. Yield: 46 mg, 88%. 1H NMR
(400 MHz, CDCl3) δ = 7.32 (t, J = 8 Hz, 2H), 7.26 (d, J = 2 Hz, 1H), 7.21-7.25 (m, 2H),
6.15 (s, 2H), 3.79 (s, 3H), 3.64 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 160.52, 158.36,
134.12, 130.82, 127.64, 126.50, 112.55, 90.93, 55.90, 55.39.
6.17.2 6daa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and 4-bromoiodobenzene (93 mg, 0.33 mmol) as a white solid. Yield: 38 mg, 53%.
1

H NMR (400 MHz, CDCl3) δ = 7.42 (d, J = 4 Hz, 2H), 7.13 (d, J = 4 Hz, 2H), 6.15 (s,

2H), 3.79 (s, 3H), 3.65 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 157.58, 156.81, 132.99,
130.79, 111.73, 109.43, 90.89, 55.86, 55.41, 29.71.
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6.17.3 6eaa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and 3-bromoiodobenzene (42 µL, 0.33 mmol) as a white solid. Yield: 40 mg, 57%.
1

H NMR (400 MHz, CDCl3) δ = 7.40 (s, 1H), 7.33 (td, J = 8, 4 Hz, 1H), 7.15-7.19 (m, 2H),

6.14 (s, 2H), 3.79 (s, 3H), 3.66 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 160.92, 158.26,
136.29, 134.18, 129.97, 129.44, 129.07, 121.63, 110.98, 90.81, 76.30, 55.87, 55.41, 45.82,
29.71.
6.17.4 6faa
Prepared as described in the general procedure Trimethoxybenzene (37 mg, 0.22
mmol) and 1-iodo-4-nitrobenzene (82 mg, 0.33 mmol) as a yellow solid. Yield: 24 mg,
38%. 1H NMR (400 MHz, CDCl3) δ = 8.15 (d, J = 4 Hz, 2H), 7.43 (d, J = 4 Hz, 2H), 6.16
(s, 2H), 3.81 (s, 3H), 3.67 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 160.55, 157.14, 145.21,
140.74, 131.22, 121.73, 109.08, 89.83, 54.80, 54.43, 52.40, 28.69.
6.17.5 6gaa
Prepared as described in the general procedure Trimethoxybenzene (37 mg, 0.22
mmol) and 4-iodoanisole (37 µL, 0.33 mmol) as a white solid. Yield: 45 mg, 74%. 1H NMR
(400 MHz, CDCl3) δ = 7.19 (d, J = 8 Hz, 2H), 6.86 (d, J = 4 Hz, 2H), 6.15 (s, 2H), 3.79 (s,
3H), 3.76 (s, 3H), 3.65 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 160.28, 158.45, 158.12,
132.19, 126.16, 113.24, 112.10, 90.94, 65.88, 55.91, 55.39, 55.14, 15.29.
6.17.6 6haa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and 4-bromo-4’-iodobiphenyl (118 mg, 0.33 mmol) as a white solid. Yield: 33 mg,
38%. 1H NMR (400 MHz, CDCl3) δ = 7.42-7.51 (m, 6H), 7.35 (d, J = 4 Hz, 2H), 6.18 (s,
2H), 3.80 (s, 3H), 3.70 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 159.65, 157.34, 139.24,
136.85, 132.59, 130.34, 127.65, 125.18, 120.17, 110.73, 89.89, 54.88, 54.38.

192

6.17.7 6iaa
Prepared as described in the general procedure Trimethoxybenzene (37 mg, 0.22
mmol) and 4-fluoroiodobenzene (38 µL, 0.33 mmol) as a white solid. Yield: 42 mg, 72%.
1

H NMR (400 MHz, CDCl3) δ = 7.27 (t, J = 8 Hz, 2H), 7.05 (t, J = 8 Hz, 2H), 6.21 (s, 2H),

3.85 (s, 3H), 3.71 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 163.46, 162.63, 160.69, 158.41,
132.86, 114.60, 111.43, 90.93, 55.95, 55.48.19F NMR (376 MHz, CDCl3) δ = -116.46.
6.17.8 6jaa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and 2-iodoanisole (77 mg, 0.33 mmol) as a white solid. Yield: 49 mg, 82%. 1H
NMR (400 MHz, CDCl3) δ = 7.30 (t, J = 12 Hz, 1H), 7.16 (d, J = 4 Hz, 1H), 6.98 (q, J =
16 Hz, 2H), 6.23 (s, 2H), 3.85 (s, 3H), 3.75 (s 3H), 3.70 (s, 6H); 13C NMR (101 MHz,
CDCl3) δ = 160.74, 158.75, 157.78, 132.69, 128.44, 123.57, 120.33, 111.29, 109.09, 91.11,
56.07, 55.92, 55.40.
6.17.9 6kaa
Prepared as described in the general procedure Trimethoxybenzene (37 mg, 0.22
mmol) and 1-iodonaphthalene (84 mg, 0.33 mmol) as a white solid. Yield: 57 mg, 88%. 1H
NMR (400 MHz, MeCN-d3) δ = 7.85 (q, J = 20 Hz, 2H), 7.52 (q, J = 24 Hz, 2H), 7.43 (t,
J = 12 Hz, 1H), 7.34 (t, J = 16 Hz, 2H), 6.29 (s, 2H), 3.91 (s, 3H), 3.62 (s, 6H); 13C NMR
(101 MHz, CDCl3) δ = 160.44, 158.48, 136.13, 131.09, 128.61, 112.46, 90.92, 55.96,
55.47, 29.80, 21.45.
6.17.106laa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and 4-iodotoluene (80 mg, 0.33 mmol) as a white solid. Yield 45 mg, 80%. 1H NMR
(400 MHz, CDCl3) δ = 7.20 (q, J = 16 Hz, 4H), 6.22 (s, 2H), 3.85 (s, 3H), 3.71 (s, 6H),
2.37 (s, 3H); 13C NMR (101 MHz, CDCl3) δ = 160.44, 158.48, 136.13, 131.09, 128.61,
112.46, 90.92, 55.96, 55.47, 29.80, 21.45.
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6.17.116maa
Prepared as described in the general procedure Trimethoxybenzene (37 mg, 0.22
mmol) and 4ethyl 4-iodobenzoate (54.8 µL, 0.33 mmol) as a white solid. Yield: 45 mg,
64%. 1H NMR (400 MHz, CDCl3) δ = 8.04 (d, J = 8 Hz, 2H), 7.40 (d, J = 2 Hz, 2H), 6.21
(s, 2H), 4.36 (q, J = 16 Hz, 2H), 3.85 (s, 3H), 3.71 (s, 6H), 1.37 (t, J = 12 Hz, 3H); 13C
NMR (101 MHz, CDCl3) δ = 171.27, 166.89, 161.09, 158.32, 139.40, 131.39, 128.92,
128.46, 111.54, 90.95, 60.79, 60.49, 55.93, 55.49.
6.17.126naa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and 1,2-diiodobenzene (43.3 µL, 0.33 mmol) as a white solid. Yield: 56 mg, 62%.
1

H NMR (400 MHz, CDCl3) δ = 7.19 (s, 4H), 6.16 (s, 2H), 5.94 (s, 2H), 3.77 (s, 3H), 3.71

(s, 3H), 3.64 (s, 6H), 3.47 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 160.55, 159.80, 159.14,
158.25, 134.71, 132.01, 126.41, 112.73, 91.37, 90.52, 89.93, 56.14, 55.28, 29.72. GC-MS
(m/z) calcd. 410.17; found: 410.10.
6.17.136oaa
Prepared as described in the general procedure. Trimethoxybenzene (37 mg, 0.22
mmol) and 3-iodophenol (73 mg, 0.33 mmol) as a white solid. Yield: 29.2 mg, 51%. 1H
NMR (400 MHz, CDCl3) δ = 7.19 (s, 1H), 6.83 (d, J = 12 Hz, 1H), 6.71 (t, J = 16 Hz, 2H),
6.15 (s, 2H), 3.79 (s, 3H), 3.65 (s, 6H); 13C NMR (101 MHz, CDCl3) δ = 160.58, 158.33,
154.91, 135.72, 128.76, 123.83, 118.23, 113.61, 112.08, 90.92, 55.39.
6.17.146cab
Prepared as described in the general procedure. 3,5-dimethoxyphenol (34 mg, 0.22
mmol) and iodobenzene (37 µL, 0.33 mmol) as a white solid. Yield: 27 mg, 53%. 1H NMR
(400 MHz, CDCl3) δ = 7.48 (t, J = 16 Hz, 2H), 7.34 -7.48 (m, 3H), 6.23 (d, J = 1 Hz, 1H),
6.16 (d, J = 2 Hz, 1H), 5.30 (s, 1H), 3.82 (s, 3H), 3.71 (s, 3H); 13C NMR (101 MHz, CDCl3)
δ = 160.84, 158.13, 154.32, 132.42, 131.07, 129.20, 127.87, 109.97, 92.76, 91.62, 55.75,
55.41, 29.72.
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6.17.156cac
Prepared as described in the general procedure. N-propylresorcinol (33 mg, 0.22
mmol) and iodobenzene (37 µL, 0.33 mmol) as a colorless oil. Yield: 38 mg, 75%. 1H
NMR (400 MHz, CDCl3) δ = 7.36-7.50 (m, 5H), 6.95 (d, J = 8 Hz, 1H), 6.46 (d, J = 8 Hz,
1H), 2.69 (t, J = 12 Hz, 2H), 1.64 (sx, J = 54 Hz, 2H), 1.02 (t, J = 16 Hz, 3H); 13C NMR
(101 MHz, CDCl3) δ = 154.31, 151.38, 137.52, 129.40, 129.23, 127.54, 120.96, 115.41,
107.61, 65.89, 25.54, 22.28, 15.27, 14.29.
6.17.166dac
Prepared as described in the general procedure. N-propylresorcinol (33 mg, 0.22
mmol) and 4-fluoroiodobenzene (38 µL, 0.33 mmol) as a colorless oil. Yield: 38 mg, 70%.
1

H NMR (400 MHz, CDCl3) δ = 7.32 (t, J = 8 Hz, 2H), 7.08 (t, J = 16 Hz, 2H), 6.83 (d, J

= 4 Hz, 1H), 6.38 (d, J = 4 Hz, 1H), 2.59 (t, J = 24 Hz, 2H), 1.56 (sx, J = 40 Hz, 2H), 0.94
(t, J = 16 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ = 163.48, 161.02, 154.45, 151.37, 133.45,
130.97, 127.58, 119.95, 116.31, 116.10, 115.51, 107.67, 65.88, 53.43, 25.51. 19F NMR
(376 MHz, CDCl3) δ = -114.70
6.17.176eac
Prepared as described in the general procedure. N-propylresorcinol (33 mg, 0.22
mmol) and 1-iodonaphthalene (84 mg, 0.33 mmol) as a white solid. Yield: 40 mg, 65%. 1H
NMR (400 MHz, CDCl3) δ = 7.83 (q, J = 16 Hz, 2H), 7.61 (d, J = 8 Hz, 1H), 7.43 (m, 4H),
6.89 (d, J = 8 Hz, 1H), 6.45 (d, J = 8 Hz, 1H), 2.64 (t, J = 12 Hz, 2H), 1.75 (m, 2H), 1.07
(t, J = 12 Hz 3H); 13C NMR (101 MHz, CDCl3) δ = 171.24, 154.64, 152.11, 134.45, 134.08,
132.31, 128.58, 128.52, 128.45, 128.42, 126.65, 126.29, 125.80, 118.70, 115.39, 107.39,
60.44, 43.42, 34.67.
6.17.186fac
Prepared as described in the general procedure. N-propylresorcinol (33 mg, 0.22
mmol) and 4-iodotoluene (80 mg, 0.33 mmol) as a white solid. Yield: 44 mg, 82%. 1H
NMR (400 MHz, CDCl3) δ = 7.21 (m, 4H), 6.85 (d, J =8 Hz, 1H), 6.37 (d, J = 8 Hz, 1H),
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2.60 (t, J = 12 Hz, 2H), 2.32 (s, 3H), 1.75 (sx, J = 32 Hz, 2H), 0.91 (t, J = 12 Hz, 3H); 13C
NMR (101 MHz, CDCl3) δ = 154.17, 151.43, 137.34, 134.45, 130.11, 129.09, 127.48,
120.88, 115.35, 107.52, 60.52, 31.61, 25.57.
6.17.196cad
Prepared as described in the general procedure. 2,3,4-trimethoxy acetophenone (40
µL, 0.22 mmol) and iodobenzene (37 µL, 0.33 mmol) as a colorless oil. Yield: 61 mg, 97%.
1

H NMR (400 MHz, CDCl3) δ = 7.48 (t, J = 8 Hz, 3H), 7.40 (t, J = 12 Hz, 2H), 7.33 (t, J

= 12 Hz, 1H), 4.01 (s, 3H), 3.94 (s, 3H), 3.72 (s, 3H), 2.62 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ = 198.61, 155.32, 153.65, 146.70, 131.37, 129.18, 128.33, 127.44, 126.16,
123.74, 105.28, 61.57, 61.10, 56.15, 31.23, 29.80.
6.17.206dad
Prepared as described in the general procedure. 2,3,4-trimethoxy acetophenone (40
µL, 0.22 mmol) and 4-fluoroiodobenzene (38 µL, 0.33 mmol) as a colorless oil. Yield: 63
mg, 98%. 1H NMR (400 MHz, CDCl3) δ = 7.40-7.36 (m, 3H), 7.33 (tt, J = 12, 4 Hz, 2H),
3.94 (s, 3H), 3.88 (s, 3H), 3.66 (s, 3H), 2.56 (s, 3H);

13

C NMR (101 MHz, CDCl3) δ =

189.45, 163.49, 161.04, 155.12, 153.66, 146.66, 133.20, 130.78, 130.26, 128.36, 125.85,
115.27, 115.06, 61.47, 61.00, 31.16, 29.71. 19F NMR (376 MHz, CDCl3) δ = -115.12.
6.17.216ead
Prepared as described in the general procedure. 2,3,4-trimethoxy acetophenone (40
µL, 0.22 mmol) and 1-iodonaphthalene (84 mg, 0.33 mmol) as a yellow oil. Yield: 62 mg,
90%. 1H NMR (400 MHz, CDCl3) δ = 7.81 (t, J = 16 Hz, 2H), 7.52 (d, J = 8 Hz, 1H), 7.467.30 (m, 5H), 4.00 (s, 3H), 3.90 (s, 3H), 3.49 (s, 3H), 2.58 (s, 3H); 13C NMR (101 MHz,
CDCl3) δ = 198.41, 155.90, 153.89, 135.54, 133.52, 132.00, 128.22, 128.11, 128.03,
127.38, 127.28, 126.06, 125.98, 125.81, 125.27, 61.55, 61.06, 36.09, 34.68, 29.07, 25.29.
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6.17.226fad
Prepared as described in the general procedure. 2,3,4-trimethoxy acetophenone (40
µL, 0.22 mmol) and 4-iodotoluene (80 mg, 0.33 mmol) as a colorless oil. Yield: 57 mg,
91%. 1H NMR (400 MHz, CDCl3) δ = 7.41 (s, 1H), 7.40 (d, J = 8 Hz, 2H), 7.33 (d, J = 8
Hz, 2H), 3.94 (s, 3H), 3.84 (s, 3H), 3.65 (s, 3H), 2.56 (s, 3H), 2.32 (s, 3H); 13C NMR (101
MHz, CDCl3) δ = 189.59, 155.20, 153.44, 146.61, 137.11, 1234.31, 131.22, 128.93,
128.30, 126.00, 61.49, 61.00, 31.09, 21.21.
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APPENDICES
APPENDIX 1. X-RAY CRYSTAL STRUCTURE FIGURES, DATA, AND TABLES
Table S-1. Crystal Data for 2a, 2b, and 2c.
Crystal Data

2a

2b

2c

Empirical Formula

C12H8Au2Cl4N2

C12H8Au2Cl5N2

C12H8AuCl3N2O4

Crystal Size (mm)

0.06 x 0.05 x 0.03

0.06 x 0.06 x 0.05

0.09 x 0.07 x 0.07

Crystal System

Triclinic

Triclinic

Orthorhombic

Space Group

90.0(2)

P1�

Pbca

Temperature (K)

P1�

90.0(2)

90.0(2)

Volume (Å3)

760.78(4)

807.22(3)

2877.18(11)

a (Å)

7.3559(2)

7.4092(2)

15.2841(3)

b (Å)

7.9171(2)

7.7822(2)

12.1249(3)

c (Å)

13.8613(4)

14.3986(3)

15.5256(3)

α (°)

74.929(1)

84.463(1)

90

β (°)

77.645(1)

77.729(1)

90

γ (°)

84.574(1)

87.429(1)

90

FW (g/mol)

715.94

751.39

547.52

Z

2

2

8

F000

640

674

2048

Radiation (Å)

0.71073

0.71073

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

1.199

1.138

1.096

wR2

0.0461

0.0254

0.0256

Npar

184

194

200

Table S-2. Crystal Data for 2d, 2e, and 2f.
Crystal Data

2d

2e

2f

Empirical Formula

C12H8AuCl3N2

C14H12AuCl2F6N2P

C10H8AuCl2F6N2P

Crystal Size

0.08 x 0.04 x 0.03

0.09 x 0.08 x 0.05

0.07 x 0.07 x 0.05

Crystal System

Orthorhombic

Monoclinic

Monoclinic

Space Group

Cmcm

P2(1)/n

P2(1)/n

Temperature (K)

90.0(2)

90.0(2)

90.0(2)

Volume (Å3)

1296.7(3)

1724.59(7)

1416.08(5)

a (Å)

11.2927(17)

7.0330(2)

6.6826(1)

b (Å)

17.827(3)

14.1302(3)

14.7624(3)

c (Å)

6.4414(8)

17.3904(4)

14.6209(3)

α (°)

90

90

90

β (°)

90

93.714(1)

100.956(1)

γ (°)

90

90

90

FW (g/mol)

483.52

621.09

569.02

Z

4

4

4

F000

896

1168

1056

Radiation (Å)

0.71073

0.71073

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

1.162

1.126

1.127

wR2

0.0870

0.0303

0.0265

Npar

57

238

200

199

Table S-3. Crystal Data for 2g, [H-phen][AuCl4], and [H-phen][ClO4].
Crystal Data

2g

[H-phen][AuCl4]

[H-phen][ClO4]

Empirical Formula

C12H8AuCl2F6N2P

C12H9AuCl4N2

C15H15ClN3O5

Crystal Size

0.08 x 0.08 x 0.03

0.07 x 0.07 x 0.03

0.32 x 0.18 x 0.16

Crystal System

Orthorhombic

Monoclinic

Monoclinic

Space Group

Pbca

P2(1)/c

C2/c

Temperature (K)

90.0(2)

90.0(2)

90.0(2)

Volume (Å3)

3055.78(10)

1441.10(12)

1584.41(8)

a (Å)

12.9909(2)

7.9901(4)

10.6388(3)

b (Å)

15.1581(3)

7.1845(4)

22.4647(6)

c (Å)

15.5181(3)

25.2782(10)

6.6296(2)

α (°)

90

90

90

β (°)

90

96.726(2)

90.431(1)

γ (°)

90

90

90

FW (g/mol)

593.04

519.98

352.75

Z

8

4

4

F000

2208

968

732

Radiation (Å)

0.71073

0.71073

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

1.069

1.044

1.067

wR2

0.0295

0.0341

0.0994

Npar

218

176

116

200

Table S-4. Crystal data for [H-phen][PF6], 3c, and 3f.
Crystal Data

[H-phen][PF6]

3c

3f

Empirical Formula

C15H15F6N3OP

C18H18AuF6N2OPS2

C15H16AuF6N2PS2

Crystal Size

0.24 x 0.16 x 0.16

0.08 x 0.07 x 0.05

0.10 x 0.08 x 0.04

Crystal System

Orthorhombic

Monoclinic

Orthorhombic

Space Group

Pbcn

P2(1)/c

P2(1)2(1)2(1)

Temperature (K)

90.0(2)

90.0(2)

90.0(2)

Volume (Å3)

1656.94(12)

4246.6(15)

1874.83(7)

a (Å)

11.0858(5)

24.858(5)

7.7242(2)

b (Å)

22.9703(10)

7.8812(16)

11.1154(2)

c (Å)

6.5069(2)

21.855(4)

21.8365(4)

α (°)

90

90

90

β (°)

90

97.33(3)

90

γ (°)

90

90

90

FW (g/mol)

398.27

984.40

630.35

Z

4

8

4

F000

812

2624

1200

Radiation (Å)

0.71073

0.71073

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

0.963

1.021

0.890

wR2

0.0619

0.0323

0.0246

Npar

134

560

247

201

Table S-5. Crystal data for 3g, 3g-[ClO4], and 3h.
Crystal Data

3g

3g-[ClO4]

3h

Empirical Formula

C17H20AuF6N2PS2

C18H21.5AuClN2.5O4S2

C18H20AuF6N2PS2

Crystal Size

0.11 x 0.03 x 0.02

0.20 x 0.14 x 0.10

0.09 x 0.09 x 0.05

Crystal System

Orthorhombic

Triclinic

Orthorhombic

Space Group

Pna2(1)

Pna2(1)

Temperature (K)

90.0(2)

P1�

90.0(2)

90.0(2)

Volume (Å3)

2086.4(1)

1078.35(5)

2109.27(10)

a (Å)

14.1989(4)

9.2541(2)

14.4750(4)

b (Å)

18.1306(5)

10.8208(3)

17.9946(5)

c (Å)

8.1046(2)

11.1378(3)

8.0979(2)

α (°)

90

78.2816(9)

90

β (°)

90

89.0566(8)

90

γ (°)

90

80.9588(9)

90

FW (g/mol)

658.41

633.41

670.42

Z

4

2

4

F000

1264

614

1288

Radiation (Å)

0.71073

0.71073

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

1.304

1.183

1.055

wR2

0.0517

0.0318

0.0345

Npar

311

281

272

202

Table S-6. Crystal data for 3j, 5c, and 5d.
Crystal Data
Empirical
Formula

3j

5c

5d

C26H30AuF6N3PO1.5PS2 C28H23AuF6N2PSb C30H23AuF6N2AsSb

Crystal Size

0.11 x 0.10 x 0.06

0.08 x 0.07 x 0.05

0.12 x 0.11 x 0.09

Crystal System

Triclinic

Triclinic

Triclinic

Space Group
Temperature (K)

P1�

90.0(2)

P1�

90.0(2)

P1�

90.0(2)

Volume (Å3)

1404.09(5)

1344.58(4)

1413.83(4)

a (Å)

9.7833(2)

11.3162(2)

11.0384(2)

b (Å)

10.9241(2)

11.3701(2)

11.6249(2)

c (Å)

13.6127(3)

11.5687(2)

12.1580(2)

α (°)

104.794(1)

80.967(1)

77.723(1)

β (°)

90.616(1)

71.945(1)

73.203(1)

γ (°)

93.105(1)

72.244(1)

72.939(1)

FW (g/mol)

814.58

851.17

919.14

Z

2

2

2

F000

798

808

868

Radiation (Å)

0.71073

0.71073

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

1.089

1.090

1.043

wR2

0.0344

0.0297

0.0303

Npar

392

353

375

203

Table S-7. Crystal data for 5f, 5h, and 5i.
Crystal Data
Empirical
Formula

5f

5h

5i

C28H23AuF6N2AsSb C40H47AuF6N2O2PSb C50H51AuF6N2O2PSb

Crystal Size

0.09 x 0.07 x 0.04

0.11 x 0.10 x 0.08

0.15 x 0.11 x 0.08

Crystal System

Triclinic

Monoclinic

Triclinic

Space Group

P2(1)/n

Temperature (K)

P1�

90.0(2)

90.0(2)

P1�

90.0(2)

Volume (Å3)

1362.41(4)

3857.32(16)

2227.73(8)

a (Å)

11.2990(2)

14.6761(4)

10.6778(2)

b (Å)

11.4091(2)

17.2897(4)

14.6519(3)

c (Å)

11.6754(2)

16.0080(3)

15.1311(3)

α (°)

80.746(1)

90

91.4611(7)

β (°)

72.122(1)

108.264(1)

104.7596(7)

γ (°)

72.527(1)

90

102.3939(7)

FW (g/mol)

895.12

1051.48

1175.61

Z

2

4

2

F000

844

2064

1160

Radiation (Å)

0.71073

0.71073

0.71073

Data
Refinement
Method

Full-matrix Least Squares on F2

S

1.078

1.057

1.076

wR2

0.0354

0.0331

0.0364

Npar

353

483

570

204

Table S-8. Crystal data for 5j, 5k, and 6a.
Crystal Data

5j

5k

6a

Empirical Formula

C36H43AuF6N2O2PSb

C18H15AuClSb

C32H27AuF6N2PSb

Crystal Size

0.11 x 0.08 x 0.04

0.11 x 0.10 x 0.08

0.13 x 0.11 x 0.07

Crystal System

Monoclinic

Orthorhombic

Triclinic

Space Group

P2(1)/n

P2(1)2(1)2(1)

Temperature (K)

90.0(2)

90.0(2)

P1�

90.0(2)

Volume (Å3)

3578.28(12)

1659.22(6)

1500.53(5)

a (Å)

14.4178(3)

10.9124(2)

8.5324(2)

b (Å)

15.4506(3)

11.9952(3)

10.9462(2)

c (Å)

16.0747(3)

12.6758(3)

16.7013(3)

α (°)

90

90

90.730(1)

β (°)

92.175(1)

90

104.030(1)

γ (°)

90

90

104.030(1)

FW (g/mol)

999.41

585.47

903.24

Z

4

4

2

F000

1952

1080

864

Radiation (Å)

0.71073

0.71073

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

1.058

1.038

1.087

wR2

0.0342

0.0353

0.0358

Npar

449

191

390

205

Table S-9. Crystal data for 6b.
Crystal Data

6b

Empirical Formula

C32H27AuF6N2AsSb

Crystal Size

0.09 x 0.06 x 0.04

Crystal System

Triclinic

Space Group

P1�

Temperature (K)

90.0(2)

Volume (Å3)

1516.80(4)

a (Å)

8.5893(1)

b (Å)

10.9496(2)

c (Å)

16.8019(3)

α (°)

89.988(1)

β (°)

89.988(1)

γ (°)

89.988(1)

FW (g/mol)

947.19

Z

2

F000

900

Radiation (Å)

0.71073

Data Refinement
Method

Full-matrix Least Squares on F2

S

1.076

wR2

0.0422

Npar

394

206

Figure S-1-1. Ellipsoid plot of 2a. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-2. Ellipsoid plot of 2b. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.
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Figure S-1-3. Ellipsoid plot of 2c. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-4. Ellipsoid plot of 2d. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.
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Figure S-1-5. Ellipsoid plot of 2e. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-6. Ellipsoid plot of 2f. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.
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Figure S-1-7. Ellipsoid plot of 2g. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-8. Ellipsoid plot of [H-phen][AuCl4]. Ellipsoids are drawn at the 50%
probability level. Solvent molecules are omitted for clarity. Only the protonated – H atom
is shown for visualization of the [H-phen]+ cation.
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Figure S-1-9. Ellipsoid plot of [H-phen][ClO4]. Ellipsoids are drawn at the 50%
probability level. Solvent molecules are omitted for clarity. Only the protonated – H atom
is shown for visualization of the [H-phen]+ cation.

Figure S-1-10. Ellipsoid plot of [H-phen][PF6]. Ellipsoids are drawn at the 50%
probability level. Solvent molecules are omitted for clarity. Only the protonated – H atom
is shown for visualization of the [H-phen]+ cation.
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Figure S-1-11. Ellipsoid plot of 3c. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity. Compound 3c crystallizes out with two
cation/anion pairs.

Figure S-1-12. Ellipsoid plot of 3g. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.
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Figure S-1-13. Ellipsoid plot of the perchlorate analogue of 3g (3g-[ClO4]). Ellipsoids
are drawn at the 50% probability level. Hydrogen atoms and solvent molecules (MeCN)
are omitted for clarity.

Figure S-1-14. Ellipsoid plot of the perchlorate analogue of 3h. Ellipsoids are drawn at
the 50% probability level. Hydrogen atoms are omitted for clarity.
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Figure S-1-15. Ellipsoid plot of the perchlorate analogue of 3j. Ellipsoids are drawn at
the 50% probability level. Hydrogen atoms are and solvent (Et2O) are omitted for clarity.

Figure S-1-16. Ellipsoid plot of 5c. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.
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Figure S-1-17. Ellipsoid plot of 5d. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-18. Ellipsoid plot of 5f. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.
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Figure S-1-19. Ellipsoid plot of 5h. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-20. Ellipsoid plot of 5i. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.
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Figure S-1-21. Ellipsoid plot of 5j. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-22. Ellipsoid plot of 5k. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity. Selected bond lengths include: Au1-Cl1,
2.2931(13) Å; Au1-Sb1, 2.4831(4) Å.
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Figure S-1-23. Ellipsoid plot of 6a. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

Figure S-1-24. Ellipsoid plot of 6a. Ellipsoids are drawn at the 50% probability level.
Hydrogen atoms are omitted for clarity.

218

APPENDIX 2. SUPPLEMENTARY FIGURES FOR CHAPTER 2

Figure S-1-25. Full Q – VT – 1H NMR spectra of conversion of 2c to the protonolysis
product in DMSO-d6. Trimethoxybenzene (6.09 ppm) was used as the internal standard.

Figure S-1-26. Q – VT – 1H NMR spectra of conversion of 2c at 20 °C to the
protonolysis product in DMSO-d6. Trimethoxybenzene (6.09 ppm) was used as the
internal standard.
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Figure S-1-27. Q – VT – 1H NMR spectra of conversion of 2c at 40 °C to the
protonolysis product in DMSO-d6. Trimethoxybenzene (6.09 ppm) was used as the
internal standard.

Figure S-1-28. Q – VT – 1H NMR spectra of conversion of 2c at 60 °C to the
protonolysis product in DMSO-d6. Trimethoxybenzene (6.09 ppm) was used as the
internal standard.
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Figure S-1-29. Q – VT – 1H NMR spectra of conversion of 2c at 75 °C to the
protonolysis product in DMSO-d6. Trimethoxybenzene (6.09 ppm) was used as the
internal standard.

Figure S-1-30. Q – VT – 1H NMR spectra of conversion of 2c once returned to 20 °C to
the protonolysis product in DMSO-d6. Trimethoxybenzene (6.09 ppm) was used as the
internal standard.
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APPENDIX 3. SUPPLEMENTARY FIGURES FOR CHAPTER 3

Figure S-1-31. UV-vis spectrum of 3a in PBS (50 μM).

Figure S-1-32. UV-vis spectrum of 3b in PBS (50 μM).

Figure S-1-33. UV-vis spectrum of 3c in PBS (50 μM).

Figure S-1-34. UV-vis spectrum of 3d in PBS (50 μM).
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Figure S-1-35. UV-vis spectrum of 3e in PBS (50 μM).

Figure S-1-36. UV-vis spectrum of 3g in PBS (50 μM).
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Figure S-1-37. UV-vis spectrum of 3h in PBS (50 μM).

Figure S-1-38. UV-vis spectrum of 3i in PBS (50 μM).
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Figure S-1-39. UV-vis spectrum of 3j in PBS (50 μM).

Figure S-1-40. UV-vis spectrum of 3a in DMEM (50 μM).
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Figure S-1-41. UV-vis spectrum of 3b in DMEM (50 μM).

Figure S-1-42. UV-vis spectrum of 3c in DMEM (50 μM).
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Figure S-1-43. UV-vis spectrum of 3d in DMEM (50 μM).

Figure S-1-44. UV-vis spectrum of 3e in DMEM (50 μM).
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Figure S-1-45. UV-vis spectrum of 3g in DMEM (50 μM).

Figure S-1-46. UV-vis spectrum of 3h in DMEM (50 μM).
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Figure S-1-47. UV-vis spectrum of 3i in DMEM (50 μM).

Figure S-1-48. UV-vis spectrum of 3j in DMEM (50 μM).
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Figure S-1-49. UV-vis spectrum of 3a in RPMI-1640 (50 μM).

Figure S-1-50. UV-vis spectrum of 3b in RPMI-1640 (50 μM).
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Figure S-1-51. UV-vis spectrum of 3c in RPMI-1640 (50 μM).

Figure S-1-52. UV-vis spectrum of 3d in RPMI-1640 (50 μM).
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Figure S-1-53. UV-vis spectrum of 3e in RPMI-1640 (50 μM).

Figure S-1-54. UV-vis spectrum of 3g in RPMI-1640 (50 μM).
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Figure S-1-55. UV-vis spectrum of 3h in RPMI-1640 (50 μM).

Figure S-1-56. UV-vis spectrum of 3i in RPMI-1640 (50 μM).
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Figure S-1-57. UV-vis spectrum of 3j in RPMI-1640 (50 μM).
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Figure S-1-58. UV-vis spectrum of 3a + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-59. UV-vis spectrum of 3b + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-60. UV-vis spectrum of 3c + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-61. UV-vis spectrum of 3d + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-62. UV-vis spectrum of 3e + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-63. UV-vis spectrum of 3f + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-64. UV-vis spectrum of 3g + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-65. UV-vis spectrum of 3h + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-66. UV-vis spectrum of 3i + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-67. UV-vis spectrum of 3j + GSH (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-68. UV-vis spectrum of 3a + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-69. UV-vis spectrum of 3b + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-70. UV-vis spectrum of 3c + NAC (1:1 ratio, 25 μM) diluted in PBS.

241

A b so r b a n c e

1 .0

3d
3 d + N A C ( 5 m in )
0 .5

3 d + N A C (1 2 h )

0 .0
300

400

500

W a v e le n g t h ( n m )

Figure S-1-71. UV-vis spectrum of 3d + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-72. UV-vis spectrum of 3e + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-73. UV-vis spectrum of 3f + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-74. UV-vis spectrum of 3g + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-75. UV-vis spectrum of 3h + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-76. UV-vis spectrum of 3i + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-77. UV-vis spectrum of 3j + NAC (1:1 ratio, 25 μM) diluted in PBS.
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Figure S-1-78. LC-MS chromatogram of the adduct formed between 3f + GSH, (2.5
mM, λ = 280 nm).
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Figure S-1-79. Full 1H NMR spectrum (400 MHz, DMSO-d6) of 3f (20 mM), GSH (20
mM), and 3f + GSH (10 mM).

Figure S-1-80. Full 1H NMR spectrum (400 MHz, DMSO-d6) of 3f + GSH (10 mM) at
different time intervals. The spectrum is consistent across all time periods indicating the
reaction occurs immediately and that the adduct is stable in solution.
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Figure S-1-81. Cyclic voltammogram of (2-benzylpyridine)AuCl2 (2 mM) in DMSO
with NBu4PF6 (0.1 M) as the electrolyte.

Figure S-1-82. Cyclic voltammogram of sodium diethyldithiocarbamate (2 mM) in
DMSO with NBu4PF6 (0.1 M) as the electrolyte.
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Figure S-1-83. Cyclic voltammogram of GSH (2 mM) in DI H2O with NaClO4 (0.1 M)
as the electrolyte.

20

C u r r e n t (µ A )

10
0
-1 0

1

0

-1

-2

-2 0
-3 0
P o te n tia l (V )

Figure S-1-84. Cyclic voltammogram of 3f (2 mM) in DMSO with NBu4PF6 (0.1 M) as
the electrolyte.
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Figure S-1-85. %Cell survival of 3f and 3f + GSH over 72 hours, data are plotted as the
mean ± s.e.m. (n = 3).

Figure S-1-86. %Cell survival of 3a in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-87. %Cell survival of 3b in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-88. %Cell survival of 3c in a panel of cell lines, data are plotted as the mean
± s.e.m. (n = 3).
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Figure S-1-89. %Cell survival of 3d in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-90. %Cell survival of 3e in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-91. %Cell survival of 3f in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-92. %Cell survival of 3g in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-93. %Cell survival of 3h in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-94. %Cell survival of 3i in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).

253

Figure S-1-95. %Cell survival of 3i in a panel of cell lines, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-96. %Cell survival of 3a in MRC5, data are plotted as the mean ± s.e.m. (n =
3).
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Figure S-1-97. %Cell survival of 3b in MRC5, data are plotted as the mean ± s.e.m. (n =
3).

Figure S-1-98. %Cell survival of 3c in MRC5, data are plotted as the mean ± s.e.m. (n =
3).
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Figure S-1-99. %Cell survival of 3d in MRC5, data are plotted as the mean ± s.e.m. (n =
3).

Figure S-1-100. %Cell survival of 3e in MRC5, data are plotted as the mean ± s.e.m. (n =
3).
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Figure S-1-101. %Cell survival of 3f in MRC5, data are plotted as the mean ± s.e.m. (n =
3).
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Figure S-1-102. %Cell survival of 3g in MRC5, data are plotted as the mean ± s.e.m. (n =
3).
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Figure S-1-103. %Cell survival of 3h in MRC5, data are plotted as the mean ± s.e.m. (n =
3).
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Figure S-1-104. %Cell survival of 3i in MRC5, data are plotted as the mean ± s.e.m. (n =
3).
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Figure S-1-105. %Cell survival of 3j in MRC5, data are plotted as the mean ± s.e.m. (n =
3).

Figure S-1-106. Mitochondrial membrane potential FOV (20x objective). 3f was added
to MDA-MB-231 at 10 μM for 6 hours. J-aggregates were imaged with
(excitation/emission: 488/ 590 nm) and J-monomers with (excitation/emission: 488/525
nm).
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Figure S-1-107. Optimization of cell seeding density with the Seahorse XF96 analyzer.
Different cell densities were seeded and allowed to adhere overnight. Optimal cell line
density was determined by cutoff of OCR (maximum 300 pmol/min and minimum 100
pmol/min).

Figure S-1-108. Further optimization of FCCP concentration (uncoupler). Two
concentrations (0.6 μM and 1.2 μM) were used. The optimal concentration was chosen to
be 0.6 μM, illustrated by the higher response after injection.

260

Figure S-1-109. GF-AAS standard curve with Au concentrations of 0, 10, 20 and 50
µg/mL. Data points are representative of triplicate and plotted as the mean ± s.d.

Figure S-1-110. GF-AAS standard curve with Au concentrations of 0, 10, 20 and 50
µg/mL. Data points are representative of triplicate and plotted as the mean ± s.d.
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Figure S-1-111. GF-AAS standard curve with Au concentrations of 0, 10, 20 and 50
µg/mL. Data points are representative of triplicate and plotted as the mean ± s.d.
APPENDIX 4. SUPPLEMENTARY FIGURES FOR CHAPTER 4

Figure S-1-112. Mitostress test of K562 with pneumatic injection of AuDTC. Data are
normalized per 1,000 cells. Data are plotted as the mean ± s.e.m., (n = 8).
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Figure S-1-113. Mitostress test of HCC1937 with pneumatic injection of AuDTC. Data
are normalized per 1,000 cells. Data are plotted as the mean ± s.e.m., (n = 8).
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Figure S-1-114. MMP analysis of MCF-10A using JC-1 after treatment of AuDTC. Loss
of J-aggregates was analyzed using FACS (PE channel). Plots are representative of 5
replicates. 30,000 gated events were used for each sample.
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Figure S-1-115. MMP analysis of HMEC using JC-1 after treatment of AuDTC. Loss of
J-aggregates was analyzed using FACS (PE channel). Plots are representative of 5
replicates. 30,000 gated events were used for each sample.
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Figure S-1-116. MMP analysis of 4T1 using JC-1 after treatment of AuDTC. Loss of Jaggregates was analyzed using FACS (PE channel). Plots are representative of 5
replicates. 30,000 gated events were used for each sample.
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Figure S-1-117. MMP analysis of MCF-10A using JC-1 after treatment of AuDTC. Loss
of J-aggregates was analyzed using FACS (PE channel). Plots are representative of 5
replicates. 30,000 gated events were used for each sample.
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Figure S-1-118. Calculated parameters from normalized PER data from the HMEC
glycolytic assay. Data was normalized per 1,000 cells before calculations. Left to right:
basal glycolysis, time period between AuDTC and rotenone/antimycin A (Rot./AA),
compensatory glycolysis, time period from Rot./AA to 2-deoxyglucose (2-DG),
mitoOCR/glycoPER ratio. Data are plotted as the mean ± s.d., n = 8.

Figure S-1-119. Confocal microscopy analysis of mtROS production in 4T1 for a visual
representation. Images were taken using a 60x oil objective. Cells were treated for 2
hours at 5 µM with AuDTC prior to imaging. Fluorescent stains used are as follows: blue
(Hoechst for nuclear counterstain), green, (MitoTracker Green FM) for localization of
mitochondria, and red (MitoSOX) for detection of mtROS. The orange fluorescent color
represent overlap of green and red fluorescence, indicating localization of the mtROS
within the mitochondria.
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Figure S-1-120. FACS analysis of general ROS production in MDA-MB-231 (left) and
4T1 (right) using DCF-DA (FITC channel) after treatment with AuDTC. Histograms are
representative of 3 replicates.

Figure S-1-121. FACS analysis of mitochondrial specific ROS production in MDA-MB231 (left) and 4T1 (right) using MitoSOX (PE channel) after treatment with AuDTC.
Histograms are representative of 3 replicates.
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Figure S-1-122. Confocal microscopy in MDA-MB-468 of mitochondrial cytochrome c
release after treatment with AuDTC. Images were taken using a 60x oil objective. Full
panels are shown for overview of the total cell. From left to right: blue (Hoechst
counterstain for nucleus), green (MitoTracker Green FM) for localization of
mitochondria, red (cytochrome c) imaged using cytochrome c primary antibody and a
secondary antibody tagged with a fluorophore, merge (all three individual channels), to
illustrate overlap of cytochrome c with the mitochondria. Top row represents treatment
with AuDTC. Bottom row represents the control sample.

Figure S-1-123. Confocal microscopy in MDA-MB-468 of click chemistry controls.
Images were taken using a 60x oil objective. From left to right: blue (Hoechst
counterstain for nucleus), green (treatment with 4-alkyne with no Alexa Fluor 488 azide),
red (MitoTracker Red) for localization of mitochondria, merge (all three individual
channels), to illustrate overlap of individual components.
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Figure S-1-124. Confocal microscopy in MDA-MB-468 of click chemistry controls.
Images were taken using a 60x oil objective. From left to right: blue (Hoechst
counterstain for nucleus), green (no treatment with 4-alkyne followed by incubation with
Alexa Fluor 488 azide), red (MitoTracker Red) for localization of mitochondria, merge
(all three individual channels), to illustrate overlap of individual components.

Figure S-1-125. Click chemistry visualized with confocal microscopy in MDA-MB-468.
Images were taken using a 60x oil objective. Cells were treated for 2 µM for 1 hour.
Panels: A) Hoechst as the nuclear counterstain, B) 4-alkyne – Alexa Fluor 488 azide
adduct, C) MitoTracker Red CM-H2XRos (MTR) alone, D) Merge of all three channels,
E) Merge of Hoechst and 4-alkyne, F) Merge of 4-alkyne and MTR.
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Figure S-1-126. Click chemistry visualized with confocal microscopy in MDA-MB-468.
Images were taken using a 60x oil objective. Cells were treated for 25 µM for 1 hour.
Panels: A) Hoechst as the nuclear counterstain, B) 4-alkyne – Alexa Fluor 488 azide
adduct, C) MitoTracker Red CM-H2XRos (MTR) alone, D) Merge of all three channels,
E) Merge of Hoechst and 4-alkyne, F) Merge of 4-alkyne and MTR.
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Figure S-1-127. Click chemistry visualized with confocal microscopy in MDA-MB-468.
Images were taken using a 20x air objective for a wider field of view. Cells were treated
for 25 µM for 1 hour. Panels: A) Hoechst as the nuclear counterstain, B) 4-alkyne –
Alexa Fluor 488 azide adduct, C) MitoTracker Red CM-H2XRos (MTR) alone, D) Merge
of all three channels, E) Merge of Hoechst and 4-alkyne, F) Merge of 4-alkyne and
MTR.
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Figure S-1-128. Click chemistry visualized with confocal microscopy in MDA-MB-468.
Images were taken using a 60x oil objective. Cells were treated for 50 µM for 1 hour.
Panels: A) Hoechst as the nuclear counterstain, B) 4-alkyne – Alexa Fluor 488 azide
adduct, C) MitoTracker Red CM-H2XRos (MTR) alone, D) Merge of all three channels,
E) Merge of Hoechst and 4-alkyne, F) Merge of 4-alkyne and MTR.
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APPENDIX 5. SUPPLEMENTARY FIGURES AND TABLES FOR CHAPTER 5

Figure S-1-129. %Cell survival of 5a in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-130. %Cell survival of 5b in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-131. %Cell survival of 5c in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-132. %Cell survival of 5d in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-133. %Cell survival of 5e in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-134. %Cell survival of 5f in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-135. %Cell survival of 5g in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-136. %Cell survival of 5h in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-137. %Cell survival of 5i in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).

Figure S-1-138. %Cell survival of 5j in MDA-MB-231, data are plotted as the mean ±
s.e.m. (n = 3).
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Figure S-1-139. %Cell survival of bidentate ligands used in this study, auranofin,
cisplatin, and NaSbF6 as controls in MDA-MB-231, data are plotted as the mean ± s.e.m.
(n = 3).

Figure S-1-140. UV-vis spectrum of 5a in DMEM at 37 °C monitored over a 24 hour
time period.
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Figure S-1-141. UV-vis spectrum of 5b in DMEM at 37 °C monitored over a 24 hour
time period.

Figure S-1-142. UV-vis spectrum of 5c in DMEM at 37 °C monitored over a 24 hour
time period.
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Figure S-1-143. UV-vis spectrum of 5d in DMEM at 37 °C monitored over a 24 hour
time period.

Figure S-1-144. UV-vis spectrum of 5e in DMEM at 37 °C monitored over a 24 hour
time period.
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Figure S-1-145. UV-vis spectrum of 5f in DMEM at 37 °C monitored over a 24 hour
time period.

Figure S-1-146. UV-vis spectrum of 5g in DMEM at 37 °C monitored over a 24 hour
time period.
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Figure S-1-147. UV-vis spectrum of 5h in DMEM at 37 °C monitored over a 24 hour
time period.

Figure S-1-148. UV-vis spectrum of 5j in DMEM at 37 °C monitored over a 24 hour
time period.
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Figure S-1-149. Full immunoblots of 5i, actin and SOD1. Two cell lines were analyzed:
RPE-NEO and MDA-MB-231. Treatments consisted of 4 time points: 0, 0.5, 12, and 24
hours with 4 technical replicates.

Figure S-1-150. Full immunoblots of 5i, SOD2 and NRF2. Two cell lines were analyzed:
RPE-NEO and MDA-MB-231. Treatments consisted of 4 time points: 0, 0.5, 12, and 24
hours with 4 technical replicates.
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Figure S-1-151. Full immunoblots of 5i, KEAP1, phosphorylated-ERK, pan-ERK, and
SOD1. Two cell lines were analyzed: RPE-NEO and MDA-MB-231. Treatments
consisted of 4 time points: 0, 0.5, 12, and 24 hours with 4 technical replicates.

Figure S-1-152. Full immunoblots of 5i, actin and OPA1. Two cell lines were analyzed:
RPE-NEO and MDA-MB-231. Treatments consisted of 4 time points: 0, 0.5, 12, and 24
hours with 4 technical replicates.

Figure S-1-153. Full immunoblots of 5i, cytochrome c, mitofusin, and TOM20. Two cell
lines were analyzed: RPE-NEO and MDA-MB-231. Treatments consisted of 4 time
points: 0, 0.5, 12, and 24 hours with 4 technical replicates.
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Table S-10. Complete ANOVA table for treatment with 5i (OPA1, Mitofusin1, TOM20,
and SOD1). Statistical significance was computed for comparison between cell type,
treatment times with respect to the untreated sample, and ratios between protein and
actin.
Anova
(OPA1)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 24.46

<0.001

5i exposure time (h)

F (3, 24) = 16.27

<0.001

Interaction

F (3, 24) = 15.19

<0.001

(Mitofusin 1)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 22.61

<0.01

5i exposure time (h)

F (3, 24) = 32.57

<0.01

Interaction

F (3, 24) = 26.14

<0.001

(TOM20)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 64.61

<0.001

5i exposure time (h)

F (3, 24) = 27.55

<0.001

Interaction

F (3, 24) = 26.94

<0.001

(SOD1)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 21.2

<0.001

5i exposure time (h)

F (3, 24) = 0.9257

0.4434

Interaction

F (3, 24) = 0.8766

0.467
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Table S-11. Complete ANOVA table for treatment with 5i (SOD2, NRF2, KEAP1, and
cytochrome c). Statistical significance was computed for comparison between cell type,
treatment times with respect to the untreated sample, and ratios between protein and
actin.
Anova
(SOD2)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 19.4

<0.001

5i exposure time (h)

F (3, 24) = 0.5064

0.6815

Interaction

F (3, 24) = 0.4173

0.7422

(NRF2)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 21.2

0.7845

5i exposure time (h)

F (3, 24) = 0.9257

0.7552

Interaction

F (3, 24) = 0.8766

0.8186

(KEAP1)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 73.01

<0.001

5i exposure time (h)

F (3, 24) = 7.66

<0.001

Interaction

F (3, 24) = 8.767

<0.001

(Cytochrome C)

F (DFn, DFd)

P value (Sig.)

Cell type

F (1, 24) = 60.01

<0.01

5i exposure time (h)

F (3, 24) = 5.451

<0.01

Interaction

F (3, 24) = 8.548

<0.001
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Figure S-1-154. GF-AAS standard curve with Au concentrations of 10, 20, and 50
µg/mL. Data points are representative of triplicate and plotted as the mean ± s.d., (n = 3).

Figure S-1-155. GF-AAS standard curve with Au concentrations of 10, 20, 50, and 80
µg/mL. Data points are representative of triplicate and plotted as the mean ± s.d., (n = 3).
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APPENDIX 6. SUPPLEMENTARY FIGURES AND TABLES FOR CHAPTER 6

Figure S-1-156. Experimental set-up using a heating block and glass test-tubes for all
reaction conditions.
Table S-12. Optimization of Au(I) catalyst 6a. Yields were determined with GC-MS
using 0.022 mmol of dodecane as an internal standard.
Entry

Ar-I
Equivalents

Au(I) cat.
mol%

Yield %

1

1

10

62

2

1.5

5

88

3

1.5

1

41

290

Table S-13. Optimization of Ar-I and Ar’-H stoichiometric equivalents. Yields were
determined with GC-MS using 0.022 mmol of dodecane as an internal standard.
Entry

Ar-I
Equivalents

Ar’-H
Equivalents

Yield %

1

1

1

62

2

1

2

42

3

1

3

4

4

1.5

1

86

5

1.5

2

21

6

2

1

73

7

2

2

39

Table S-14. Optimization of AgSbF6. Yields were determined with GC-MS using 0.022
mmol of dodecane as an internal standard, * indicates 8 hour reaction time.
Entry

Ar-I
Equivalents

AgSbF6 mol%

Yield %

1

1.5

10

0.3

2

1.5

20

31

3

1.5

50

62

4

1.5

50

75*

5

2

10

10

6

2

20

11

7

2

50

50

8

1.5

200

22

291

Table S-15. Optimization of additive. Yields were determined with GC-MS using 0.022
mmol of dodecane as an internal standard, * indicates 12 hour reaction time, n.d. = not
detected, trace = < 5%.
Entry

Additive

mol%

Yield %

1

LiOAc

100

n.d.

2

NaOAc

100

n.d.

3

Cu(OAc)2 –
H2O

100

n.d.

4

NH4OAc

100

n.d.

5

KOAc

100

n.d.

6

NMe4Cl

100

n.d.

7

AgBF4

100

73

8

AgNO3

100

trace

9

NH4OTf

100

n.d.

10

AgCN

100

n.d.

Table S-16. Optimization of additive. Yields were determined with GC-MS using 0.022
mmol of dodecane as an internal standard.
Entry

Base

Equivalents

1

K3PO4

1

88

2

NaOH

1

45

3

Cs2CO3

1

73

4

NaOtBu

1

71

5

Na2CO3

1

51

6

Et3N

1

34

7

KOH

1

67

292

Yield %

Figure S-1-157. GC-MS spectrum of control reaction without gold catalyst, t = 4.692
min. (iodobenzene), t = 7.662 min. (TMB).

Figure S-1-158. GC-MS spectrum of control plus additive of triphenylphosphine and
4,7-dimethyl phenanthroline, t = 4.701 min. (iodobenzene), t = 7.671 min. (TMB), t =
11.873 (PPh3), t = 12.871 (4,7-dmp).
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Figure S-1-159. GC-MS spectrum of reaction mixture with 1,2-diiodobenzene, 3naa (t =
11.790).

Figure S-1-160. HMBC NMR spectrum of 6dad in CDCl3 at 298K.
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Figure S-1-161. HMBC NMR spectrum of 6ead in CDCl3 at 298K.

Figure S-1-162. HMBC NMR spectrum of 6fad in CDCl3 at 298K.
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